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Post-stroke fatigue (PSF) is a common and distressing problem after stroke. It 
impedes patients’ participation in daily activities and is associated with higher risks 
of institutionalisation and death following stroke. Despite its high prevalence and 
detrimental consequences, little research has been conducted to develop effective 
treatments for PSF. Psychological interventions are effective in treating fatigue in 
other conditions such as cancer and chronic fatigue syndrome. This thesis described 
the development of a psychological intervention for PSF.  
Methods 
This thesis was based on the theoretical, modelling and part of the piloting phases of 
the Medical Research Council (MRC) framework for designing and evaluating 
complex interventions. This intervention was developed in collaboration with a 
multidisciplinary group of stroke clinicians, clinical psychologists, a psychotherapist, 
and stroke survivors. Both qualitative and quantitative methods were used. 
Systematic reviews were conducted to explore the natural history of PSF and to 
identify potential targets for a psychological intervention for PSF. The format of the 
intervention was adapted from existing psychological interventions for cancer-related 
fatigue and chronic fatigue syndrome. The intervention was delivered by a clinical 
psychologist (i.e. the therapist) to 12 patients with PSF (i.e. the participants) to test 
its acceptability and feasibility in the local health system. After the feasibility study, 
the intervention was refined according to the feedback from the participants and the 
therapist. A Cochrane review of interventions for PSF was updated to identify any 
new evidence that could inform future studies. 
Results 
Systematic reviews suggested that PSF often occurred early after stroke and persisted 
over time (which justified the need for interventions for PSF) and that PSF was 
associated with distressed mood, lower self-efficacy, reduced physical activity and 
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sleeping problems (which were potential targets for the treatment of PSF). Based on 
interventions that have been used to treat fatigue in other conditions, these 
psychological and behavioural factors could be addressed by psychological 
interventions that challenge patients’ thoughts and behaviours (i.e. the cognitive 
behavioural therapy, CBT). Thus a manualised CBT was developed for PSF. This 
CBT was delivered to each participant individually, through six face-to-face 
treatment sessions over a period of 12 weeks, followed by a telephone-delivered 
review session one month later. Both the participants and the therapist gave 
favourable opinions on the acceptability of the intervention. The recruitment and 
follow-up procedures were feasible in the local health system. Following the 
feedback from participants and therapist, the intervention manual was refined for 
future use, where the last two treatment sessions will be combined to a single session 
and the review session will be delivered in person by the therapist. There were 
statistically significant improvements in fatigue, mood, mobility, and participation in 
social activity from baseline to three months after the end of treatment. The updated 
Cochrane review concluded that there was insufficient evidence to recommend any 
specific intervention for PSF; psychological interventions are one type of 
interventions worth being investigated in future trials. 
Conclusions 
PSF is associated with distressed mood, lower self-efficacy, reduced physical activity 
and sleeping problems, which are potential targets for the treatment of PSF. 
Although there was insufficient evidence to recommend any intervention for the 
treatment of PSF, psychological interventions are one type of promising 
interventions worth future investigation. The promising results from this 
uncontrolled feasibility study support the need for a subsequent exploratory 





Post-stroke fatigue (PSF) is a common and distressing problem after stroke, but we 
know little about how to treat fatigue in people with stroke. Talking therapies are 
effective in treating fatigue in other conditions such as cancer and chronic fatigue 
syndrome. Thus, in this thesis I have developed and tested a talking therapy for PSF. 
Methods 
I developed this therapy together with stroke clinicians, clinical psychologists, a 
psychotherapist, and stroke patients. I reviewed the existing research studies of PSF 
to develop the theory for this therapy. I adapted the current therapy from existing 
talking therapies for cancer-related fatigue and chronic fatigue syndrome. The 
therapy was delivered by a clinical psychologist (i.e. the therapist) to 12 stroke 
patients with PSF (i.e. the participants), to test whether it would be acceptable and 
feasible in the local health system. I refined the therapy according to the feedback 
from participants and therapist. I also reviewed studies to identify if there is any new 
evidence to guide treatment of PSF. 
Results 
Based on existing studies, I identified that distressed mood, reduced physical 
activity, and sleeping problems were associated with PSF. Thus the therapy was 
developed to treat these factors with an aim to reduce fatigue. We delivered the 
current talking therapy to each participant through six face-to-face treatment sessions 
and gave a review session by telephone one month after the final treatment session. 
Both participants and therapist reported that the intervention was acceptable to them. 
The study procedures worked well in the local health system. There were significant 
improvements in fatigue, mood, mobility, and participation in social activity from 
before treatment to three months after the end of treatment. Following the feedback 
from participants and therapist, I made changes to the therapy for future studies, 
which included the combination of the last two treatment sessions into a single 
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treatment session and delivering the review session in person by the therapist. My 
review of literature suggested no new evidence to inform the treatment of PSF. 
Conclusions 
In this thesis, I present information which increases our knowledge of people with 
fatigue after stroke. I have tried to develop a talking therapy to reduce PSF and tested 
it with a small group of stroke patients. The next stage would be a clinical study to 
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CHAPTER I Introduction 
The purpose of this PhD study was to develop a psychological intervention for post-
stroke fatigue (PSF). This thesis has six chapters. Chapter 1 provides an overview of 
stroke and a general introduction of PSF, a common symptom after stroke. Chapter 2 
explores the natural history and clinical correlates of PSF, and then focuses on its 
psychological associations. Based on the factors identified as being associated with 
PSF, a conceptual model is proposed for understanding PSF, which indicates that 
psychological and behavioural factors play important roles in maintaining fatigue 
symptoms. Chapter 3 describes a multi-stage and iterative process of developing a 
manualised intervention for PSF, which involves identifying the evidence, 
developing the treatment rationale, and designing the intervention programme.  In 
Chapter 4, a feasibility study is conducted to test the acceptability of the intervention 
and the feasibility of the study design. Chapter 5 is an update of the Cochrane review 
of interventions for PSF, which aims to identify any new evidence that could be 
included in future studies. This review suggests that psychological interventions are 
promising treatment strategies for PSF, whilst their efficacy should be investigated in 
further randomised controlled trials (RCTs). Finally, Chapter 6 discusses clinical 
implications of the current study and directions for future research. 
This initial chapter (Chapter 1) starts with a brief introduction of stroke, followed by 
a focus on PSF. Section 1.1 introduces the definition, epidemiology, and common 
consequences of stroke. Section 1.2 discusses PSF in general, reviewing its 
prevalence, definition, measurement, potential mechanisms, and impacts on life after 
stroke. This section also reviews interventions for fatigue after stroke and in other 
conditions, with a conclusion that psychological interventions are promising 
strategies to treat PSF. Section 1.3 introduces a framework for the development of 




Section 1.1 Overview of stroke 
1.1.1 Definition and types of stroke 
Stroke is defined as “rapidly developed clinical signs of focal (or global) disturbance 
of cerebral function, lasting more than 24 hours or leading to death, with no apparent 
cause other than of vascular origin” (Aho et al., 1980). Stroke occurs when the blood 
flow that supplies the brain is disrupted, resulting in death of brain cells due to the 
lack of oxygen and nutrients. There are two types of stroke, depending on whether 
the brain blood flow is disrupted by the blockage (i.e. ischaemic stroke) or the 
rupture (i.e. haemorrhagic stroke) of a blood vessel. According to the Oxfordshire 
Community Stroke Project (OCSP) in 1980s, ischaemic stroke accounts for 80% of 
all stroke events and haemorrhagic stroke accounts for 15%, with the other 5% of the 
uncertain type (Bamford et al., 1990). A later study (the Oxford Vascular Study, 
OXVASC) with the same general population of the OCSP study reported that of 262 
first-ever incident stroke occurred between 2002 and 2004, 223 (85%) were 
ischaemic stroke, 33 (13%) were haemorrhagic stroke and six (2%) were of the 
unknown type (Rothwell et al., 2004). Similar results were reported in North 
America that, of all stroke events, 87% are ischaemic stroke and 13% are 
haemorrhagic stroke (American Heart Association, 2014). 
Ischaemic stroke 
There are mainly two subtypes of ischaemic stroke: thrombotic stroke (the blood clot 
develops in the brain blood vessel, known as atherosclerosis) and embolic stroke (the 
blood clot develops in other part of the body, usually from carotid arteries or heart, 
and travels through the bloodstream to the brain). In addition, ischaemic stroke can 
be caused by some rare aetiologies such as non-atherosclerotic vasculopathies. 
Furthermore, the stenosis or occlusion of brain blood vessels can occur in either large 
arteries or small arteries, or both. Thus according to the aetiologies, ischaemic stroke 
can be classified to five subtypes: large-artery atherosclerosis, cardioembolism, 
small-vessel occlusion, stroke of other determined aetiology, and stroke of 
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undetermined aetiology, which is known as the TOAST (Trial of Org 10172 in 
Acute Stroke Treatment) classification (Adamas et al., 1993).  
Different blood vessels supply different brain areas, which control different body 
functions. The disruption of blood flow to certain brain area could impair the 
corresponding functions. Thus according to the presenting impairments (i.e. 
symptoms and signs), the OCSP classification suggests four subtypes of ischaemic 
stroke: lacunar infarcts (LACI), total anterior circulation infarcts (TACI), partial 
anterior circulation infarcts (PACI), and posterior circulation infarcts (POCI) 
(Bamford et al., 1991). 
Haemorrhagic stroke 
Haemorrhagic stroke occurs when a blood vessel that supplies the brain ruptures and 
bleeds into the brain. Apart from the death of brain cells due to the lack of oxygen 
and nutrients, the leaking blood can cause pressure and swelling to the surrounding 
brain tissues, which can result in further brain damage. There are two major causes 
of haemorrhagic stroke: intracerebral haemorrhage and subarachnoid haemorrhage. 
Intracerebral haemorrhage is the bleeding of blood vessels within the brain 
parenchyma, of which hypertension is an important risk factor. Subarachnoid 
haemorrhage is the bleeding in the subarachnoid space between the brain 
parenchyma and the membrane that covers it (i.e. arachnoid mater), which is often 
caused by an aneurysm or arteriovenous malformation.  
1.1.2 Epidemiology of stroke 
The World Health Organisation (WHO) estimates that approximately 15 million 
people suffer a stroke worldwide each year (Mackay et al., 2004). Based on the 
findings of the Global Burden of Diseases (GBD) study, it is estimated that 33 
million people had stroke in the year 2010 and 17 million of them were incident 
stroke (Feigin et al., 2014). Despite the difference in the incidence trends of stroke 
across countries, the global burden of stroke continues to increase due to the ageing 
population (Mackay et al., 2004). Over the past few decades, the stroke incidence has 
decreased in high-income countries but increased substantially in low to middle 
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income countries (Feigin et al., 2009). From 1990 to 2010, the absolute number of 
people with incident stroke has increased worldwide , while the mortality rate has 
decreased during this period, resulting in a significant increase (by 84%) of the 
absolute number of stroke survivors (Feigin et al., 2014). It is estimated that the 
global burden of stroke would rise from 38 million disability-adjusted life years 
(DALYs, a measure of overall illness burden, i.e. the number of years lost due to ill-
health, disability, and early death, compared with life expectancy) in 1990 to 61 
million DALYs in 2020 (Mackay et al., 2004). 
1.1.3 Consequences of stroke 
Although the survival rate following stroke has increased, stroke is still the second 
most common cause of death in the world (Lozano et al., 2013). It is estimated that 
stroke caused 6.7 million deaths in 2012 worldwide (World Health Organization, 
2014). Immediate mortality of stroke is high and about 20% of people die within 30 
days following their stroke (Scottish Intercollegiate Guidelines Network, 2010). The 
reported survival rates differ between stroke subtypes: patients who have ischaemic 
stroke have higher survival rates than patients who have haemorrhagic stroke 
(Krishnamurthi et al., 2013); in addition, patients with anterior circulation ischaemic 
stroke have relatively low survival rates by one year after stroke than patients with 
posterior circulation ischaemic stroke (Bamford et al., 1991). The outcome also 
varies across different countries, for example, for both ischaemic and haemorrhagic 
stroke, the survival rates are relatively high in high-income countries than those in 
the countries with lower income (Krishnamurthi et al., 2013).  
The increased number of people with incident stroke and the improved survival rate 
following stroke result in an increase in the number of stroke survivors. Stroke is the 
third most common cause of disability in the world (Murray et al., 2013). The 
American Heart Association suggests classifying clinical outcomes of stroke as 
impairments, functional disabilities, and handicap (American Heart Association, 
1998), which is consistent with the International Classification of Functioning, 
Disability and Health (ICF) (World Health Organization, 2001). Impairments are 
symptoms and signs of underlying pathology of brain damage, which can present as 
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dysfunctions in the following one or more domains: movement, sensory, vision, 
affect, cognition, or language (American Heart Association, 1998). Disabilities are 
the result of functional impairments, presenting as restriction in performing daily 
functional activities. Handicap is the loss of role in daily living and social life 
because of the inability in functional activities. According to the ICF framework 
(World Health Organization, 2001), impact of stroke can be further categorised as 
functioning and disability. Functioning refers to integrity of body functions and 
structures, as well as adequate performance in activities and participation; disability 
refers to having problems in any of these domains, i.e. functional impairments, 
activity limitations, or participation restrictions. This framework also considers the 
external (i.e. environmental factors) and internal (i.e. personal factors) factors that 
influence functioning and disability (World Health Organization, 2001).  
A stroke may result in impairments in all aspects of body functions (American Heart 
Association, 1998). Symptoms of stroke vary from person to person based on the size 
and location of stroke lesions. Dysfunctions following stroke correspond to the 
responsible brain areas that have been damaged. When brain cells in a certain area 
are damaged by a stroke, the function controlled by this area may be impaired. For 
example, anterior circulation stroke can be characterised by higher cerebral 
dysfunctions such as dysphasia and visuospatial disorders, and posterior circulation 
stroke can be characterised by symptoms of cerebellar dysfunctions and the damage 
in brainstem can affect vital functions such as breathing. Lesion size is a determinant 
of the severity of stroke symptoms. A mild stroke may only cause limb weakness, 
whilst a severe stroke can result in paralysis or even death. Although activities and 
participation may be primarily limited by functional impairments, other factors such 
as emotions (personal factors) and social relationships (environmental factors) may 
also play roles in affecting functional abilities. 
Although the location and size of stroke lesions are important determinants of stroke 
symptoms, some people with pathological brain lesions do not have stroke 
symptoms. For example, research studies reported that 8% to 28% of the general 
population had brain infarcts on Magnetic Resonance Imaging (MRI) but did not 
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have any history of stroke symptoms (Vermeer et al., 2007). In contrast, about 30% 
of patients with symptomatic lacunar stroke syndromes did not have any visible 
subcortical infarct on MRI (Doubal et al., 2011). 
In general, stroke has multi-level and diverse impacts on individuals, from body 
functioning (impairments), independence in daily activities (disabilities), to roles in 
participating in family and social life (handicap), and involves personal factors and 
relationships with other people. Taking account these factors, clinical guidelines 
recommend that rehabilitation of stroke should target the individual needs of stroke 
patients, and aim to maximise the individual’s activity, participation and quality of 




Section 1.2 Post-stroke fatigue 
In the United Kingdom (UK), about 150,000 incident strokes occur each year and 
there are 1.2 million stroke survivors (Stroke Association, 2015). Stroke is the 
leading cause of adult disability and approximately half of all stroke survivors have a 
disability and more than one third of stroke survivors are dependent on others (Stroke 
Association, 2015). Of the wide range of symptoms experienced after stroke, fatigue 
is one of the most common and debilitating problems. In 2011, a UK-based James 
Lind Alliance survey was conducted with stroke patients, their caregivers and stroke-
related health professionals, which reported that ‘how to manage fatigue’ was ranked 
among the top ten research priorities of all 226 unique unanswered treatment 
uncertainties relating to life after stroke (Pollock et al., 2012).  
This section outlines a comprehensive account of PSF, including its prevalence, 
definition, measurement, potential mechanisms, impacts on life, and treatment 
interventions. This section is based on a systematic review of studies of PSF 
published previously (Wu et al., 2015b), with an updated search of the recent 
literature. Although briefly introduced in this section, the natural history and clinical 
correlates of PSF will be discussed in detail in the next chapter, as they provided the 
theoretical basis for the development of the psychological intervention for PSF 
described in this thesis.  
1.2.1 Prevalence of post-stroke fatigue 
Fatigue is ubiquitous but is more common and more severe in people with acute and 
chronic conditions, including stroke. Observational studies reported that the 
prevalence of self-reported fatigue in stroke patients could be twice or more as high 
as that in general controls (Ingles et al., 1999, van der Werf et al., 2001, Naess et al., 
2005, Christensen et al., 2008, Smith et al., 2008). In addition, some patients reported 
that their fatigue after stroke was different from the fatigue that they had experienced 
prior to their stroke, because of its persistent presence and negative impacts on daily 
life (Barbour and Mead, 2011). PSF is often present early after stroke and tends to be 
persistent in some stroke patients (Duncan et al., 2012). The reported proportion of 
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patients with fatigue after stroke ranges from 23% to 75% (Choi-Kwon and Kim, 
2011). The variation in proportion reflects the heterogeneity in the studied 
populations, time since stroke, and assessment methods of PSF.  
1.2.2 Definition of post-stroke fatigue 
The perception of fatigue is subjective (Chalder et al., 1993). Many different 
synonyms have been used in clinical practice and research studies to describe the 
feeling of fatigue, such as tiredness, exhaustion, weariness, drowsiness, lassitude, 
asthenia, boredom, sleepiness, lethargy, low vitality, and lack of energy or 
motivation. This diversity in terminology reflects that fatigue is a complex 
phenomenon, which can be defined from different perspectives.   
Some researchers distinguish between ‘physiological fatigue’ (i.e. a state of general 
tiredness that is the result of excessive physical and/or mental activities, and can be 
improved after rest) and ‘pathological fatigue’ (i.e. a constant state of weariness that 
is unrelated to previous activity levels, and is usually not improved by rest) (de Groot 
et al., 2003). Physiological fatigue is a normal experience in daily life, usually with a 
single, readily identifiable cause and characterised as acute (i.e. with rapid onset and 
short duration), whilst pathological fatigue is perceived as abnormal or excessive, 
usually with multiple or unknown causes and characterised as chronic (i.e. with 
persistent presence) (de Groot et al., 2003). In neurological disorders such as stroke, 
fatigue can occur during the acute phase and persist to the chronic phase, and the 
persistent fatigue is usually considered pathological, which is of interest in this 
thesis. 
Persistent fatigue after stroke (i.e. PSF) is different from the feeling of tiredness 
triggered by sustained physical activity. Tseng and colleagues found that aerobic 
fitness was the only independent predictor of the level of fatigue immediately after 
physical exercise, whereas depression was the only independent predictor of chronic 
fatigue in stroke patients (Tseng et al., 2010). In addition, the presentation of PSF is 
not limited in the physical domain. In qualitative studies, stroke patients described 
their fatigue as “a general feeling of tiredness”, “a tiredness in the muscles”, or 
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“mental tiredness” (Barbour and Mead, 2011). Thus the concept of PSF should 
encompass physical as well as mental fatigue. To identify fatigue that matters to 
stroke patients and warrants clinical assessment and treatment, Lynch and colleagues 
developed a case definition for PSF, which reads “over the past month, there has 
been at least a 2-week period when the patient has experienced fatigue, a lack of 
energy, or an increased need to rest every day or nearly every day. This fatigue has 
led to difficulty taking part in everyday activities” (Lynch et al., 2007). This 
definition describes fatigue as a feeling of lack of energy or need to rest rather than 
lack of motivation, boredom, or sleepiness (Lynch et al., 2007). Also it reflects the 
chronic nature of PSF and emphasises its impact on everyday activities, both 
physical and mental. 
Our understanding of the causes of PSF is limited. Fatigue can be classified as 
‘primary’ if it is present in the absence of any obvious causes apart from stroke itself, 
or ‘secondary’ if it develops in relation to any other comorbidities (e.g. depression, 
anaemia, or hypothyroidism) or the use of certain medications (e.g. beta-blockers, 
antidepressants, or anticonvulsants) (Kutlubaev et al., 2015). Also it can be divided 
into ‘somatic fatigue’ if related to organic diseases, ‘psychological fatigue’ if 
associated with poor motivation, ‘physical fatigue’ if occurring after muscular 
exertion, and ‘mental fatigue’ if appearing with cognitively demanding tasks (Staub 
and Bogousslavsky, 2001b). However, these subtypes are not mutually exclusive and 
there is little empirical evidence for the concept of these subtypes from stroke studies 
(Hackett et al., 2014).  
Considering the pathophysiology, fatigue in neurological disorders can be classified 
as ‘central fatigue’ and ‘peripheral fatigue’ (Chaudhuri and Behan, 2004). Central 
fatigue is a subjective sense of fatigue perceived at the level of central nervous 
system, which is due to the failure of signal transmission in the central nervous 
system during the physical and/or mental activities. Peripheral fatigue refers to 
muscle weakness (i.e. fatigability) due to disorders of muscle and/or neuromuscular 
junction. However, the pathophysiological mechanism of fatigue in stroke patients is 
underinvestigated, which was recently reported in a small study with 70 stroke 
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patients that the reduced motor cortex excitability was associated with higher levels 
of fatigue after stroke (Kuppuswamy et al., 2015). No study has explored the 
peripheral mechanisms of PSF and yet the association between the subjective sense 
of fatigue and muscle weakness is unknown. 
1.2.3 Measurement of post-stroke fatigue 
Self-reported fatigue scales 
Clinical assessment of fatigue often relies on patients’ subjective reporting. A 
number of structured self-report scales have been used to assess the presence or 
severity of fatigue in stroke patients. However, these scales, which are usually 
devised in non-stroke populations, may lack validity in patients with stroke. Among 
over one hundred fatigue scales that have been used in research studies (Egerton et 
al., 2015), only 11 (as far as I am aware) have been specifically tested for their 
psychometric properties in stroke populations (see Table 1.1). Other scales were 
frequently used in stroke studies but their psychometric properties have not been 
established in stroke populations (see Table 1.2). Some of these scales are 
multidimensional scales, reflecting the multidimensional nature of PSF that may 
involve physical, cognitive, psychological, and behavioural components. However, 
there is no distinct boundary between different subtypes of fatigue. Due to complex 
interactions between physical and mental elements in completing tasks in daily life, it 
is difficult to separate these elements. 
Table 1.1 summarises the scales that have been specifically tested for their 
psychometric properties in measuring fatigue in stroke patients. Although all of these 
scales showed satisfactory results of the tested psychometric properties, none of them 
satisfied all criteria for assessing the quality of self-report scales (i.e. reliability, 
validity, responsiveness, and interpretability (Mokkink et al., 2010)). Furthermore, it 
is difficult to determine the criterion validity of these scales, as there is no generally 
accepted definition of PSF.  
With an aim to identify a fatigue scale that is most valid, feasible, and reliable in 
stroke patients, Mead and colleagues reviewed fatigue scales used in research studies 
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(Mead et al., 2007). They identified five scales with best face validity as these 
captured the phenomenon of PSF and was free from items indistinguishable from the 
effects of stroke. Of these five scales, the Brief Fatigue Inventory (Mendoza et al., 
1999) was excluded for further analysis after the initial selection because some 
stroke patients had difficulty in completing this scale (i.e. poor feasibility in stroke 
patients). The other four scales showed moderate to good test-retest reliability and 
good inter-rater reliability in measuring fatigue in stroke patients. These four scales 
were the Fatigue Assessment Scale (FAS) (Michielsen et al., 2003), the fatigue 
subscale of the Profile of Mood States (POMS-fatigue) (McNair and Lorr, 1964), the 
general subscale of the Multidimensional Fatigue Symptom Inventory (MFSI-
general) (Stein et al., 1998), and the vitality subscale of the Short Form-36 version 
2.0 (SF-36 v2-vitality) (Jenkinson et al., 1999). In addition, these four scales showed 
good convergent validity against each other, which reflects the common or similar 
items they share. Mead and colleagues recommended using the FAS to measure PSF 
as it had good feasibility in stroke patients, best test-retest reliability and high 
convergent validity as compared to the other three scales (Mead et al., 2007). 
Although the internal consistency of the FAS was low in this study, this might be due 
to that the FAS measures both physical and mental aspects of fatigue (Mead et al., 
2007). 
Fatigue Assessment Scale 
Considering its good feasibility, validity, and reliability in measuring fatigue in 
stroke patients (Mead et al., 2007), I used the FAS to assess fatigue severity in this 
thesis. Another reason for choosing this scale was that it measures not only patients’ 
subjective feelings but also the impact of fatigue on daily life. I did not use fatigue 
scales that only measure subjective feelings (see Table 1.1), as focusing on fatigue 
itself would make patients feel worse. Although the Fatigue Severity Scale (FSS) 
(Krupp et al., 1989) is the most commonly used fatigue scale in research studies, I 
did not use it because it does not contain any item related to the mental aspect of 
fatigue, which is a common presentation of PSF.  
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The FAS has items for both physical (e.g. ‘physically, I feel exhausted’) and mental 
(e.g. ‘I have problems thinking clearly’) aspects of fatigue, whilst it still has good 
unidimensionality in measuring fatigue severity as indicated by the exploratory 
factor analysis that the FAS showed a unique factor on the scree plot (Michielsen et 
al., 2003). In addition, the FAS has good divergent validity against depression. The 
principal component analysis on a combined pool of items from the FAS and 
depression scales showed a two-factor construct in both the health working 
population (Michielsen et al., 2003) and the stroke population (Smith et al., 2008). 
This psychometric property is important for the FAS to be used in this thesis. Fatigue 
is often confounded by depressive symptoms but the current study was not intended 
to target patients with severe depression, thus a fatigue scale that has good divergent 
validity against depression (i.e. FAS) is preferable as it would help to identify 
patients with fatigue that is not because of depression.  
Case definition of post-stroke fatigue 
‘Clinically significant’ fatigue is usually defined by certain cut-off scores of fatigue 
scales. However, dichotomising patients on the basis of a single cut-off score does 
not fully characterise fatigue. To identify fatigue that matters to stroke patients and 
warrants clinical assessment and treatment, Lynch and colleagues developed a case 
definition of PSF (which I have introduced in Section 1.2.2) (Lynch et al., 2007). 
This case definition showed good test-retest and inter-rater reliability in identifying 
the clinically significant fatigue with a mixture of 55 stroke patients from hospital 
and community (36% met the case definition) and also good convergent validity with 
other four fatigue scales including the FAS (Lynch et al., 2007). I used this case 
definition in this thesis as a dichotomous measure (i.e. for the presence or absence) 
for clinically significant fatigue in stroke patients. 
A screening question for post-stroke fatigue 
Although the case definition is a good measure for the clinically significant fatigue, it 
may be too strict to be used as a screening tool for PSF because it has specific 
requirements for the frequency and duration of fatigue. The Greater Manchester 
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Stroke Assessment Tool (GM-SAT) is a feasible tool to assess the unmet needs of 
community-dwelling stroke patients, which covers 35 common problems after stroke 
(Rothwell et al., 2013). In a survey using the GM-SAT to assess the needs of 137 
stroke patients who were six months after stroke, fatigue was identified as the most 
frequent (34%) unmet need among all 35 proposed problems, by a single question 
‘Do you feel tired all the time or get tired very quickly since your stroke?’ (Rothwell 
et al., 2013). This is consistent with the proportion of stroke patients with PSF (33%) 
as identified by the PSF case definition in a longitudinal cohort study (Duncan et al., 




Table 1.1 Fatigue scales specifically developed or validated in stroke populations 
Fatigue scales Constructs assessed No. of 
items 
Validation studies  
(No. of stroke patients) 
Validated 
language version 
Unidimensional (sub)scales     
Fatigue Severity Scale-9 (FSS-9) Fatigue feeling and impact 9 Valko 2008 (n=235) (Valko et al., 2008) German 
   Lerdal 2011 (n=119) (Lerdal et al., 2009) Norwegian 
Fatigue Severity Scale-7 (FSS-7) Fatigue feeling and impact 7 Lerdal 2011 (n=119) (Lerdal et al., 2009) Norwegian 
Fatigue Assessment Scale (FAS) Fatigue feeling and impact 10 Mead 2007 (n=55) (Mead et al., 2007) English 
Fatigue subscale of Profile of Mood States 
(POMS-fatigue) 
Fatigue feeling 7 Mead 2007 (n=55) (Mead et al., 2007) English 
General subscale of Multidimensional Fatigue 
Symptom Inventory (MFSI-general) 
Fatigue feeling 6 Mead 2007 (n=55) (Mead et al., 2007) English 
Vitality subscale of Short Form-36 version 2.0 
(SF-36v2-vitality) 
Fatigue feeling 4 Mead 2007 (n=55) (Mead et al., 2007) English 
Brief Fatigue Inventory (BFI) Fatigue feeling and impact 9 Mead 2007 (n=55) (Mead et al., 2007) English 
Fatigue subscale of Newcastle Stroke-specific 
Quality of Life (NEWSQOL-fatigue) 
Fatigue feeling and impact 3 Buck 2004 (n=106) (Buck et al., 2004) English 
Fatigue subscale of Functional Assessment of 
Chronic Illness Therapy (FACIT-fatigue) 
Fatigue feeling and impact  13 Butt 2013 (n=51) (Butt et al., 2013) English 
Multidimensional scales     
Neurological Fatigue Index for Stroke (NFI-
stroke) 
 
Physical symptoms, cognitive 
symptoms, responsiveness to 
rest/sleep, and sleep 
22 Mills 2012 (n=282) (Mills et al., 2012) English 
Mental Fatigue Scale (MFS) Affective, cognitive and sensory 
symptoms, duration of sleep, and 
daytime variation in symptoms 
severity 





Table 1.2 Fatigue scales used in stroke studies without being previously investigated for psychometric properties in stroke populations 
Fatigue scales Domains assessed No. of items Original target populations Examples of stroke studies 
using the scale 
Single question for fatigue Unidimensional: presence of 
fatigue 
1 Different versions (Appelros, 2006, Glader et 
al., 2002) 
Visual Analogue Scale for 
Fatigue (VAS-fatigue) 
Unidimensional: fatigue severity 1 Different versions (Choi-Kwon et al., 2007, 
Michael et al., 2006) 
Fatigue subscale of Checklist 
Individual Strength (CIS-fatigue) 
Unidimensional: fatigue severity 8 Chronic fatigue syndrome (Vercoulen et 
al., 1994) 
(van der Werf et al., 2001, 
Zedlitz et al., 2012) 
Chalder Fatigue Scale (CFS)  Physical symptoms 
Mental symptoms 
11 Patients in general hospitals and health 
controls (Chalder et al., 1993) 








20 Cancer (Smets et al., 1995) (Christensen et al., 2008, 
Andersen et al., 2012) 
Fatigue Scale for Motor and 
Cognitive Functions (FSMC)  
Cognitive fatigue 
Motor fatigue 
20 Multiple sclerosis (Penner et al., 2009) (Hubacher et al., 2012) 




Consequences of fatigue 
Responsiveness to rest/sleep 
29 Mixed clinical groups (multiple sclerosis, 
chronic fatigue, Lyme disease, lupus, and 
dysthymia) and health controls  
(Schwartz et al., 1993) 
(Brioschi et al., 2009, 
Radman et al., 2012) 
Fatigue Impact Scale (FIS)  Cognitive functioning 
Physical functioning 
Psychosocial functioning 
40 Chronic fatigue syndrome, multiple 
sclerosis and hypertension (Fisk et al., 
1994) 
(Ingles et al., 1999, Jaracz et 
al., 2007, Parks et al., 2012) 
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1.2.4 Mechanisms of post-stroke fatigue 
Mechanisms of PSF are unclear. Qualitative studies reported that PSF might be 
triggered by factors that occur at the time of stroke (e.g. the stroke lesion or 
admission to hospital) and then be exacerbated by behavioural changes such as poor 
sleep and boredom (Barbour and Mead, 2011). Observational studies suggested that 
the development of PSF involved an interaction of biological, psychological, 
behavioural and environmental factors (Chaudhuri and Behan, 2004). Our 
understanding of how PSF develops is mainly based on potential associations rather 
than definite causal relationships. To identify clinical factors that are associated with 
PSF, I conducted a systematic review of observational studies of PSF. Drawing on 
the literature, I developed a conceptual model of PSF, which illustrates the 
development of PSF as a temporal process that involves a mixture of pre-existing 
factors, stroke-specific impairments, and co-existing conditions (Wu et al., 2015b). 
Of these factors, some are shown as predictors of PSF in longitudinal studies, such as 
depressive symptoms (Wu et al., 2014b) and reduced physical activity (Duncan et al., 
2015). In addition, some associated factors, such as reduced physical activity and 
sleeping problems, are modifiable. Thus management of these psychological and 
behavioural factors may help to reduce the impact of PSF on daily life. (The 
systematic review of observational studies of PSF and the model of PSF will be 
discussed in detail in Chapter 2) 
1.2.5 Impact of post-stroke fatigue 
Fatigue is a common and detrimental problem for stroke patients. In a study with 90 
stroke patients who were at least one year after stroke, 50% of patients reported 
fatigue as their main complaint following stroke (van der Werf et al., 2001). 
Similarly, in another study with 88 stroke patients between three and 13 months after 
stroke, 40% of patients reported fatigue as the, or one of the worst, sequelae of their 
stroke, and 68% of them attributed their functional limitations to fatigue (Ingles et 
al., 1999). A population-based study found that, at two years after stroke, the 
presence of PSF was associated with being dependent on other people in daily living, 
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higher risk of institutionalisation, and having a poorer self-perception of general 
health (Glader et al., 2002). In addition, fatigued patients had a higher mortality rate 
at follow-up than those without fatigue (Glader et al., 2002) and a higher level of 
fatigue was associated with shorter subsequent survival (Mead et al., 2011).  
PSF may be present as an “on and off” feeling in some patients but in others it is a 
feeling of tiredness “nearly every day” (White et al., 2012). Some researchers 
reported that the impact of PSF on daily living was more severe on physical domain 
as compared with cognitive or psychosocial domains (Choi-Kwon et al., 2005), 
whilst in the clinical practice we have observed that some stroke patients, who were 
physically active, reported their fatigue to be characterised by problems with 
concentration and thinking. 
PSF impedes patients’ participation in daily activities and stroke rehabilitation 
(Michael, 2002). In a qualitative study of the consequences of living with PSF, 
patients attributed their limitations in carrying out activities to fatigue (Carlsson et 
al., 2004). A small study suggested that fatigue was related to mobility deficits and 
cardiovascular deconditioning and resulted in the reduced ambulatory activities in 
daily living (Michael et al., 2006). Cross-sectional studies found that PSF was 
associated with patient-perceived disability (van der Werf et al., 2001, Appelros, 
2006). Another study found that higher fatigue scores were associated with poorer 
performance in activities in daily living (ADLs) (Chen et al., 2015). In a pilot study 
with 20 stroke patients, physiotherapists reported that six patients had been limited 
by their fatigue to participate in rehabilitation sessions (Morley et al., 2005). In 
addition, stroke patients with PSF had a lower rate of returning to work and more 
deductions in work load at two years after stroke than non-fatigued stroke patients 
(Pihlaja et al., 2014). 
PSF is associated with profound deterioration of several aspects of life after stroke. 
Cross-sectional studies found that fatigue scores were negatively associated with 
total scores of the Stroke-specific Quality of Life (SSQOL) (Chen et al., 2015) as 
well as scores on all of its subscales (including physical, cognitive, emotional, and 
social domains) (Visser-Meily et al., 2009). Similar results were reported by studies 
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that assessed quality of life using the Short Form-36 (SF-36). One study found that 
higher fatigue scores were associated with lower scores on all subscales of the SF-36, 
including physical functioning, physical role, mental health, emotional role, vitality, 
bodily pain, social functioning, and general health (Tang et al., 2010b). However, 
another study found associations between PSF and all subscales of SF-36 except for 
emotional role (Naess et al., 2006), whilst the third study reported that poorer 
outcomes of both mental health and emotional role function were associated with 
increased fatigue in stroke patients (Mead et al., 2011). Furthermore, a longitudinal 
study found significant cross-sectional associations between fatigue and both 
physical and mental health as assessed by the SF-36, at both acute phase and 18 
months after stroke; and acute phase fatigue was an independent predictor for poor 
physical health at 18 months (Lerdal and Gay, 2013). 
Fatigue could be present in patients with minor stroke (Carlsson et al., 2003) or those 
having made good neurological recovery (Powell et al., 2004). Some researchers 
proposed that fatigue could be a particularly salient problem in stroke patients with 
minor or no physical impairment (Ingles et al., 1999); this might be because of the 
relative lack of other sequelae of stroke, and that patients with subtle disability would 
have higher expectation for full recovery and attempt to take part in more activities 
in daily life (de Groot et al., 2003). 
1.2.6 Treatment for fatigue after stroke and in other conditions 
Cochrane review of interventions for post-stroke fatigue 
Despite its high prevalence and detrimental consequences, little research has been 
carried out to develop effective treatments for PSF. A Cochrane review of 
interventions for post-stroke fatigue, which was published in 2009, concluded that 
there was insufficient evidence to inform the management of PSF (McGeough et al., 
2009). 
This Cochrane review included three completed RCTs which investigated the 
efficacy of interventions in stroke patients and measured fatigue as an outcome. One 
trial recruited 83 stroke patients with self-reported fatigue and randomised them to 
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receive either fluoxetine or placebo 20 mg daily for three months. After correcting 
for the effect of baseline fatigue severity, there was no difference in fatigue severity 
between groups at either three months or six months after the start of treatment 
(Choi-Kwon et al., 2007). The second trial recruited 31 women patients with 
subarachnoid haemorrhage and randomised them to receive either tirilazad mesylate 
or placebo 150 mg daily for 10 consecutive days after the onset of subarachnoid 
haemorrhage. Of 18 patients available for neuropsychological tests three months 
later, the tirilazad group had lower percentage of patients with fatigue than that in the 
placebo group (Ogden et al., 1998). The third trial investigated a Chronic Disease 
Self-management Programme (CDSMP) in 1140 patients with chronic diseases, of 
whom 125 were stroke patients. Patients were randomised to either the immediate 
treatment group (who immediately received seven weekly sessions of the CDSMP 
after randomisation) or the wait-list group (who received the CDSMP six months 
after randomisation). Fatigue scores were assessed at baseline and at six months, and 
mean changes of scores were calculated for each group. In the subgroup of 125 
stroke patients, there was no significant between-group difference in the change of 
fatigue scores (Lorig et al., 2001).  
This Cochrane review also identified two ongoing trials (McGeough et al., 2009). 
One trial investigated the continuous positive airway pressure (CPAP) for stroke 
patients with sleep-disordered breathing. This trial was terminated due to the poor 
recruitment. The interim results suggested no difference in fatigue scores after 
treatment between the active treatment group and the sham group (Brown et al., 
2013). The other ongoing trial was completed and published in 2012, in which 83 
stroke patients with fatigue were randomised to receive either a group-based 
cognitive treatment or the cognitive treatment plus graded activity training 
(COGRAT) for 12 weeks (Zedlitz et al., 2012). Fatigue scores were decreased 
significantly from before treatment to immediately after treatment in both groups, but 
changes of scores were not significantly different between groups. At six-month 
follow-up, the COGRAT group showed better clinically relevant improvement (i.e. 
higher proportion of patients with a decrease of CIS-fatigue ≥ 8 points) in fatigue 
than the cognitive treatment group (Zedlitz et al., 2012). This trial suggested that 
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both cognitive treatment and physical training are feasible with stroke patients and 
are promising to treat fatigue, and COGRAT is better than cognitive treatment alone. 
However, this trial did not have a ‘usual care’ arm thus the specific efficacy of either 
cognitive treatment or physical training is unknown. 
Clinical management of post-stroke fatigue 
Although some clinical guidelines for stroke management have incorporated a 
section for PSF, there is insufficient evidence to recommend any specific strategies 
for its management. The UK national clinical guideline for stroke (2012) offers two 
recommendations: fatigue should be assessed in medically stable patients, and 
fatigued patients should be given information and reassured that the symptom is 
likely to improve with time (Intercollegiate Stroke Working Party, 2012). The 
Canadian Stroke Best Practices (2015) also recommends the routine assessment of 
fatigue in stroke patients and providing information for fatigue education (Heart 
Stroke Foundation Canada, 2015). In addition, the Canadian guideline suggests a 
number of strategies to manage PSF, which include treatment of co-morbid 
conditions that could cause fatigue (e.g. mood disorders and sleep disorders), 
prioritising daily activities, exercise scheduling, sleep hygiene, communication with 
other people, and care by health professionals with knowledge of PSF (Heart Stroke 
Foundation Canada, 2015). However, these recommendations are all based on the 
level C evidence, that is, determined by the writing group consensus and supported 
by limited research evidence (Heart Stroke Foundation Canada, 2015). In addition, 
both the UK and Canadian guidelines suggest that there is insufficient evidence to 
recommend specific pharmacological treatment for PSF (Intercollegiate Stroke 
Working Party, 2012, Heart Stroke Foundation Canada, 2015). 
Psychological interventions for fatigue in other conditions 
Given that little evidence is available from stroke research to guide the treatment of 
PSF, interventions used to treat fatigue in other conditions may be informative. The 
UK National Institute for Health and Care Excellence (NICE) has recommended the 
cognitive behavioural therapy (CBT) and the graded exercise training for the 
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management of chronic fatigue syndrome (National Institute for Health and Care 
Excellence, 2007). This recommendation is further supported by a multicentre RCT, 
which found that both CBT and graded exercise training were effective in improving 
outcomes of chronic fatigue syndrome as compared to the specialist medical care 
(White et al., 2011). Furthermore, this RCT demonstrated that, compared with 
graded exercise training and specialist medical care, CBT was the most cost-effective 
strategy in managing chronic fatigue syndrome (McCrone et al., 2012). CBT is a 
type of psychological interventions that targeting people’s thoughts and behaviours, 
which is also effective in treating fatigue in patients with cancer (Armes et al., 2007) 
and multiple sclerosis (Thomas et al., 2013). Patients with PSF have some 
psychosocial characteristics comparable to patients with chronic fatigue syndrome, 
cancer, and multiple sclerosis, such as lower self-efficacy, maladaptive coping 
patterns, and lower social support (Zedlitz et al., 2011). Therefore, psychological 
interventions are promising strategies to treat PSF. 
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Section 1.3 Aim and objectives of the thesis 
Aim 
The aim of this PhD study was to develop a psychological intervention for PSF and 
to evaluate its feasibility in stroke patients in the UK National Health System (NHS). 
Psychological interventions are complex interventions that consist of multiple 
therapeutic components. The UK Medical Research Council (MRC) has proposed a 
framework for the development and evaluation of complex interventions (Figure 
1.1), illustrating a phased process from identifying the evidence to long-term 
implementation, which is analogue to the four-phased drug development (Campbell 
et al., 2000, Craig et al., 2008a). This framework suggests that the early stages of 
identifying theory, modelling and piloting should be taken as an iterative activity 
(Campbell et al., 2007), which is the focus of this thesis. The framework also 
suggests that complex interventions may work best if they are tailored to local 
contexts (Craig et al., 2013). Therefore, although a number of psychological 
interventions have shown to be effective in reducing fatigue in other conditions 
(Armes et al., 2007, Thomas et al., 2013, White et al., 2011), they need to be adapted 









Figure 1.1 Key elements of the design and evaluation of complex interventions 
(Craig et al., 2008a) 
Feasibility/piloting 
 Testing procedures 
 Estimating recruitment/retention 
 Determining sample size 
Development 
 Identifying the evidence base 
 Identifying/developing theory 
 Modelling process and outcomes 
Evaluation 
 Assessing effectiveness 
 Understanding change process 
 Assessing cost-effectiveness 
Implementation 
 Dissemination 
 Surveillance and monitoring 




This chapter has provided an overview of PSF. I started with an introduction of 
stroke, and then focused on PSF, which is a common symptom after stroke. I have 
covered the following topics in this chapter: 
 Section 1.1 Overview of stroke: definition, epidemiology, and consequences 
 Section 1.2 Introduction of post-stroke fatigue: prevalence, definition, 
measurement, potential mechanisms, impacts on life after stroke, and 
interventions for fatigue after stroke and in other conditions 
 Section 1.3 Aim and objectives of this thesis 
In the following chapters of this thesis, I will describe how I developed a 
psychological intervention for PSF, from identifying evidence, developing treatment 
rationale, modelling intervention, testing feasibility, updating evidence, to refining 
intervention. This was an evidenced-based process following the MRC framework of 
developing complex interventions (Craig et al., 2008a). It is important to note that 
this development process is not a linear but an iterative approach, although it will be 
described in a linear pattern in the subsequent chapters.  
The objectives of each chapter of this thesis are: 
 Chapter 1: to provide an overview of stroke and post-stroke fatigue 
 Chapter 2: to identify evidence to justify the choice of a psychological 
intervention and identify intervention targets 
 Chapter 3: to develop the treatment rationale and design the intervention 
programme 
 Chapter 4: to assess the feasibility of the intervention and study process 
 Chapter 5: to update knowledge of interventions for post-stroke fatigue 
 Chapter 6: to discuss the clinical implication of the current study and 
directions for future research 
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CHAPTER II: Theoretical Basis of a Psychological 
Intervention for Post-stroke Fatigue 
In Chapter 1, I provided a general introduction of PSF. In brief, fatigue is a common 
and chronic problem in stroke patients. PSF has negative associations with stroke 
recovery and quality of life after stroke. Our understanding of its mechanisms is 
mainly based on potential associations, but the causal mechanisms of PSF are 
unknown. Despite its high prevalence, there is insufficient evidence to recommend 
any intervention for the treatment of PSF (McGeough et al., 2009). Psychological 
interventions are effective in reducing fatigue in conditions other than stroke, such as 
cancer (Armes et al., 2007), multiple sclerosis (Thomas et al., 2013), and chronic 
fatigue syndrome (White et al., 2011). As patients with PSF share some psychosocial 
characteristics with patients of these other conditions (Zedlitz et al., 2011), 
psychological interventions may be also effective to treat fatigue in stroke patients. 
Therefore, the aim of this thesis was to develop a psychological intervention for PSF. 
This chapter is the initial stage of the intervention development, which aims to 
explore the evidence to justify the choice of the contents of a psychological 
intervention for PSF. In this chapter, I begin with a literature review of observational 
studies of PSF on its natural history (Section 2.1) and clinical correlates (Section 
2.2), and then focus on psychological associations of PSF (Section 2.3). Drawing on 
the evidence from literature, I propose a conceptual model for understanding PSF 
(Section 2.4). This model suggests that the development of PSF is a temporal process 
and involves interactions of various biological, psychological, and behavioural 
factors. Although it is unclear whether these relationships are causal, many of these 
psychological and behavioural factors have bidirectional associations with PSF and 
are usually modifiable. Thus a psychological intervention targeting these 
psychological and behavioural factors is a promising approach to treat PSF. 
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Section 2.1 Natural history of post-stroke fatigue 
2.1.1 Fatigue, an early and chronic problem after stroke 
Fatigue is common immediately after stroke. In a qualitative study exploring the 
experience of PSF in 31 community-dwelling stroke patients, all patients reported 
that their fatigue first became evident during the hospital admission (White et al., 
2012). In another study that recruited 220 patients who were between three and 27 
months after stroke, 125 (57%) had self-reported PSF; of these fatigued patients, 
77% reported that their fatigue started within the first week after stroke (Choi-Kwon 
et al., 2005). Similarly, in observational studies that investigated the presence of 
fatigue within the first two weeks after stroke, more than one third (30% to 60%) of 
stroke patients had fatigue at this early stage (Christensen et al., 2008, Lerdal et al., 
2011, Chen et al., 2015, Wu et al., 2014a). Emerging early after stroke, fatigue is also 
common at the chronic stage after stroke. The longest research observation of PSF 
was reported in a Dutch study, which found that fatigue was present in 41% of 325 
patients at a mean follow-up of 9.8 years after stroke (Maaijwee et al., 2014).  
If PSF is a persistent problem rather than a transitory phenomenon, this will justify 
the development of interventions to manage it. Also a better understanding of natural 
history of PSF will allow clinicians and researchers to determine the optimum timing 
for intervention delivery. Therefore, I updated a systematic review of natural history 
of PSF (Duncan et al., 2012), by searching for longitudinal studies that investigated 
the presence of fatigue at more than one time point after stroke. Through the updated 
search, I identified four new studies (Duncan et al., 2014, Radman et al., 2012, van 
Eijsden et al., 2011, Pihlaja et al., 2014) in addition to the nine studies included in the 
previous review, making a total of 13 longitudinal cohort studies included.  
Table 2.1 summarises these 13 longitudinal studies, by presenting proportions of 
patients with PSF at each assessment time point. Of these studies, the observational 
period of PSF ranges from within the first 10 days to three years after stroke. 
Although the estimates of prevalence vary according to the participant 
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characteristics, time since stroke and assessment methods of PSF, the general pattern 
of fatigue prevalence is consistent across studies. A considerable proportion of stroke 
patients (25% to 59%) had fatigue at the initial assessment, which was usually within 
the first few months after stroke. Also, in most studies, more than one third of 
patients had fatigue at a later assessment, which was usually at one year or later after 
stroke. In summary, fatigue is common at the acute phase as well as the chronic 
phase after stroke. 
Attrition is a common problem in longitudinal studies. According to how the attrition 
data were managed, these 13 studies listed in Table 2.1 can be categorised into two 
groups. The first group (i.e. the first eight studies in Table 2.1) analysed and reported 
the data of patients who completed all assessments (Schepers et al., 2006, Snaphaan 
et al., 2011, van Eijsden et al., 2011, Pihlaja et al., 2014, van de Port et al., 2007, 
Sisson, 1995, Christensen et al., 2008, Duncan et al., 2014). These studies 
investigated the time course of PSF (i.e. changes of proportions or severity of fatigue 
over time), which I will discuss shortly in this section (in Subsection 2.1.2). The 
second group (i.e. the remaining five studies in Table 2.1) calculated proportions of 
patients with PSF at each assessment based on different numbers of patients at 
different assessment time points (Radman et al., 2012, Hellawell et al., 1999, Noble 
et al., 2008, Ogden et al., 1994, Skaner et al., 2007). For these five studies, it is 
difficult to interpret their results of the comparison of fatigue severity or proportions 
of patients with fatigue between different time points in individual studies, because 
the number of patients changed over time and the reasons for dropouts were not 
reported. If the dropouts were associated with more severe fatigue, the reported 
prevalence of PSF at follow-up might have been underestimated, as it was based on 
patients retained in the study (i.e. those who had less severe fatigue). Thus, I will not 
discuss the time course of PSF in these five studies, although the initial assessment of 
PSF in these studies could have provided useful information of the incidence of PSF.
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Table 2.1 Numbers and proportions of stroke patients with post-stroke fatigue (PSF) at different time points after stroke 
Studies 
(fatigue measures) 
Number of patients with PSF/total number of patients (proportions of patients with PSF) 
10 days 1 month 2 months 3 months 6 months 1 year 18 months 2 years 3 years 
(Christensen et al., 
2008) (MFI-20 general) 
81/138 
(59%) 
  61/138 (44%)  52/138 (38%)  55/138 (40%)  
(Sisson, 1995)  
(Single question) 
 12/13 (92%)   11/13 (85%)     
(Schepers et al., 2006) 
(FSS) 
 86/167 (52%)   107/167 (64%) 116/167 (69%)    
(Snaphaan et al., 2011) 
(CIS) 
  38/108 
(35%) 
   36/108 
(33%) 
  
(van Eijsden et al., 
2011) (FSS) 
   141/242 
(58%) 
 133/242 (55%)    
(Pihlaja et al., 2014) 
(POMS-Fatigue) 
   33/133 (25%) 34/133 (26%)   25/133 (19%)  
(van de Port et al., 
2007) (FSS) 
    152/223 (68%) 165/223 (74%)   129/223 
(58%) 
(Duncan et al., 2014) 
(PSF case definition 
and FAS) 








   
(Ogden et al., 1994) 
(Single question) 
  10 weeks: 79/89 (89%)  57/66 (86%)    
(Skaner et al., 2007) 
(Single question) 
   72/106 (69%)  61/97 (58%)    
(Hellawell et al., 1999) 
(Single question) 
    18/28 (64%) 13/22 (59%)  13/19 (68%)  
(Radman et al., 2012) 
(FAI) 
    33/109 (30%) 34/99 (34%)    
(Noble et al., 2008) 
(MFSI-SF) 
   24 – 251 days (mean 109 days):  
43/73 (59%) 
335 – 672 days (mean 406 days):  
31/87 (36%) 
 
CIS, Checklist Individual Strength; FAI, Fatigue Assessment Instrument; FAS: Fatigue Assessment Scale; FSS, Fatigue Severity Scale; MFI-20, Multidimensional 
Fatigue Inventory; MFSI-SF: Multidimensional Fatigue Symptom Inventory – Short Form; POMS, Profile of Mood States. 
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2.1.2 Time course of fatigue after stroke 
Presence or absence of fatigue over time 
Of the eight studies that reported the data of patients who completed all assessments 
(the first eight studies in Table 2.1), seven reported a general trend of decrease in 
proportions of patients with PSF over time (Duncan et al., 2014, Sisson, 1995, 
Snaphaan et al., 2011, van Eijsden et al., 2011, Christensen et al., 2008, Pihlaja et al., 
2014, van de Port et al., 2007) and one reported an increase in proportions (Schepers 
et al., 2006). It is important to note that in some studies the changes of proportions 
were small (i.e. less than 5%) and some changes fluctuated over time (i.e. first 
increase and then decrease, or vice versa). In addition, in one study with a general 
trend of decrease, the proportion decreased significantly from 10 days (59%) to three 
months (44%) after stroke, but no major change afterwards (38% at one year and 
40% at two years) (Christensen et al., 2008). Furthermore, none of these eight studies 
performed any statistical analysis to compare the proportions at different time points, 
thus we do not know whether these differences were statistically significant.  
Of these eight studies, six studies also investigated the natural history of PSF in 
individual patients (Table 2.2). In general, about half of stroke patients in each study 
did not have fatigue at any assessments; in the other half of patients, the majority of 
patients had fatigue at all assessments, about 10% of patients had fatigue at the initial 
assessment but recovered at a later assessment, and another 10-15% of patients did 
not have fatigue at the initial assessment but developed it at a later assessment. In 
addition, a small proportion (less than 5%) of patients had a fluctuating course of 
fatigue over time, i.e. some had fatigue at the initial assessment, recovered later, but 
relapsed by the final assessment.  
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Table 2.2 Natural history of post-stroke fatigue (PSF) in patients who completed all assessments over the study course 
Studies (number of patients): 
Assessment time points 
(Proportions of patients with 
PSF) 
Numbers (proportions) of patients with or without PSF at each assessment  Proportions in patients 
who completed all 
assessments 
Proportions in 
patients with (or 
without) PSF at the 
initial assessment 
Snaphaan 2011 (n=108): 
1st: 2 months (35%) 
2nd: 18 months (33%) 
(Snaphaan et al., 2011) 
 
38 (35%) patients with fatigue at the initial assessment   
 28 patients had fatigue at both assessments  26% (persistent fatigue) 74% 
 10 patients had fatigue at 2 months but not 18 months  9% (recovered fatigue) 26% 
70 (65%) patients without fatigue at the initial assessment   
 9 patients developed fatigue between 2 and 18 months  8% (late onset fatigue) 13% 
 61 patients did not have fatigue at either assessment 57% (no fatigue) 87% 
van Eijsden 2011 (n=242): 
1st: at discharge (97±46.9 days) 
(58%) 
2nd: 24 weeks later (55%) 
(van Eijsden et al., 2011) 
141 (58%) patients with fatigue at the initial assessment   
 98 patients had fatigue both at discharge and 24 weeks later 40%  (persistent fatigue) 70% 
 43 patients had fatigue at discharge but not at 24 weeks later  18% (recovered fatigue) 30% 
101 (42%) patients without fatigue at the initial assessment   
 35 patients developed fatigue after discharge  15% (late onset fatigue) 35% 
 66 patients did not have fatigue at either assessment 27% (no fatigue) 65% 
Christensen 2008: 
1st: 10 days (59%) 
2nd: 3 months (44%) 
3rd: 1 year (38%) 
4th: 2 years (40%) 
(Christensen et al., 2008) 
81 (59%) patients with fatigue at the initial assessment   
 72% remained either fatigued or non-fatigued between 10 days and 3 months (persistent fatigue or no fatigue) 
 75% remained either fatigued or non-fatigued during the interval between 3 
months and 2 years 
(persistent fatigue or no fatigue) 
 9% developed fatigue between 3 months and 2 years 
 
(late onset fatigue)  
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  Table 2.2 Natural history of post-stroke fatigue (PSF) in patients who completed all assessments over the study course (continued) 
Studies (number of 
patients): Assessment 
time points (Proportions 
of patients with PSF) 
Numbers (proportions) of patients with or without PSF at each assessment  Proportions in patients 
who completed all 
assessments 
Proportions in 
patients with (or 
without) PSF at 
the initial 
assessment 
Schepers 2006 (n=167): 
1st: at admission (6±4 
weeks) (52%) 
2nd: 6 months (64%) 
3rd: 12 months (69%) 
(Schepers et al., 2006) 
86 (52%) patients with fatigue at the initial assessment   
 63 patients had fatigue at all three assessments  38% (persistent fatigue) 73% 
 7 patients had fatigue at admission, and recovered by 6 months  4% (recovered fatigue) 8% 
 10 patients had fatigue at both admission and 6 months, and recovered by 12 months  6% (recovered fatigue) 12% 
 6 patients had fatigue at initial assessment, recovered by 6 months, and relapsed 
between 6 and 12 months  
4% (early onset fatigue 
with fluctuating course) 
7% 
81 (48%) patients without fatigue at the initial assessment   
 29 patients developed fatigue between the admission and 6 months, and persisted at 12 
months  
17% (late onset fatigue) 36% 
 18 patients developed fatigue between 6 and 12 months  11% (late onset fatigue) 22% 
 5 patients developed fatigue by 6 months, and recovered at 12 months  3% (late onset recovered 
fatigue) 
6% 
 29 patients did not have fatigue at any assessment 17% (no fatigue) 36% 
Duncan 2014 (n=86): 
1st: 1 month (28%) 
2nd: 6 months (23%) 
3rd: 12 months (21%) 
(Duncan et al., 2014) 
24 (28%) patients with fatigue at the initial assessment   
 7 patients had fatigue at all three assessments  8% (persistent fatigue) 29% 
 13 patients had fatigue at 1 month, and recovered by 6 months  15% (recovered fatigue) 54% 
 1 patient had fatigue at both 1 and 6 months, and recovered between 6 and 12 months  1% (recovered fatigue) 4% 
 3 patients had fatigue at 1 month, recovered by 6 months, and relapsed between 6 and 
12 months  
4% (early onset fatigue 
with fluctuating course) 
13% 
62 (72%) patients without fatigue at the initial assessment   
 3 patients developed fatigue between 1 and 6 months, and persisted to 12 months  4% (late onset fatigue) 5% 
 5 patients developed fatigue between 6 and 12 months  6% (late onset fatigue) 8% 
 9 patients developed fatigue between 1 and 6 months, and recovered between 6 and 12 
months  
10% (late onset 
recovered fatigue) 
14% 
 45 patients did not have fatigue at any assessment 52% (no fatigue) 73% 
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  Table 2.2 Natural history of post-stroke fatigue (PSF) in patients who completed all assessments over the study course (continued) 
Studies (number of 
patients): Assessment time 
points (Proportions of 
patients with PSF) 
Numbers (proportions) of patients with or without PSF at each assessment  Proportions in patients 
who completed all 
assessments 
Proportions in 
patients with (or 
without) PSF at the 
initial assessment 
Pihlaja 2014 (n=133): 
1st: 3 months (25%) 
2nd: 6 months (26%) 
3rd: 24 months (19%) 
(Pihlaja et al., 2014) 
33 (25%) patients with fatigue at the initial assessment   
 13 patients had fatigue at all three assessments  10% (persistent fatigue) 39% 
 9 patients had fatigue at 3 months, and recovered by 6 months  7% (recovered fatigue) 27% 
 7 patients had fatigue at both 3 and 6 months, and recovered between 6 and 12 
months  
5% (recovered fatigue) 22% 
 4 patients had fatigue at 3 months, recovered by 6 months, and relapsed  fatigue 
between 6 and 24 months 
3% (early onset fatigue 
with fluctuating course) 
12% 
100 (75%) patients without fatigue at the initial assessment   
 5 patients developed fatigue between 3 and 6 months, and persisted at 24 months 4% (late onset fatigue) 5% 
 3 patients developed fatigue between 6 and 24 months 2% (late onset fatigue) 3% 
 9 patients developed fatigue between 3 and 6 months, and recovered between 6 
and 24 months 
7% (late onset recovered 
fatigue) 
9% 
 83 patients did not have fatigue at any assessment 62% (no fatigue) 83% 
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Although the proportion varies across studies, findings from the longitudinal studies 
revealed four general trajectories of the temporal course of fatigue after stroke, i.e. 
persistent fatigue, recovered fatigue, late onset fatigue, and fluctuating fatigue. A 
‘persistent fatigue’ is present at all assessments over time after stroke; a ‘recovered 
fatigue’ is present at early but not late assessment after stroke; a ‘late onset fatigue’ is 
not present at the early assessment but develops during the follow-up and is present 
at a later assessment; and a ‘fluctuating fatigue’ is developed early, recovered later, 
but relapsed again. Table 2.3 summarises the exact proportions of patients with 
persistent fatigue, recovered fatigue, late onset fatigue, and a fluctuating course of 
fatigue in each longitudinal studies.  
 
Table 2.3 Proportions of stroke patients with persistent fatigue, recovered fatigue, late 
onset fatigue, or a fluctuating course in individual longitudinal studies  
Study ID No. of 
patient  
Patients with fatigue 
at the initial assessment 
 Patients without fatigue 
at the initial assessment 











Snaphaan 2011 108 26% 9% NA  8% 57% 
van Eijsden 2011 242 40% 18% NA  15% 27% 
Radman 2012 99 25% 8% NA  9% 58% 
Schepers 2006 167 38% 10% 4%  31% 17% 
Duncan 2014 86 8% 16% 4%  20% 52% 
Pijlaja 2014 133 10% 12% 3%  13% 62% 
Christensen 2008 138 NA NA NA  9% NA 
NA: not applicable 
Severity of fatigue over time 
Some studies investigated the change of fatigue severity over time, assessed by mean 
scores of fatigue of the entire cohort. A Dutch study (167 patients) reported a 
significant contribution of time (p < 0.001) on the variation of fatigue scores, with an 
increase of fatigue scores from admission, to three months and later one year after 
stroke (Schepers et al., 2006). In contrast, a Norwegian study (95 patients) assessed 
the fatigue severity at the acute phase, six months, 12 months and 18 months after 
stroke and found no effect of time on fatigue scores (Lerdal et al., 2012). However, 
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these two studies only investigated the general effect of time over the entire course of 
observation rather than comparing fatigue scores between specific time points. A 
Danish study (138 patients) found a significant decrease of fatigue scores from 10 
days after stroke to three months (p < 0.05), but no further significant changes from 
three months to two years (Christensen et al., 2008). This change of fatigue scores 
might reflect the change of proportions of patients with PSF in this longitudinal study 
as discussed previously. Similarly, another study (86 patients) found a significant 
decrease of fatigue scores from one month to six months (p = 0.03) but no significant 
change from six months to one year (p = 0.19) (Duncan et al., 2014). In addition, a 
small study (58 patients) found no significant changes of fatigue scores from the 
initial assessment at a mean of three months to a later assessment at a mean of 13 
months after stroke (Noble et al., 2008). Another Dutch study (242 patients) explored 
changes of fatigue severity in individual patients from the initial assessment at a 
mean of three months to the assessment six months later, which found no significant 
change of fatigue scores in the majority of patients (161 patients, 66%), and only 
16% had a significant increase and another 18% had a significant decrease during 
this period (van Eijsden et al., 2011). These studies reported a common observation 
that fatigue severity tends to be stable over time, but if it does resolve naturally, it 
often occurs in the first few months after stroke. Thus the best timing for 
implementing interventions for PSF may be the chronic phase of stroke (e.g. three 
months or six months after stroke onset), as at this stage fatigue is usually a 
persistent problem that does not resolve spontaneously. 
2.1.3 The concept of early fatigue and late fatigue 
When studying fatigue after stroke, we should take into consideration that the 
prevalence of fatigue in the general population is relatively high (prevalence of 
chronic fatigue in general population ranges from 15% to 32%), and that fatigue 
present at an early stage after stroke may be not necessarily caused by stroke. The 
presence of fatigue after stroke is associated with the presence of fatigue prior to 
stroke (I will return to the issue of pre-stroke fatigue in the next section of factors 
associated with PSF). Similarly, for fatigue present at a later stage after stroke, it is 
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unclear whether this is a persistent status since when the fatigue is first present, or if 
it is developed later, or even there is a fluctuation over time, as the presence of 
fatigue is not continuously monitored in research studies. For example, “persistent 
fatigue” represents the fatigue present at all assessments over the course of the study, 
but we do not know the status of fatigue in-between these assessments. Thus the 
identified temporal course of fatigue may vary depends on the length of follow-up, 
the number of assessments, and the time of each assessment since stroke. To 
investigate whether these factors affect the identified temporal course of PSF, I 
compared the proportions of patients with ‘persistent fatigue’, ‘recovered fatigue’, 
‘late onset fatigue’, ‘fluctuating fatigue’ and those ‘without fatigue’ between 
different numbers and time points of assessments, using the data from a longitudinal 
study (Schepers et al., 2006) that reported the numbers of patients who had fatigue at 
admission, six months and 12 months after stroke (Table 2.4). 
Table 2.4 Influence of the length of follow-up and times of assessments on the 
identified pattern of temporal course of post-stroke fatigue 









Three assessments: at 
admission, 6 months, and 
12 months 
 
63 (38%) 17 (10%) 52 (31%) 6 (4%) 29 (17%) 
Two assessments: 
admission and 12 months 
 
69 (41%) 17 (10%) 47 (28%) NA 34 (21%) 
Two assessments: 
admission and 6 months 
 
73 (44%) 13 (8%) 34 (20%) NA 47 (28%) 
Two assessments: 6 
months and 12 months 
92 (55%) 15 (9%) 24 (14%) NA 36 (22%) 
NA: not applicable. 
Table 2.4 shows that comparing the results of having two assessments at different 
time points in the first year after stroke (i.e. at admission and 12 months, versus at 
admission and six months, versus at six and 12 months), there is no significant 
difference in proportions of the identified patterns of temporal course of PSF, except 
that there is a lower proportion of patients with ‘late onset fatigue’ and a higher 
proportion of ‘persistent fatigue’ if assessed between six and 12 months, compared 
with those assessed between admission and six months or those between admission 
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and 12 months. This suggests that more patients had fatigue that started in the first 
six months after stroke and the fatigue status tended to be stable after six months. 
Also compared with any two assessments during the first year, three assessments 
during this period identified no significant difference in the proportions of any 
temporal pattern of PSF, except that three assessments rather than two identified a 
small proportion of patients (4%) who had a fluctuating course of fatigue. In 
summary, fatigue tends to be present early after stroke and persist in long term, 
regardless of the number and time points of assessments. This implies that the 
clinical observation of fatigue does not need to be frequent, as two assessments, one 
at an early stage (e.g. acute phase) and the other at a later stage (e.g. several months 
after stroke onset), would be sufficient to reveal temporal course of fatigue in most 
stroke patients. 
Because of the difficulty in determining the starting time of fatigue and limitations in 
continuous monitoring of fatigue status, here I propose the concepts of “early 
fatigue” and “late fatigue” which will be used in the subsequent chapters of this 
thesis. “Early fatigue” describes the presence of fatigue at an early stage after stroke 
(i.e. at the initial assessment, usually within the first few weeks after stroke) and “late 
fatigue” describes the presence of fatigue at a later assessment after stroke (usually 
several months or years after stroke onset). These concepts are focused on the 
presence of fatigue at certain time points, regardless of when the fatigue starts and 





Figure 2.1 Concepts of early fatigue and late fatigue after stroke  
It is important to note that fatigue present early after stroke (i.e. early fatigue) and 
fatigue present at a later stage after stroke (i.e. late fatigue) should be viewed as part 
of an evolving process. In longitudinal studies of PSF, early fatigue is always 
associated with, or the independent predictor of, late fatigue (Lerdal and Gay, 2013, 
Snaphaan et al., 2011). However, it is plausible that different factors contribute to 
fatigue present at different time points after stroke. Two studies investigated factors 
associated with fatigue at different time points after stroke. In one study, 
infratentorial stroke was associated with fatigue at two months but not 18 months 
after stroke, whilst baseline depressive symptoms and anxiety were associated with 
fatigue at both assessments (Snaphaan et al., 2011). In the other study, the three 
strongest correlates of fatigue at six months after stroke were stroke severity, 
functional disability and depressive symptoms, whilst at one year the strongest 
correlates were depressive symptoms, anxiety, and language impairment (Radman et 
al., 2012). These findings suggest that the nature of the stroke itself may be a more 
important determinant of early rather than late fatigue, with psychological factors 




Understanding the natural history of PSF informs whether an intervention is 
necessary and helps us to determine the optimum timing for delivering the 
intervention. About half of stroke patients experienced PSF at some time after their 
stroke, and most of them had fatigue at an early stage after stroke. PSF is a persistent 
problem as the majority of patients who had fatigue at an early stage also had fatigue 
at a later stage, with only a small proportion of patients recovering from fatigue. 
Some studies reported the decrease of proportions or severity of fatigue occurred 
during the first few months after stroke, but in the chronic phase (e.g. three months 
after stroke onset) the status of fatigue often tended to be stable. In general, PSF is a 
common and persistent problem that requires medical interventions. 
Due to the difficulties in continuous observation of fatigue in research studies and 
clinical practice, I proposed the concepts of ‘early fatigue’ and ‘late fatigue’, which 
are focused on the presence of fatigue at different time points after stroke. Some 
studies indicated that the nature of stroke itself may be a more important determinant 
of early rather than late fatigue, with psychological factors are important for both 
phases. This may explain the natural resolution of fatigue during the first few months 
after stroke, that is, early fatigue, which is more attributable to stroke lesions, would 
be relieved as the neurological deficits gradually recover over time. Also some 
patients reported that changes in life following stroke (e.g. hospitalisation) caused 
their fatigue, and as they gradually adapted their life to these changes the feeling of 
fatigue could resolve. Therefore, the target population of interventions to treat PSF 
need be those who had fatigue during the chronic phase after stroke rather than those 
during the acute phase, because some patients with early fatigue can recover 
spontaneously. 
The lack of effective intervention for PSF is partly due to our lack of understanding 
of its aetiologies and mechanisms. In the next section, I will systematically review 
factors that are associated with PSF and explore whether and how these factors 
contribute to fatigue at different stages after stroke. These contributing factors may 
help us to understand PSF and identify potential targets for the management of PSF. 
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Section 2.2 Factors associated with post-stroke fatigue 
Although PSF is a common problem, its aetiologies are unknown and our 
understanding of its mechanisms is mainly based on potential associations. A number 
of clinical factors have been reported to be associated with PSF. Given the concepts 
of early and late fatigue after stroke and the observation that specific lesion sites of 
stroke were associated with early but not late fatigue (Snaphaan et al., 2011), it is 
important to consider the time at which any related factors might exert most 
influence on PSF. This section reviews factors associated with fatigue at early and 
late stages after stroke and explores possible causal relationships. The concepts of 
early and late fatigue indicate that the development of PSF is a temporal process, 
thus in this section I will discuss factors associated with PSF according to the time of 
their presence in relation to stroke onset, i.e. pre-stroke factors, stroke-specific 
factors, and co-existing factors. 
2.2.1 Pre-stroke factors 
Some factors that exist prior to stroke may contribute to people’s vulnerability to 
fatigue or may be indicators of this vulnerability. 
Age 
The reports regarding the influence of age on PSF are conflicting. Many studies 
found no significant associations between age and the presence or severity of PSF 
(Appelros, 2006, Carlsson et al., 2003, Chen et al., 2015, Choi-Kwon et al., 2005, 
Christensen et al., 2008, Crosby et al., 2012, Harbison et al., 2009, Hoang et al., 
2012, Ingles et al., 1999, Kutlubaev et al., 2013, Lerdal et al., 2011, Lerdal and Gay, 
2013, Naess et al., 2005, Passier et al., 2011, Pihlaja et al., 2014, Stokes et al., 2011, 
Tang et al., 2010a, Tang et al., 2013, Tang et al., 2010b, van Eijsden et al., 2011, 
Vuletic et al., 2011, Wang et al., 2014, Wu et al., 2014a). However, some studies 
reported that patients with older age were more likely to have fatigue than younger 
patients or the advancing age was related to more severe fatigue (Feigin et al., 2012, 
Glader et al., 2002, Jaracz et al., 2007, Mead et al., 2011, Naess et al., 2012, Radman 
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et al., 2012, Schepers et al., 2006), whilst other studies found that younger age was 
associated with a greater likelihood of fatigue (Parks et al., 2012, Snaphaan et al., 
2011). One may assume that elderly people are prone to fatigue due to the declined 
body function with ageing, while others may argue that fatigue is more evident in 
younger people as they are likely to lead a more active life.  
Sex 
Of studies that investigated the association between sex and PSF, not all of them 
found a significant association. However, of studies that found a significant effect of 
sex on PSF, all reported that women patients were more likely to have PSF (Crosby 
et al., 2012, Glader et al., 2002, Naess et al., 2005, Tang et al., 2010a, Tang et al., 
2013) or the fatigue level was higher in women than men (Christensen et al., 2008, 
Kutlubaev et al., 2013, Lerdal et al., 2011, Mead et al., 2011, Schepers et al., 2006, 
Tang et al., 2010b). The higher perception of fatigue in women than men is also 
reported in the general population, which may be explained by the sex difference in 
understanding the phenomenon of fatigue (Meeuwesen et al., 2002). As fatigue has a 
significant effect on participation in daily activities, another possible explanation is 
the sex difference in roles in daily activities. For example, traditionally housework is 
mainly performed by women, which would result in women more prone to fatigue in 
daily living. 
Pre-stroke fatigue 
Five studies (954 patients) asked stroke patients about the presence of fatigue prior to 
stroke and all found that patients who suffered fatigue before stroke were more likely 
to have fatigue after stroke (Choi-Kwon et al., 2005, Duncan et al., 2014, Lerdal et 
al., 2011, Chen et al., 2015, Wang et al., 2014). However, these findings should be 
interpreted with caution as there is no validated tool to measure pre-stroke fatigue 
and there is a risk of recall bias. In spite of this, these findings imply the possibility 
that factors predisposing fatigue prior to stroke may also contribute to fatigue after 
stroke. Factors such as personality and genetic factors were reported as predisposing 
factors for fatigue in non-stroke populations (Lievesley et al., 2014), but whether 
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these factors are associated with PSF is yet to be documented. In addition, PSF is 
also common in patients without pre-stroke fatigue. In a study where patients with 
pre-stroke fatigue were excluded at recruitment, 40% of the remaining 312 patients 
had PSF within the first 10 to 15 days after stroke onset (Wu et al., 2014a). 
Pre-stroke depression and white matter changes 
One study (108 patients) reported no association between PSF and pre-stroke 
depression or age-related white matter changes at either two months or 18 months 
after stroke; however, it should be noted that this was an underpowered study as only 
14 patients had pre-stroke depression and none had white matter changes (Snaphaan 
et al., 2011). In a larger study (377 patients), patients with pre-stroke depression or 
those with leucoaraiosis (non-specific white matter changes) were more likely to 
have PSF at six months after stroke (Naess et al., 2012). However, in another study 
(107 patients), which had a higher proportion of patients with white matter lesions 
(50%), there was no significant association between fatigue scores and the severity of 
white matter lesions (none, mild, moderate, severe) as assessed both globally and in 
different regions of the brain (Kutlubaev et al., 2013). 
Pre-stroke disability and activity patterns 
One study found that pre-stroke disability was associated with higher levels of 
cognitive, psychosocial and physical fatigue at 12 months after stroke (Parks et al., 
2012). In addition, dependence in daily activities before stroke was associated with 
the presence of fatigue at six months (Feigin et al., 2012) and two years after stroke 
(Glader et al., 2002). One study found that the lack of exercise before stroke was an 
independent predictor for the presence of fatigue within two weeks after stroke 
(Wang et al., 2014), whilst other studies found no significant association between 
pre-stroke exercise pattern and PSF (Choi-Kwon et al., 2005, van Eijsden et al., 
2011). These physical factors present prior to stroke are likely to also exist after 
stroke. If associations between these physical factors and PSF are confirmed in future 
studies, this may help us to identify patients who are vulnerable to PSF and to 
promote physical activity at an early stage to prevent PSF. 
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2.2.2 Stroke-specific factors 
In qualitative studies, some patients considered their fatigue as a direct result of 
stroke or part of the recovery process and reported that PSF was different from their 
experience of fatigue prior to stroke (Barbour and Mead, 2011, Flinn and Stube, 
2010). This is consistent with the idea that PSF might be triggered by specific stroke 
lesion(s). If this is the case, we might expect associations between PSF and the type, 
size and site of stroke lesions. 
Type of stroke 
Some studies investigated the effect of stroke type on PSF. There is no difference 
between patients with ischaemic stroke and those with haemorrhagic stroke in 
proportions of patients with PSF (Glader et al., 2002, Lynch et al., 2007) or fatigue 
severity (Duncan et al., 2015, Schepers et al., 2006). A study further illustrated that 
the presence of PSF was not different between patients with intracerebral 
haemorrhage, large vessel infarct, lacunar infarct, or those with embolic infarct 
(Appelros, 2006). Therefore, patients with different types or subtypes of stroke will 
not be discussed separately in this thesis. 
Stroke severity at admission 
No clear pattern has emerged for the association between PSF and stroke severity (a 
surrogate marker of the stroke lesion size, usually measured by scales for 
neurological deficits). Among 11 studies that investigated the association between 
stroke severity at admission and the presence or severity of fatigue at follow-up, 
eight studies (1502 patients) found no significant association (Appelros, 2006, 
Christensen et al., 2008, Ingles et al., 1999, Kutlubaev et al., 2013, Naess et al., 2005, 
Snaphaan et al., 2011, Tang et al., 2010a, Wu et al., 2014a). Although the other three 
studies (377 patients) found a significant association between stroke severity and 
fatigue in patients within six months after stroke, this association was no longer 
significant after the effects of psychological factors (e.g. depression and anxiety) 
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were controlled for in the regression analysis (Jaracz et al., 2007, Radman et al., 
2012, Chen et al., 2015). 
Site of stroke lesions 
Despite the observation in one study that infratentorial strokes were associated with 
early (but not late) fatigue, a systematic review of biological correlates of PSF found 
no conclusive evidence on the association between PSF and stroke lesion sites 
(Kutlubaev et al., 2012). However, the uncertainty regarding any association between 
PSF and lesion sites might be attributed to two factors: the time of fatigue assessment 
and how lesion sites were classified. In studies where a significant association 
between PSF and lesion sites was reported, fatigue was usually assessed within the 
first few months after stroke and the associations were found with specific brain 
structures, such as brainstem, basal ganglia, internal capsule, or insular lobe (Naess 
et al., 2005, Snaphaan et al., 2011, Staub and Bogousslavsky, 2001a, Tang et al., 
2010a, Manes et al., 1999, Tang et al., 2013). In contrast, in studies that reported no 
significant association, fatigue was often assessed at a later stage (e.g. six months) 
after stroke and the lesion sites were classified more broadly as anterior or posterior 
circulation, or by the affected hemisphere (Appelros, 2006, Carlsson et al., 2003, 
Choi-Kwon et al., 2005, Christensen et al., 2008, Ingles et al., 1999, Jaracz et al., 
2007, Lynch et al., 2007).  
In addition, some of the existing studies classified the lesion sites by clinical 
presentations and some used computed tomography (CT), which are not sensitive 
enough to detect specific lesion sites. The growing use of magnetic resonance 
imaging (MRI) in stroke care, along with improvements in techniques, is leading to 
the identification of more specific regional stroke damage. Prospective MRI studies 
are helpful to explore the association between regional stroke damage and the 
presence of PSF. Tang and colleagues assessed the lesion sites in 500 stroke patients 
by the diffusion-weighted imaging (DWI) MRI, reporting that caudate infarct was an 
independent predictor of the presence of PSF at three months after the index stroke 
(Tang et al., 2013). 
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Functional disconnection of nervous system 
Functional brain imaging may be more sensitive than structural imaging to reflect the 
link between stroke damage and PSF. It is hypothesised that neurological fatigue is 
mediated by dysfunction of the reticular activating system (Chaudhuri and Behan, 
2004). Although there is no direct evidence to support this hypothesis, it is consistent 
with the observation that PSF was associated with infarct in brainstem (Staub and 
Bogousslavsky, 2001a) and in subcortical white matter (Tang et al., 2014), which are 
components of the reticular activating pathways. Also, wakefulness and attention, 
two major functions regulated by the reticular activating system (Kinomura et al., 
1996), are impaired in patients with PSF (please see the section for Cognitive 
impairments).  
A positive emission tomography (PET) study for patients with multiple sclerosis 
reported that, compared with non-fatigued patients, fatigued patients had reduced 
metabolism in both the prefrontal cortex and caudate nucleus (Roelcke et al., 1997). 
Although there is no functional brain imaging study for PSF, Tang et al. reported in 
their DWI/MRI study that caudate infarct was associated with PSF (Tang et al., 
2013). Studies of brain functional connectivity demonstrated that caudate was linked 
with executive frontal areas including dorsolateral prefrontal cortex, anterior 
cingulate cortex and orbitofrontal cortex on transcranial magnetic stimulation (TMS) 
(Knoch et al., 2006, Strafella et al., 2001), PET and functional MRI (Postuma and 
Dagher, 2006). These findings indicate a possible association between PSF and 
executive functions. 
Motor cortex is another brain area that may be responsible for PSF. One recent study 
(70 patients) using TMS (applied to the primary motor cortex area) and 
electromyography techniques found that reduced excitability of corticospinal motor 





PSF can be characterised by cognitive deficits, as some patients describe their fatigue 
as “mental tiredness” or “difficulty in concentration”. The difficulty in exploring the 
relationship between PSF and cognitive deficits lies in the measures of cognitive 
functioning. In studies which assessed cognition using the Mini-mental State 
Examination (MMSE), no association was found between PSF and the total score of 
MMSE (Appelros, 2006, Carlsson et al., 2003, Kutlubaev et al., 2013, Naess et al., 
2005, Park et al., 2009, Schepers et al., 2006, Snaphaan et al., 2011, van Eijsden et 
al., 2011). A limitation in these studies was that MMSE does not measure executive 
functioning, whilst brain imaging studies have suggested a possible link between 
PSF, caudate, and executive frontal cortex. To compensate for this weakness of 
MMSE, the Cambridge Cognitive Examination (CAM-COG) incorporates a number 
of additional items including those for abstract thinking and perception (Roth et al., 
1986). Also, the Montreal Cognitive Assessment (MoCA), a cognitive scale which is 
commonly used for stroke patients, contains items for executive functions 
(Nasreddine et al., 2005). 
In a study (108 patients) which included a detailed cognitive examination (for 
memory, verbal learning, non-verbal recall, attention, visuospatial functioning, and 
executive functioning (assessed by the Brixton Spatial Anticipation Test for strategic 
thinking and with phonological fluency for concept generation)), the presence of 
cognitive impairments at three months after stroke was associated with greater 
fatigue at one-year follow-up (Passier et al., 2011). Another study (109 patients) 
further illustrated that attentional (phasic alert and divided attention) and executive 
dysfunction (assessed by a modified Stroop test) was associated with PSF at both six 
months and 12 months after stroke (Radman et al., 2012). The executive functioning 
assessed in these studies is associated with dorsolateral prefrontal cortex (Alvarez 
and Emory, 2006). Therefore, cognitive scales measuring these executive functions, 
such as CAM-COG and MoCA, need to be used in patients with PSF. 
The association between PSF and two other executive frontal regions, anterior 
cingulate cortex and orbitofrontal cortex, has not yet been investigated in patients 
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with PSF. These two brain regions are associated with decision-making, empathy, 
impulse control and emotion. Their associations with PSF need to be explored in 
future studies, for example, by observational studies for the association between PSF 
and apathy or functional imaging studies for the association between PSF and blood 
flow or metabolism in anterior cingulate cortex.  
Neuroendocrine changes 
Some researchers proposed that fatigue in neurological disorders was associated with 
dysfunctions of hypothalamic-pituitary-adrenal (HPA) axis (Chaudhuri and Behan, 
2004). The underactive HPA axis and related neuroendocrine changes were found in 
patients with chronic fatigue syndrome (Scott and Dinan, 1999), but there is scarce 
evidence from stroke studies. One study (109 patients) investigated levels of cortisol 
and adrenocorticotropic hormone (ACTH) in stroke patients, but found no 
association of these hormones with PSF at either six months or 12 months after 
stroke (Radman et al., 2012).  
Inflammatory biomarkers  
Fatigue in neurological disorders is often associated with both central nervous system 
and systemic inflammation (Morris et al., 2015). Inflammation is an important 
pathophysiological response to stroke, which is characterised by the changed levels 
of peripheral inflammatory markers (Emsley and Tyrrell, 2002). A genetic study (39 
patients) found that stroke patients carrying the minor C allele of the rs4251961 
single nucleotide polymorphism (SNP) in the interleukin-1 receptor antagonist gene 
(IL1RN, the gene for IL1rα) had higher fatigue scores than patients without this SNP 
at one month and three months after stroke, respectively (both p < 0.05), but not at 
six months or one year (Becker et al., 2015).  
The SNP rs4251961 C allele is associated with higher plasma levels of both C-
reactive protein (CRP) and IL-6 and lower levels of IL-1rα in the general population 
(Reiner et al., 2008). However, there is no robust evidence in stroke population for 
the association between PSF and any of these inflammatory biomarkers. In a pilot 
study with 28 patients within three months after stroke, the mean CRP level was not 
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significantly different between patients with and those without PSF (McKechnie et 
al., 2010). In addition, another small study (45 patients) found that the CRP level at 
acute phase was not associated with fatigue severity at six months, 12 months, or 18 
months (Ormstad et al., 2011). In this same cohort of stroke patients, higher levels of 
acute phase glucose were associated with greater fatigue at six months and 12 
months, higher levels of acute phase IL-1β were associated with greater fatigue at six 
months, and lower levels of acute IL-1rα and IL-9 were associated with greater 
fatigue at 12 months (Ormstad et al., 2011). This study also found that lower 
bioavailability for serotonin synthesis at acute phase was associated with the 
presence of PSF at 12 months (Ormstad et al., 2014). However, we should be 
cautious when interpreting the results of this study, as the critical level for statistical 
significance might have to be adjusted due to the multiple comparisons.  
One interesting finding in the study described above was that none of these 
biomarkers was associated with fatigue at 18 months. Given that the fatigue level 
observed in this study did not decline by 18 months, the investigators speculated that 
other factors such as psychosocial factors might have contributed to the sustained 
level of fatigue (Ormstad et al., 2011). This is consistent with our observation in an 
exploratory study for associations between CRP and PSF in 65 stroke patients, where 
there was a significant cross-sectional association between CRP and PSF at six 
months after stroke, but this association was no longer significant after controlling 
for the effect of anxiety, depression, and physical activity, with anxiety as the only 
significant association of PSF at six months. In addition, anxiety, depression and 
reduced physical activity but not CRP at 12 months were independently associated 
with PSF at 12 months. These findings imply that CRP is associated with early but 
not late fatigue, and the association with early fatigue is confounded by 
psychological and behavioural factors. However, this is an exploratory study with a 
relatively small sample size so the results should be repeated in larger studies in 
future. (I am the leading author of this CRP study. This work is currently in 




Fatigue after stroke may also be attributed to the increased physical effort associated 
with neurological deficits. One study (377 patients) found that in patients at one year 
after stroke the presence of PSF was associated with the residual neurological 
deficits (measured by the National Institutes of Health Stroke Scale) and perceived 
disability (measured by the modified Rankin Scale), respectively (Appelros, 2006). 
Cross-sectional associations between PSF and disability were found in patients from 
the acute phase to several years after stroke (Choi-Kwon et al., 2005, Naess et al., 
2005, van der Werf et al., 2001, Wu et al., 2014a). In addition, one study (108 
patients) reported that physical impairments at three months after stroke were 
associated with fatigue at one-year follow-up (Passier et al., 2011).  
However, fatigue is also present in stroke patients with minor or no residual 
neurological deficits (Winward et al., 2009) or those with minor physical 
impairments (Kuppuswamy et al., 2015). This suggests the possibility of other 
contributing factors to PSF. For example, one longitudinal study (108 patients) found 
that higher level of disability (by the modified Rankin Scale) at baseline was 
associated with the presence of fatigue at baseline but not at 18 month after stroke; 
furthermore, the baseline association was no longer significant after controlling for 
the effects of age, lesion site, anxiety, and depressive symptoms (Snaphaan et al., 
2011). Similar results were reported in another study (109 patients) where higher 
levels of neurological deficits (by the National Institutes of Health Stroke Scale) and 
disability (by the modified Rankin Scale) were each associated with more severe 
fatigue at six months but not 12 months after stroke; and these associations were no 
longer significant after controlling for the effects of anxiety and depressive 
symptoms (Radman et al., 2012). 
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2.2.3 Co-existing factors 
Psychological factors 
Stroke or stroke-induced changes in life can make patients feel distressed. 
Psychological factors are the most commonly reported associations of PSF. This is 
because fatigue is often a symptom of many psychological conditions, such as 
depression and anxiety. However, some patients reported that they did not have any 
of these psychological conditions and fatigue was their only problem after stroke. In 
addition to affective factors, other psychological factors, such as sense of control and 
physical cause attribution, have been found to be associated with fatigue in patients 
with multiple sclerosis and those with chronic fatigue syndrome (Vercoulen et al., 
1998). These factors may also play a role in the development of fatigue after stroke. 
Affective factors 
To explore associations between PSF and depressive symptoms and anxiety, I 
conducted a systematic review and performed meta-analyses to determine the 
strength of these associations (Wu et al., 2014b). Details of the methods and results 
of this systematic review will be discussed in Section 2.3. In brief, I identified 31 
studies that reported the association between PSF and depressive symptoms, of 
which 19 studies (6712 patients) provided data suitable for meta-analysis. The 
pooled data indicated a significant association between PSF and depressive 
symptoms (pooled Odds Ratio, OR = 4.14, 95% confidence interval, 95% CI 2.73 to 
6.27); this association was significant even in patients who did not meet clinical 
criteria of depression (433 patients, pooled OR = 1.39, 95% CI 1.27 to 1.53), or in 
studies that used depression measures without any fatigue item (4554 patients, 
pooled OR = 5.41, 95% CI 1.54 to 18.93). Of seven studies that reported the 
association between PSF and anxiety, four studies (3934 patients) provided data for 
meta-analysis and found a trend towards an association between PSF and anxiety 
(pooled OR = 2.34, 95% CI 0.98 to 5.58). Subgroup analyses indicated that this 
association was weaker (p < 0.01) in studies that controlled for the effect of 
depression (two studies, 3717 patients, pooled OR = 1.25, 95% CI 1.14 to 1.38) than 
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studies that did not control for depression (two studies, 217 patients, pooled OR = 
5.34, 95% CI 4.70 to 6.07). 
The above results were based on the literature search in October 2012 and have been 
published in Stroke (2014); 45: 1778-1783. Several new studies reporting 
psychological associations of PSF have been published since the last search, which 
were not included in the above meta-analyses. Through an updated search in August 
2015, I identified 11 additional studies (2548 patients) that had reported associations 
between PSF and depressive symptoms (Chen et al., 2015, Galligan et al., 2015, 
Lerdal and Gay, 2013, Maaijwee et al., 2014, Naess and Nyland, 2013, Pihlaja et al., 
2014, Tang et al., 2014, Tang et al., 2013, Wang et al., 2014, Wu et al., 2014a, 
Duncan et al., 2015) and four of them (955 patients) had also reported associations 
between PSF and anxiety (Chen et al., 2015, Maaijwee et al., 2014, Duncan et al., 
2015, Galligan et al., 2015). The significant association between PSF and depressive 
symptoms was consistently reported across all studies. Also four studies 
investigating the association between PSF and anxiety all found a significant 
association; however, this association might have been confounded by depressive 
symptoms, as two of these studies found that depressive symptoms and anxiety were 
highly correlated (Chen et al., 2015, Duncan et al., 2015).  
Although the causal mechanisms of PSF could not been established in observational 
studies, existing studies suggested that PSF and depressive symptoms (or anxiety) 
were associated over time and were predictors for each other, indicating a 
bidirectional relationship. Cross-sectional studies have found significant associations 
between PSF and both depressive symptoms and anxiety, with observational periods 
ranging from the first few days (Wang et al., 2014, Wu et al., 2014a) to several years 
after stroke (Maaijwee et al., 2014, Naess and Nyland, 2013). Longitudinal studies 
further illustrated that PSF was associated with these affective factors at both early 
(i.e. within the first few months) and late (i.e. beyond one year) stages after stroke 
(Radman et al., 2012, Snaphaan et al., 2011, Duncan et al., 2015). In addition, levels 
of depression and levels of anxiety at baseline were positively associated with, and 
the independent predictors for, fatigue levels at follow-up (Lerdal and Gay, 2013, 
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Snaphaan et al., 2011, Chen et al., 2015, Duncan et al., 2015); one the other hand, 
patients with PSF at baseline had more depressive symptoms at follow-up (Pihlaja et 
al., 2014). Furthermore, patients who had fatigue at both baseline and follow-up (i.e. 
persistent fatigue) had higher levels of depression and anxiety at baseline, compared 
to those who did not have fatigue or those who only had fatigue at either baseline or 
follow-up (Snaphaan et al., 2011, Tang et al., 2014).  
It is important to note that fatigue and depression are two distinct concepts, even 
though they often coexist in stroke patients and their associations are bidirectional. 
Factor analysis of the combined pool of items of the FAS and the Beck Depression 
Inventory revealed two factors that represented fatigue and depression as two 
separate constructs (Smith et al., 2008). This is consistent with the observation that 
many patients with PSF do not have depression (Choi-Kwon et al., 2005). In 
summary, PSF is significantly associated with depressive symptoms and anxiety, and 
they may have reciprocal causal relationships, but PSF could also occur in patients 
without depression and anxiety. 
Illness perceptions  
Patients’ cognitive responses to fatigue (i.e. their illness perceptions or beliefs about 
fatigue) may in turn have an impact on fatigue. In models for fatigue in multiple 
sclerosis and chronic fatigue syndrome, illness attribution to physical problems has 
negative impacts on PSF through the effect of reduced physical activity (Vercoulen 
et al., 1998). In qualitative studies of PSF, some patients attributed their fatigue to 
stroke or the relevant recovery process, while other patients were aware of other 
problems such as physical impairments, depression, medication, and ageing (Barbour 
and Mead, 2011, Flinn and Stube, 2010). However, there is no quantitative study 
investigating the association between illness attributions and fatigue in stroke 
patients.  
Self-efficacy and sense of control 
Sense of control or self-efficacy is the perceived ability to control one’s own life or 
to achieve a goal in a particular situation (e.g. after stroke or with PSF). A 
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longitudinal study (167 patients) found that stroke patients who had a locus of 
control more directed to significant others (e.g. their families and doctors) at baseline 
were more likely to develop fatigue at one-year follow-up (Schepers et al., 2006). 
Another study (77 patients) reported that, in patients who were at least six months 
after their stroke, higher levels of fatigue were associated with both the decreased 
activity and the lower self-efficacy in keeping balance and in managing chronic 
diseases (Miller et al., 2013). The negative associations of PSF with self-efficacy and 
levels of daily activities were also reported in another study with 55 patients more 
than one year after stroke; this study also found that stroke specific self-efficacy and 
levels of daily activities were positively associated with each other (Muina-Lopez 
and Guidon, 2013). Therefore, it is possible that fatigue, lower self-efficacy, and 
lower level of activities after stroke are mutually linked. 
Behavioural factors 
Physical activity 
Decreased mobility or inactivity is common in many medical conditions including 
stroke. Low level of physical activity has been identified in both hospitalised (West 
and Bernhardt, 2011) and community-dwelling stroke patients (Alzahrani et al., 
2011). A hypothesis is that the reduced activity after stroke leads to physical 
deconditioning and in turn exertional fatigue, and that exertional fatigue leads to 
further avoidance of physical activity, which then contributes to chronic fatigue 
(Kutlubaev and Mead, 2011). However, the relationship between PSF and physical 
deconditioning is unclear. One study (66 patients) reported that lower leg strength on 
the unaffected side was associated with higher levels of fatigue in stroke patients 
(Lewis et al., 2011), whilst another study (48 patients) found no association between 
PSF and walking activity or fitness measures (Michael et al., 2006). A pilot study (9 
patients) found a significant association between the peak oxygen uptake and fatigue 
levels immediately after the six-minute-walk test (Tseng and Kluding, 2009), but the 
investigators further illustrated in a larger study (21 patients) that the peak oxygen 
uptake was associated with the exercise-induced fatigue rather than the pathological 
chronic fatigue (Tseng et al., 2010). 
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The association between PSF and physical activity is likely to be bidirectional, 
although whether physical deconditioning plays a role in this is unknown. A 
longitudinal study (84 patients) reported significant cross-sectional associations 
between lower levels of physical activity and higher levels of fatigue at one, six and 
12 months after stroke, respectively, and that the lower level of physical activity at 
one month was an independent predictor of higher levels of fatigue at both six and 12 
months (Duncan et al., 2015). On the other hand, another longitudinal study (96 
patients) found that acute phase fatigue was an independent predictor for lower 
physical health at 18-month follow-up (Lerdal and Gay, 2013).  
Coping patterns 
Coping is the way that people respond to stressful events, which involves an 
interaction of emotional, cognitive and behavioural processes. Qualitative studies 
revealed a spectrum of potential strategies for coping with PSF, ranging from 
struggling to cope (patients who seek explanations for their fatigue and search for 
strategies to overcome it, often feeling frustrated, guilty or out of control because of 
their fatigue) to adjusting by taking fatigue into account (accepting fatigue as part of 
life and adjusting their daily routines to adapt) (Eilertsen et al., 2013). A cross-
sectional study (50 patients) found that, in patients at three months after stroke, both 
emotional-oriented coping (i.e. focusing on personal emotions) and avoidance-
oriented coping (i.e. attempting to avoid difficult situations) were associated with 
higher fatigue scores, whilst task-oriented coping (i.e. cognitively restructuring the 
problem or altering the situations) was associated with lower fatigue scores (Jaracz et 
al., 2007). A longitudinal study (108 patients) reported that patients who adopted a 
passive coping pattern at three months after subarachnoid haemorrhage were more 
likely to have fatigue at one-year follow-up (Passier et al., 2011). Another study (109 
patients) found no direct correlation between maladaptive coping (e.g. denial and 
avoidance) and PSF, but maladaptive coping at three months after subarachnoid 
haemorrhage was associated with post-traumatic stress disorder (PTSD) at both three 
months and 13 months, and scores of PTSD were associated with fatigue scores at 
both time points (Noble et al., 2008).  
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These findings imply that the way people response to stressful events may affect how 
they feel emotionally and the emotional distress is associated with fatigue symptoms. 
Given the positive associations between PSF and both emotional-oriented coping and 
avoidance-oriented coping and the negative association between PSF and task-
oriented coping, it is possible that adopting the active coping with fatigue problems 
and the combat with emotional conditions and avoiding-behaviours could help to 
reduce PSF. 
Social support 
Some stroke patients reported that the lack of understanding by their significant 
others (e.g. their families and doctors) complicated their coping process and invoked 
emotional distress, and they believed that appropriate understanding and support 
from their significant others would be beneficial for the management of fatigue 
(Eilertsen et al., 2013). However, external support for stroke patients is limited. 
Patients with PSF often felt disbelief and a lack of understanding from other people 
(Eilertsen et al., 2015) and complained insufficient and ineffective medical advice on 
PSF from health professionals (White et al., 2012). In a group of 41 stroke patients 
who reported fatigue as a frequent problem, only 8 (19.5%) had discussed fatigue 
with their clinical team (Crosby et al., 2012). In addition, fatigued patients often 
reported lower levels of family function (Wang et al., 2014) and poorer social 
support (Michael et al., 2006), as compared with non-fatigued stroke patients. 
Comorbidities and medications 
Sleeping problems 
About 20-40% of stroke patients experience sleep disturbances, mostly with 
hypersomnia, insomnia, daytime somnolence and sleep-disordered breathing 
(Hermann et al., 2003). Some patients thought that their fatigue was related to the 
poor sleep in hospital during the acute phase (Barbour and Mead, 2011). This is 
consistent with the observation that higher levels of fatigue were associated with 
lower quality of sleep in patients within the first week after stroke (Lerdal et al., 
2011). Sleep apnoea is common after stroke but no study has directly investigated its 
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association with PSF, apart from a small study (32 patients) which used a scale for 
daytime sleepiness “to evaluate symptoms of sleep apnoea” and found the mean 
scores of daytime sleepiness were not different between patients with and without 
PSF (Hoang et al., 2012). A larger study (136 patients) found cross-sectional 
associations between PSF and daytime sleepiness at one, six and 12 months after 
stroke, though sleepiness at one month did not predict fatigue at follow-up (Duncan 
et al., 2015). In addition, presence of other sleep disturbances (e.g. insomnia or 
frequent wakening during night) were associated with PSF (Naess et al., 2012, 
Schepers et al., 2006, Choi-Kwon et al., 2005, Appelros, 2006, Galligan et al., 2015, 
Tang et al., 2014, Wang et al., 2014). However, this association did not exist in 
regression models, when controlling for effects of other contributing factors to PSF 
(Park et al., 2009, Naess et al., 2012, Schepers et al., 2006, Appelros, 2006, Galligan 
et al., 2015, Tang et al., 2014, Wang et al., 2014).  
Depression is an important confounder for the association between PSF and sleeping 
problems. Suh and colleagues (282 patients) reported that depression but not fatigue 
was independently associated with poor quality of sleep at night, and both poor sleep 
at night and fatigue were independently associated with daytime sleepiness (Suh et 
al., 2014). Pain is possibly another confounder. Tang and colleagues recruited 97 
patients who had PSF at three months after stroke and found that patients who had 
subcortical white matter infarct, insomnia, pain or higher depression scores at three 
months were more likely to had fatigue at 15 months; adding these factors in 
multiple regression model, the other three factors but not insomnia were independent 
predictors for PSF (Tang et al., 2014). The potential association between PSF and 
subcortical white matter infarct has been discussed previously in this thesis, but 
whether it influences PSF directly or through the effect of other symptoms such as 
pain or depression is unclear. In addition, we do not know whether fatigue is a direct 
result of poor sleep or the use of sleeping pills, of which the latter usually have 
sedative effects. Two studies found that PSF was associated with both the presence 
of sleep disturbances and the use of sleeping pills, but one of these studies (312 
patients) reported that in the multivariate model only the association with sleeping 
pills was significant but not with sleep disturbances (Wang et al., 2014), whilst the 
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other study (377 patients) reported that adding the use of sleeping pills in the model 
did not change the significant association between PSF and sleep disturbances (Naess 
et al., 2012).  
Although there might be some confounding factors, PSF is associated with sleeping 
problems, either directly or indirectly. Thus stroke survivors with fatigue should be 
asked about their sleep patterns. For fatigued patients with sleeping problems, they 
should be provided advice on developing regular sleep patterns and keeping sleep 
hygiene, or even be advised to consult their doctors for more specific treatment. 
Pain 
Pain is common after stroke, of which the reported prevalence ranges from 11% to 
55% in stroke patients (Harrison and Field, 2015). Some studies reported that about 
30% of stroke patients had co-existing fatigue and pain (Naess et al., 2012, Miller et 
al., 2013). In a population-based study with 3667 patients at two years after stroke, 
self-reported feeling of tiredness was significantly associated with self-reported 
feeling of pain (Glader et al., 2002). Another study reported that 71% of fatigued 
patients had pain, which was about two times of the proportion of pain in non-
fatigued stroke patients (36%), although this difference was not statistically 
significant in this small sample of 32 stroke patients (Hoang et al., 2012). One study 
(77 patients) reported that PSF and pain were individually associated with lower self-
efficacy and reduced activity, and patients with coexisting fatigue and pain had lower 
self-efficacy and reduced activity than those without coexisting symptoms (Miller et 
al., 2013). These findings suggest that PSF and pain may have synergic effect on or 
may be affected simultaneously by self-efficacy and participation in activities, 
although there may be no direct association between the two symptoms (Appelros, 
2006, Miller et al., 2013). In addition, similar to sleeping problems, the association 
between PSF and pain may be confounded by the use of relevant medication. One 
study (377 patients) reported that the use of analgesics was associated with the 
presence of PSF (Naess et al., 2012). 
Altered blood pressure 
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One study (100 patients) found that patients with episodes of daytime hypertension 
and those with episodes of daytime hypotension had higher fatigue scores as 
compared with patients with normal blood pressure as recorded on 24-hour 
ambulatory blood pressure monitoring (Harbison et al., 2009). This study also found 
that patients receiving anti-hypertensive medication were more fatigued than those 
who did not take the medication (Harbison et al., 2009). These findings imply two 
possibilities: firstly, there may be a significant association between fatigue and 
hypertension or hypotension. The association between fatigue and lower blood 
pressure has been reported in the general population (Wessely et al., 1990); secondly, 
fatigue may be a result of the use of anti-hypertensive medication, of which fatigue is 
a common side effect (Joshi et al., 2010). Future studies comparing patients with 
normal blood pressure to patients who had medication-controlled hypertension may 
help to clarify the effect of anti-hypertensive drugs on PSF. 
Medications 
In addition to the medications discussed above (i.e. sleeping pills, analgesics and 
anti-hypertensive drugs), other medications commonly used in stroke patients can 
also cause fatigue. For example, one study (218 patients) found that higher fatigue 
scores was associated with the use of antidepressants (Chen et al., 2015). Also, 
statins are often used in stroke patients, of which muscle weakness and fatigue are 
the most common adverse effects (Golomb and Evans, 2008). In an audit (64 
patients) to assess the frequency and impact of fatigue after stroke, there was a trend 
towards statistically significant associations between the presence of PSF and the use 
of statin (p = 0.07) (Crosby et al., 2012). In addition, in a study investigating the 
impact of discontinuation of statin therapy in 631 stroke patients, 246 patients 
discontinued their statin therapy in the first year after discharge and 16 (7%) of these 
statin withdrawal were for the reason of fatigue (Colivicchi et al., 2007).  
If the patient thinks that certain medication causes his/her fatigue, clinicians may 
need to consider using alternative medications. However, clinicians and patients 
should be cautious to stop using the medication simply because of fatigue. This is 
because withdrawal of certain drugs may cause more adverse consequences to the 
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patient; for example, discontinuation of statin therapy was an independent predictor 
for mortality in the first year after stroke (Colivicchi et al., 2007) and controlling 
blood pressure and blood lipid is important for the secondary prevention of stroke 
(American Heart Association Stroke Council, 2014). Clinicians need to inform 
patients of both benefits (e.g. to prevent recurrent stroke) and potential side effects 
(e.g. fatigue) of using certain medication so that patients will be able to weigh the 
pros and cons of using or not using the medication.  
2.2.4 Summary 
In summary, the development of PSF is a temporal and dynamic process, which is 
associated with a myriad of biological (e.g. stroke lesions and inflammation), 
psychological (e.g. depressive symptoms and anxiety symptoms), behavioural (e.g. 
reduced physical activity and sleeping problems) and environmental factors (e.g. 
inadequate external support). Some people may be more vulnerable than others to 
fatigue. This vulnerability may be accounted for factors that exist prior to stroke and 
can be reflected in symptoms such as fatigue and depression, either prior to or after 
stroke. However, predisposing factors for this vulnerability is unknown in stroke 
patients and need to be investigated in future studies. Associations between PSF and 
stroke lesions and related biological changes are reported in some but not all studies. 
These stroke-specific factors may result in physical and cognitive impairments, 
which would require patients to consume more energy to complete physical and 
mental tasks in daily living thus make them feel fatigued. If PSF is associated with 
these stroke-related changes, then it is expected to resolve with stroke recovery. This 
is consistent with the observation of natural resolution of fatigue early after stroke in 
some patients. Future studies are expected to clarify how stroke triggers PSF, as our 
current understanding of its mechanisms is merely based on the observation of 
associations. 
Although the early resolution of fatigue is reported in some studies, PSF is more 
commonly to be reported as a chronic problem that persists in patients several 
months or years after stroke. Findings from longitudinal studies indicate that the 
presence and severity of fatigue tends to be stable in the chronic stage. Factors that 
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perpetuate fatigue include distressed mood, lower self-efficacy, and reduced physical 
activity, which are reflected as maladaptive coping patterns (e.g. emotional-oriented, 
avoidance-oriented, or passive patterns). There is evidence that associations between 
PSF and some of these psychological and behavioural factors are bidirectional, 
although the causal mechanisms are still elusive. Inadequate social support may 
influence PSF through the effects of emotional distress and coping patterns. In 
addition, other medical conditions (such as sleeping problems, pain, and altered 
blood pressure) and some medications commonly used in stroke patients (e.g. 
sleeping pills, analgesics, anti-hypertensive drugs, antidepressants, and statins) can 
also contribute to the development of PSF, thus need to be screened and managed in 
fatigued patients.  
These findings suggest that PSF is an early and persistent problem after stroke. 
Given its high prevalence and detrimental consequences, interventions to prevent and 
treat PSF are urgently needed. Although the causal mechanisms of PSF is unclear, 
some of its clinical correlates are possible targets for interventions for PSF. In 
Section 2.4, I will discuss how the findings in this section informed the development 
of a psychological intervention for the management of PSF.
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Section 2.3 Psychological associations of post-stroke fatigue: a 
systematic review and meta-analysis 
Psychological factors are the most commonly reported associations of PSF, 
particularly depressive symptoms. These associations might represent targets for 
treatment. In this section, I conducted a systematic review of psychological correlates 
of PSF and, where data were suitable, performed meta-analyses to determine the 
strength of associations. 
2.3.1 Abstract 
Background  
Fatigue is common after stroke but there is no effective treatment. Psychological 
interventions improve fatigue in other conditions by targeting psychological factors 
such as patients’ thoughts and behaviours. If these psychological factors correlate 
with fatigue in stroke patients, this would justify the development of similar 
psychological interventions for post-stroke fatigue (PSF). This systematic review and 
meta-analysis aimed to explore psychological factors that are associated with PSF.  
Methods  
Online databases (MEDLINE, EMBASE, CINAHL plus, AMED, and PsycINFO) 
were searched for observational studies that reported psychological associations of 
PSF. Odds ratios (ORs) were used to estimate the strength of associations and were 
pooled in a random-effects model. Subgroup analyses were used to investigate the 
impact of study design. Sensitivity analyses were limited to studies that had excluded 
patients with clinical depression, and to studies that had used depression scales which 
did not have any fatigue item.  
Results  
A total of 5863 citations were retrieved and full texts were obtained for 288 studies. 
Thirty five studies (9268 patients) fulfilled the inclusion criteria, which reported the 
association between PSF and at least one psychological factor. Nineteen studies 
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(6712 patients) reported the association between PSF and depressive symptoms 
(pooled OR = 4.14, 95% confidence interval, 95% CI 2.73 to 6.27); this association 
existed in patients without clinical depression (2 studies, 433 patients, pooled OR = 
1.39, 95% CI 1.27 to 1.53) and in studies using depression scales without fatigue 
items (6 studies, 4554 patients, pooled OR = 5.41, 95% CI 1.54 to 18.93). Four 
studies (3884 patients) reported the association between PSF and anxiety (pooled OR 
= 2.34, 95% CI 0.98 to 5.58). Two studies (123 patients) found an association with 
poor coping styles and one study (167 patients) found an association with loss of 
control. Six studies (1978 patients) reported associations between PSF and other 
emotional or behavioural symptoms. 
Conclusions  
PSF is associated with depressive symptoms, anxiety, poor coping, loss of control, 
and other emotional and behavioural symptoms. These psychological factors are 




Post-stroke fatigue (PSF) is a distressing symptom that affects more than a third of 
stroke patients (Lerdal et al., 2009). However, little research has been conducted to 
develop effective interventions and there is insufficient evidence to guide its 
treatment (McGeough et al., 2009). Psychological interventions improve fatigue in 
other conditions such as cancer, multiple sclerosis, and chronic fatigue syndrome. 
These interventions primarily aimed to change patients’ thoughts and behaviours, as 
well as to improve their emotional well-being. To determine whether to develop 
similar interventions for fatigue after stroke, we need evidence about associations 
between PSF and those factors that could be targeted as part of a psychological 
intervention. 
Although a number of narrative reviews have reported psychological associations of 
PSF (Annoni et al., 2008, Barker-Collo et al., 2007, Barritt and Smithard, 2011, 
Choi-Kwon and Kim, 2011, Colle et al., 2006, de Groot et al., 2003, Duncan et al., 
2012, Lerdal et al., 2009, Staub and Bogousslavsky, 2001a), their results are 
conflicting. For example, three reviews concluded that PSF was associated with 
depression (Barritt and Smithard, 2011, Lerdal et al., 2009, Duncan et al., 2012) but 
other six reviews reported that PSF could occur independently of depression (Annoni 
et al., 2008, Barker-Collo et al., 2007, Choi-Kwon and Kim, 2011, Colle et al., 2006, 
de Groot et al., 2003, Staub and Bogousslavsky, 2001a). Similarly, three reviews 
reported that PSF was associated with anxiety (Annoni et al., 2008, Duncan et al., 
2012, Lerdal et al., 2009) but another review reported no association (Barker-Collo et 
al., 2007). Importantly, none of these reviews used meta-analysis to estimate the 
strength of associations. Thus, we need more evidence about the nature of the 
association between PSF and psychological factors, including, but not limited to, 
depressive symptoms, anxiety, sense of control, and coping patterns. 
This systematic review and meta-analysis aimed to determine whether PSF is 






An electronic search was conducted in October 2012 to identify publications of 
observational studies of PSF in the following databases MEDLINE, EMBASE, 
CHINAHL, AMED, and PsycINFO. The search strategy was adapted from a 
Cochrane review of interventions for PSF (McGeough et al., 2009), using “stroke” 
and its synonyms in combination with search terms relating to “fatigue”.  
Study selection 
Observational studies of stroke patients were included if they reported measures of 
both PSF and at least one psychological factor, either as dichotomous variables (e.g. 
the presence or absence of fatigue) or continuous variables (e.g. scales for the 
severity of fatigue). For studies only reporting qualitative data for the associations, 
they were not included in the meta-analysis but presented in the section of 
descriptive analysis. Studies were excluded if they a) contained insufficient data to 
allow reporting of any association, b) included any patients aged 18 or younger, c) 
used unstructured assessment for PSF, or d) provided data for patients with stroke 
that could not be disaggregated from other types of patients. 
To ensure that eligible studies were not missed, I screened all titles and abstracts on 
two separate occasions. Apparently irrelevant studies were excluded and full texts 
were obtained for potentially eligible studies. I read all full texts to determine 
whether they met the inclusion criteria. Another two review authors (Amanda 
Barugh, AB and Gillian Mead, GM) each read half of the full texts, independently of 
me. Any disagreement regarding whether a study was eligible for the review was 
solved by discussion between the review authors. I also scrutinised reference lists of 





The second review author (AB) and I independently extracted data on study design, 
demographics of patients (including whether patients with a clinical diagnosis of 
depression were included or excluded at recruitment), measures of PSF, measures of 
psychological factors, and statistics for the association(s) between PSF and 
psychological factors.  
Quality assessment 
We (AB and I) also independently applied the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) checklist (Vandenbroucke et al., 
2007) to assess the methodological quality of each included studies. 
Statistical analysis 
For each study which provided raw data of the number or proportion of patients with 
PSF and the number or proportion of patients with any psychological factor(s), I 
calculated odds ratios (ORs) and 95% confidence intervals (95% CI) for associations 
between PSF and each psychological factor. If raw data were unavailable, I used ORs 
reported by study investigators for meta-analysis. If study investigators only reported 
correlation coefficients rather than raw data or ORs, I converted the correlation 
coefficients to ORs using established methods (Borenstein et al., 2009). If ORs could 
not be obtained by any of these methods, I summarised the study qualitatively not 
quantitatively in this review. I assessed publication bias using funnel plotting 
(Borenstein et al., 2009). 
I pooled summary estimates of ORs in the random-effects model (Borenstein et al., 
2009) for associations between PSF and depressive symptoms and between PSF and 
anxiety, respectively. I assessed between-study heterogeneity using the Cochran Q 
statistic, with a pre-specified critical level of 0.05 for significant heterogeneity 
(Borenstein et al., 2009). I had intended to conduct meta-analysis for psychological 
associations other than depressive symptoms and anxiety, but this was not possible 
because these studies only reported regression coefficients and p values. 
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For the association between PSF and depressive symptoms, some studies 
investigated the association using multiple regression where ORs were adjusted by 
controlling for the effects of potential confounders (e.g. age, sex, lesion site, and 
dependence in daily living), whilst other studies investigated the association using 
binary analysis where ORs were not adjusted by other factors. I compared studies 
reporting adjusted ORs with those reporting unadjusted ORs, and partitioned 
heterogeneity between these two subgroups (Borenstein et al., 2009). I conducted 
sensitivity analyses a) for studies that had excluded patients with a clinical diagnosis 
of depression at recruitment, and b) by excluding studies that had used a depression 
measure that contained any item for fatigue.  
2.3.4 Results 
5863 citations were retrieved from electronic searches and 288 full texts were 
screened to assess whether they fulfilled the inclusion criteria. The process of study 















Figure 2.2 Flowchart of electronic search, study selection, and data analysis for a 
systematic review of psychological associations of post-stroke fatigue. ORs indicate 
odds ratios 
A total of 35 studies with 9268 patients were included in this review. The mean age 
of patients ranged from 51 years (Hubacher et al., 2012) to 75 years (Appelros, 2006) 
and the women proportion ranged from 19% (Hubacher et al., 2012) to 67% (Crosby 
et al., 2012). Five studies recruited patients with ischaemic stroke (Coster et al., 
2005, Parks et al., 2012, Snaphaan et al., 2011, Tang et al., 2010a, Tang et al., 
2010b), two studies with subarachnoid haemorrhage (Noble et al., 2008, Visser-
Meily et al., 2009), 18 studies included both ischaemic and haemorrhagic stroke 
(Almborg et al., 2010, Appelros, 2006, Crosby et al., 2012, Glader et al., 2002, 
Hoang et al., 2012, Hubacher et al., 2012, Ingles et al., 1999, Jaracz et al., 2007, 
Lynch et al., 2007, Mead et al., 2011, Naess et al., 2012, Park et al., 2009, Radman et 
al., 2012, Sibon et al., 2012, Skaner et al., 2007, Tseng et al., 2010, van de Port et al., 
2007, Zedlitz et al., 2011), and the other 10 studies did not specify the type of stroke 
31 studies (n=7985) reported the association 
between fatigue and depressive symptoms 
Statistical analysis 
Inclusion and exclusion criteria 
Sensitivity analyses  
1) For two studies (n=433) that reported data for patients without clinical depression; 
2) For six studies (n=4554) that used depression measures without any item of fatigue 
Title and abstract screening 
Full texts retrieved for 288 studies 
Other psychological 
associations: 
7 studies (n=4112) for 
anxiety 
2 studies (n=123) for coping 
styles 
1 study (n=167) for locus of 
control  
6 studies (n=1978) for 
emotional symptoms 
3 studies (n=541) reported adjusted ORs 
Data for ORs were not 
available in 12 studies 
16 studies (n=6171) reported unadjusted ORs  
35 studies (n=9268) included 




(Choi-Kwon et al., 2005, Harbison et al., 2009, Lerdal et al., 2011, Lewis et al., 
2011, Schepers et al., 2006, Smith et al., 2008, Spalletta et al., 2005, Stokes et al., 
2011, van der Werf et al., 2001, Vuletic et al., 2011). 
Of the 35 included studies, the depressive symptom was the most commonly 
investigated psychological association of PSF (31 studies with 7985 patients), 
followed by the symptom of anxiety (seven studies with 4112 patients). Other 
reported associations included coping patterns (two studies with 123 patients), sense 
of control (one study with 137 patients), and general emotional status or other 
symptoms (six studies with 1978 patients). 
The study quality was generally good. The median number of the STROBE checklist 
items scored was 19 (interquartile range, 18 to 20, out of a maximal possible score of 
22; higher scores indicate better quality). Common weaknesses included not 
describing details of recruitment, not addressing potential bias, or not declaring 




Of 31 studies that investigated the association between PSF and depressive 
symptoms, ORs could be obtained from 19 studies; from these I calculated ORs from 
raw data (i.e. numbers of patients with or without the case of fatigue, and numbers 
for depression) of seven studies (Choi-Kwon et al., 2005, Crosby et al., 2012, Glader 
et al., 2002, Harbison et al., 2009, Ingles et al., 1999, Naess et al., 2012, Spalletta et 
al., 2005), extracted ORs from four studies (Appelros, 2006, Radman et al., 2012, 
Snaphaan et al., 2011, Tang et al., 2010a), and converted ORs from correlation 
coefficients from the other eight studies (Coster et al., 2005, Jaracz et al., 2007, 
Lerdal et al., 2011, Park et al., 2009, Schepers et al., 2006, Smith et al., 2008, Tang et 
al., 2010b, Tseng, 2009). The odds of fatigue in patients with depressive symptoms 
were 4.14 (95% CI 2.73 to 6.27) times of the odds in patients without depressive 
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symptoms (Figure 2.3), with no significant between-study heterogeneity (Q = 15.58, 
degrees of freedom (df) = 18, p = 0.62). 
Subgroup analysis 
The strength of the association in 16 studies of unadjusted ORs (6171 patients, 
pooled OR = 5.46, 95% CI 3.58 to 8.32) was higher (p < 0.0001) than the association 
in three studies where ORs were adjusted by other factors (541 patients, pooled OR = 
1.36, 95% CI 1.26 to 1.46). This difference might have contributed to an 
asymmetrical funnel plot (Figure 2.4), as the three studies reporting adjusted ORs 
were located in the upper left-hand corner of the plot (indicating smaller effect sizes 
with smaller variance) away from the other 16 studies. 
Sensitivity analyses 
Of the 19 studies included in meta-analysis, one study (334 patients) excluded 
patients with major depression at recruitment (Tang et al., 2010a) and another study 
(99 patients) provided data of patients without depression (Radman et al., 2012); 
pooled estimate of these two adjusted ORs was 1.39 (95% CI 1.27 to 1.53, which 
was not statistically different from the summary estimate of all three adjusted ORs, p 
= 0.91). The other 17 studies did not specify whether they had distinguished patients 
with current clinical depression. 
Thirteen studies assessed depression using a measure that contained a single item for 
fatigue (Appelros, 2006, Choi-Kwon et al., 2005, Coster et al., 2005, Ingles et al., 
1999, Jaracz et al., 2007, Lerdal et al., 2011, Park et al., 2009, Radman et al., 2012, 
Smith et al., 2008, Spalletta et al., 2005, Tang et al., 2010a, Tang et al., 2010b, Tseng 
et al., 2010) and two of them also assessed the presence of fatigue by this fatigue 
item of the depression measure (Coster et al., 2005, Spalletta et al., 2005). For the 
remaining six studies (4554 patients) that used depression measures without any 
fatigue item, the pooled OR was 5.41 (95% CI 1.54 to 18.93), which was not 
significantly different from either the summary estimate for the other 13 studies 
(pooled OR = 3.45, 1.82 to 6.57; p = 0.53) or from that of the total 19 studies 
(pooled OR = 4.14, 95% CI 2.73 to 6.27; p = 0.84).  
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ID No. OR 95% CI  
Tseng(2010) 21 20.36 2.58-160.76* 
Tang(2010b) 458 15.74 10.37-23.90 
Glader(2002) 3820 14.54 11.06-19.11 
Naess(2012a) 352 11.31 3.86-33.12 
Crosby(2012) 57 11.20 1.30-96.64* 
Lerdal(2011) 115 6.90 3.25-14.66 
Park(2009) 40 6.90 1.90-25.06 
Smith(2008) 80 5.91 2.43-14.39 
Schepers(2006) 167 4.65 2.55-8.47 
Choi-Kwon(2005) 220 4.48 2.11-9.51 
Coster(2005) 206 3.41 2.02-5.75 
Appelros(2006) 247 3.20 1.70-6.01 
Spalletta(2005) 200 2.84 1.59-5.07 
Jaracz(2007) 50 2.77 0.96-7.97 
Harbison(2009) 50 2.75 0.83-9.09 
Ingles(1999) 88 1.61 0.63-4.13 
Tang(2010a) 334 1.37 1.24-1.51 
Snaphaan(2011) 108 1.36 1.17-1.58 
Radman(2012) 99 1.33 1.14-1.55 
 
Figure 2.3 Random-effects meta-analysis for the association between post-stroke fatigue and depressive symptoms. The horizontal 
axis is the odds ratio (OR) comparing the occurrence of depressive symptoms in patients with and without fatigue after stroke. 
Horizontal error bars represent the 95% confidence interval (CI) of OR in individual studies, and vertical gray bar represents the 95% CI 
of the summary estimate of OR. The triangle symbol size represents the log of the number of patients in that study. *The upper limit of 




Figure 2.4 Funnel plot for publication bias. The horizontal axis represents the log 
odds ratios (ORs) for the association between post-stroke fatigue and depressive 
symptoms, and the vertical axis represents the inverse standard error. 
 
Qualitative analysis 
Twelve studies investigated the association between PSF and depressive symptoms 
but did not report sufficient data to be included in meta-analysis. Of these studies, 
nine studies (1053 patients) reported a significant association between PSF and 
depression (Almborg et al., 2010, Hubacher et al., 2012, Lynch et al., 2007, Parks et 
al., 2012, Sibon et al., 2012, Skaner et al., 2007, van de Port et al., 2007, van der 
Werf et al., 2001, Vuletic et al., 2011), whereas one small study (32 patients) 
reported ‘no significant difference’ in depression scores between fatigued and non-
fatigued groups (Hoang et al., 2012), another study (100 patients) reported that 
depressive symptoms were associated with mental fatigue but not with other fatigue 
domains (Stokes et al., 2011), one further study (88 patients) used two measures for 
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PSF and two measures for depression, but reported four conflicting results of the 
association (Zedlitz et al., 2011). 
Anxiety 
Seven studies reported the association between PSF and anxiety, of which four 
studies (3934 patients) provided data for meta-analysis (Glader et al., 2002, Harbison 
et al., 2009, Radman et al., 2012, Snaphaan et al., 2011). The summary estimate of 
OR was 2.34 (95% CI 0.98 to 5.58) with no significant between-study heterogeneity 
(Q = 2.36, df = 3, p = 0.50). Subgroup analysis indicated that the strength of 
association between PSF and anxiety in two studies (Radman et al., 2012, Snaphaan 
et al., 2011) not having controlled for the effect of depression (217 patients, pooled 
OR = 5.34, 95% CI 4.70 to 6.07) was higher (p < 0.01) than that in the other two 
studies (Glader et al., 2002, Harbison et al., 2009) having controlled for the effect of 
depression (3717 patients, pooled OR = 1.25, 95% CI 1.14 to 1.38). 
Of the three studies that had provided insufficient data to be included in the meta-
analysis, two studies (90 patients) reported a significant association between fatigue 
and anxiety (Lynch et al., 2007, Vuletic et al., 2011), whereas the other study (88 
patients) excluded patients with depression at recruitment and found a non-
significant association between PSF and anxiety (Zedlitz et al., 2011). 
Other psychological factors 
Associations between PSF and coping styles were investigated by two studies. One 
study (50 patients) reported that patients focusing on personal emotions and self-
blame were more likely to have a higher level of PSF (p < 0.01) (Jaracz et al., 2007). 
Another study (73 patients) found that ‘maladaptive coping’ (e.g. denial and self-
distraction) was the main cause of Post-traumatic Stress Disorder (PTSD, p < 
0.0001) and the latter was associated with PSF (p < 0.0001) (Noble et al., 2008). One 
study (167 patients) reported that patients who were not confident in their own ability 
to control their health had more severe fatigue (p = 0.002) (Schepers et al., 2006). 
Three studies (1527 patients) assessed mental health and emotional role by the SF-36 
and all reported that PSF was associated with poor outcomes of both mental and 
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emotional subscales (Lewis et al., 2011, Mead et al., 2011, Tang et al., 2010b). Such 
an association was also reported by another study (141 patients) using the emotional 
subscale of Stroke-specific Quality of Life (SSQOL) (Visser-Meily et al., 2009). PSF 
was also associated with inappropriate laughing (one study, 220 patients) (Choi-
Kwon et al., 2005) and alertness behaviour (measured by the Sickness Impact Scale 
in one study, 90 patients) (van der Werf et al., 2001). 
2.3.5 Discussion  
This is, to our knowledge, the first meta-analysis to report associations between post-
stroke fatigue, and mood or other psychological factors. We found a statistically 
significant association between PSF and depressive symptoms, and a trend towards 
an association between PSF and anxiety. Two studies reported associations with 
inadequate coping styles, one study for loss of control, and six studies for other 
emotional or behavioural symptoms. The named psychological factors, i.e. 
depressive symptoms, anxiety, locus of control and coping patterns, have already 
been targeted by psychological interventions for fatigue in other conditions such as 
cancer and multiple sclerosis. This review provides the necessary evidence to justify 
the development of a similar intervention for fatigue in stroke patients. However, our 
findings should be interpreted with caution because only a small number of studies 
investigated each factor except for depressive symptoms. Also there are some 
weaknesses in the quality of the included studies in that most of them did not report 
how patients were recruited and how study size was achieved; thus it is difficult to 
determine whether the sample is representative of the entire stroke population. 
PSF is associated with depressive symptoms, even in patients not meeting clinical 
criteria for depression. A previous study reported the presence of depressive 
symptoms in stroke patients without clinical depression, where 41% of the patients 
reported depressed mood but only half of them met clinical criteria for depression 
(Fedoroff et al., 1991). This suggests that clinicians should be aware of depressive 
symptoms in stroke patients and screen for them in patients with PSF, even in those 
without a clinical depression. We also noticed that some of the included studies had 
measured depression by using scales or criteria that contain a single item of fatigue. 
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We therefore performed a sensitivity analysis to determine whether this might result 
in an overestimation of the strength of the association between fatigue and depressive 
symptoms. The result indicated that this association remained significant even after 
excluding studies that had used a depression measure containing a fatigue item. In 
fact in these depression measures, fatigue only contributes a small proportion to the 
total score of depression (from one out of nine points to one out of 66 points). Thus 
the association that we identified was not because of the overlap between fatigue and 
depression measures. 
In some of the included studies, age, sex, lesion site and dependence in daily life 
were considered as confounders for the association between PSF and depressive 
symptoms. Based on the current data, however, we could not analyse the effect of 
each individual confounder on the association. Previous studies reported that age and 
sex are associated with fatigue (Mead et al., 2011) but not with depression (Allan et 
al., 2013). There is insufficient evidence for the association between lesion site and 
either fatigue (Kutlubaev et al., 2012) or depression (Carson et al., 2000). The 
association between PSF and dependence in daily living has been widely reported in 
the studies included in this review. Dependence was also reported to be associated 
with post-stroke depression (Kutlubaev and Hackett, 2014) . Future research is 
expected to investigate the effect of these confounders. 
There is a trend towards an association between PSF and anxiety, but the association 
was weaker after controlling for the effect of depressive symptoms. One study 
(included in our systematic review but not in meta-analysis) which had excluded 
patients with depression at recruitment reported no significant association between 
PSF and anxiety (Zedlitz et al., 2011). It is reported that anxiety is strongly correlated 
with depression after stroke (Barker-Collo, 2007). To better clarify whether 
depressive symptoms are confounders, the association between PSF and anxiety 
needs to be compared between stroke patients with and without depressive 
symptoms. 
Our study has several strengths. It is the first systematic review to pool the results 
from studies that reported the associations between PSF and depressive symptoms or 
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anxiety. We performed a comprehensive search, had a pre-specified protocol, and 
used a well-established statistical approach. We also used a funnel plot to detect 
publication bias, where the asymmetrical plot might indicate certain publication bias 
caused by the ‘missing’ studies in the bottom left-hand corner of the plot. These 
studies are likely to be of small sample size and/or reported less significant results. A 
possible source for this publication bias might be the exclusion of conference 
abstracts and studies not published in English, although we have attempted to obtain 
further data by contacting the study authors but did not get any response. One 
limitation of our study is that only one author read all the abstracts to identified 
potentially eligible studies. However, this was done on two separate occasions to 
reduce the possibility of missing any relevant studies. 
2.3.6 Conclusions 
This review provides robust evidence for the association between post-stroke fatigue 
and depressive symptoms. This implies the screening and treatment of PSF in stroke 
patients needs to integrate strategies targeting mood. PSF is also associated, either 
directly or indirectly, with anxiety, loss of control, poor coping styles, emotional and 
behavioural symptoms; these factors are potential targets for the treatment of PSF. 
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Section 2.4 Implications for the management of PSF 
In this Chapter, I have systematically reviewed the literature to explore the natural 
history and clinical correlates of PSF. In this section, I will discuss how these 
findings from the literature facilitate our understanding of PSF and inform its clinical 
management. 
2.4.1 A conceptual model for understanding post-stroke fatigue 
Drawing on the literature on natural history and clinical correlates of PSF, here I 
propose a conceptual model of potential mechanisms of PSF (Figure 2.5). This 
model illustrates the development of PSF as a temporal process that involves 
interactions of various biological, psychological, behavioural and environmental 
factors. A previous version of this model has been published in Stroke (2015); 46: 
893-898 (Wu et al., 2015b). Here I present an updated version, by incorporating the 
perpetuating factors for chronic fatigue into a vicious cycle. 
Factors existing prior to stroke predispose the vulnerability to fatigue. Fatigue 
present early after stroke is associated with specific lesion sites of stroke and some 
stroke-related impairments; together with the observation that PSF resolved 
spontaneously in some patients in the first few months after stroke, this suggests that 
early fatigue might be a result of stroke lesion or restorative response to the stroke 
event. Although fatigue resolves spontaneously in some patients, most patients had 
their fatigue persist over time. Patients’ cognitive representation of fatigue (e.g. their 
illness beliefs, sense of control and self-efficacy) interact with their distressed mood 
and reduced physical activity, together with environmental factors, forming a vicious 
cycle that perpetuate fatigue symptoms. Thus the cognitive presentation of fatigue 
would be a potential treatment target to break this vicious cycle and thus reduce 
fatigue. 
Although factors contributing to fatigue present early and late after stroke might be 
different, it is better to view these two types of fatigue as a continuous process, as 
early fatigue is associated with, or the most important predictor for, chronic fatigue 
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(van Eijsden et al., 2011, Lerdal and Gay, 2013, Snaphaan et al., 2011). Also, no 
single factor could fully explain the phenomenon of PSF. Even depressive 
symptoms, which is the most commonly reported association of PSF, explains only 
less than 20% of variance in fatigue scores in stroke patients (van der Werf et al., 
2001). In addition, there are interactions between different contributing factors. For 
example, depressive symptoms and anxiety are highly correlated in stroke patients 
(Chen et al., 2015, Duncan et al., 2015), and fatigue, lower self-efficacy and reduced 
activities after stroke are linked with each other (Muina-Lopez and Guidon, 2013). 
Furthermore, there is no distinct boundary between predisposing, triggering and 
perpetuating factors, and they may overlap with each other. For example, symptoms 
of depression and anxiety at baseline were predictors for follow-up fatigue. However, 
these factors are not exclusively developed after stroke but may be present prior to 
stroke, thus it is unclear whether these factors play roles in predisposing or triggering 
PSF. Also, longitudinal studies found cross-sectional associations between these 






















Figure 5.2 Conceptual model of post-stroke fatigue. The unidirectional arrows 
indicate a potential causal direction to PSF; the bidirectional arrows indicate 
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2.4.2 Potential targets for the management of PSF 
This conceptual model broadens our understanding of PSF from focusing on its 
potential triggers to factors that predispose fatigue and factors that prevent fatigue to 
resolve. The development of PSF involves interactions of a mixture of biological, 
psychological, behavioural and environmental factors. Some of these factors are 
potential targets for the management of PSF. 
Although our understanding of PSF is mainly based on observational studies and its 
causal mechanisms are unknown, some identified factors are modifiable and their 
associations with PSF are bidirectional, i.e. they are independent predictors for and 
are also predicted by fatigue in longitudinal studies. These factors include distressed 
mood, lower self-efficacy and reduced physical activity. Interventions targeting these 
factors may help to reduce PSF. Also other potential causes for fatigue, including 
sleeping problems, pain, altered blood pressures and fatigue-inducing medications, 
can be readily identified and need to be managed in fatigued patients in clinical 
practice. 
Predisposing factors 
Studies for chronic fatigue syndrome suggest that some people may be more 
vulnerable than others to fatigue; this vulnerability can be attributed to personality or 
genetics and reflected in pre-existing conditions such as depression (Lievesley et al., 
2014). This vulnerability hypothesis may apply to PSF because associations were 
found between PSF and some pre-stroke conditions (such as pre-stroke fatigue and 
pre-stroke depression), which are potential indicators of the fatigue vulnerability. 
However, predisposing factors for such vulnerability to fatigue in stroke patients are 
unknown. Future research is expected to explore these predisposing factors. This will 
help clinicians and researchers to identify people who are vulnerable to PSF and to 
develop strategies to adjust the predisposing factors. Early interventions to the 
predisposing factors in vulnerable people, where possible, will help to prevent PSF. 
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Other medical conditions and medications 
Some medical conditions, including sleep disturbances, pain and altered blood 
pressure, are common in stroke patients and often coexist with PSF. These conditions 
need to be screened for, and properly treated in patients with PSF. Some medications 
that are often prescribed to stroke patients can cause muscle weakness or have 
sedative effects, resulting in the feeling of fatigue. These drugs include sleeping pills, 
analgesics, anti-hypertensive drugs, antidepressants, and statins. If the fatigue is 
suspected to be caused by certain drugs, it may be worth trying alternative 
medications. However, clinicians and patients should cautiously weigh the pros and 
cons of stopping using certain drugs only for avoiding the side effect of fatigue. This 
is because withdrawal of certain drugs may cause more adverse consequences to the 
patient; for example, drugs for controlling hypertension and dyslipidemia are 
important strategies for the secondary prevention of stroke (American Heart 
Association Stroke Council, 2014).  
Stroke lesions and related impairments 
Some studies reported that PSF was associated with specific lesion sites, residual 
neurological deficits, attentional-executive dysfunction, and inflammatory and 
neuroendocrine changes after stroke. These findings fit a brain fatigue model which 
was proposed for post-polio fatigue and chronic fatigue syndrome (Bruno et al., 
1998). In this model, brain lesions interrupt the neural networks regulating attention 
and wakefulness function, which consequently lead to impaired concentration and 
the feeling of drowsiness. However, existing stroke studies on the biological 
mechanisms of PSF are small and the results are inconsistent, thus future studies are 
needed. 
If this brain fatigue model is justified in stroke patients, PSF is expected to be 
resolved over time as neurological symptoms tend to get better. This is consistent 
with the observation of natural resolution of PSF in the first few months after stroke 
in some patients (Christensen et al., 2008, Duncan et al., 2014), during which the 
stroke recovery is most active but would subside afterwards (Jørgensen et al., 1995, 
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Newman, 1972). However, this does not mean that fatigue present at the early stage 
after stroke should be ignored. Early fatigue is always associated with or the most 
important predictor for late fatigue (Lerdal and Gay, 2013, Snaphaan et al., 2011). 
Early identification of and interventions for PSF may prevent it from becoming 
entrenched.  
PSF could be present in patients who have minor or no neurological deficits 
(Carlsson et al., 2004, Powell et al., 2004) and the status of fatigue tends to be stable 
in the chronic stage after stroke (Christensen et al., 2008, Duncan et al., 2014). In 
addition, associations between PSF and stroke lesion sites or related biological 
changes are often found at an early but not late stage following stroke. These 
findings suggest that there might be other factors contributing to PSF than stroke per 
se, particularly in chronic stage. 
Psychological and behavioural factors 
Stroke patients who recover physically may be left with emotional and psychological 
dysfunctions (Tyrrell and Smithard, 2005). Affective factors are the most commonly 
reported associations of PSF. Quantitative analyses indicated a strong association 
between PSF and depressive symptoms and a trend of association between PSF and 
anxiety (Wu et al., 2014b). Furthermore, longitudinal studies demonstrated that these 
associations existed over time after stroke, and baseline depressive symptoms and 
anxiety were predictors for fatigue at follow-up (Lerdal and Gay, 2013, Snaphaan et 
al., 2011, Chen et al., 2015, Duncan et al., 2015). In addition, lower self-efficacy is 
common in people with chronic conditions such as stroke, and is associated with 
both fatigue and reduced activity in stroke patients (Muina-Lopez and Guidon, 
2013). Although causal relationships between these psychological factors and PSF 
are elusive, there is evidence that their associations are bidirectional, i.e. they are 
predictors for each other in longitudinal studies. Therefore, clinical management of 
these psychological factors may help to reduce PSF. 
Reduced physical activity at one month after stroke is an independent predictor for 
PSF at both six and 12 months (Duncan et al., 2015) and, vice versa, baseline fatigue 
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is an independent predictor for poor physical health at follow-up (Lerdal and Gay, 
2013). These findings suggest a vicious cycle between PSF and inactivity, where the 
reduced activity after stroke leads to physical deconditioning and in turn exertional 
fatigue, and that exertional fatigue leads to further avoidance of physical activity, 
which then contributes to chronic fatigue (Kutlubaev and Mead, 2011). This 
hypothesis is further supported by the observation that stroke patients who had the 
avoidance coping pattern were more likely to have fatigue (Jaracz et al., 2007), 
which implies the possibility that the avoidance of physical activity in response to the 
feeling of fatigue in turn perpetuates fatigue symptoms. Increased physical activity is 
effective in improving physical fitness in stroke patients (Saunders et al., 2014), 
which may be helpful to combat the self-perpetuating cycle of inactivity, 
deconditioning, and PSF. 
Conclusions 
Future studies are needed to explore predisposing factors and biological mechanisms 
of PSF. Psychological and behavioural factors often coexist with fatigue in stroke 
patients. Some of these factors (i.e. distressed mood, lower self-efficacy and reduced 
physical activity) have bidirectional associations with PSF and are often modifiable, 
which are potential targets for the treatment of PSF. In addition, other medical 
conditions (i.e. sleep disorders, pain and altered blood pressure) and some 
medications (i.e. sleeping pills, analgesics, anti-hypertensive drugs, antidepressants 
and statins) can cause the feeling of fatigue, thus need to be screened for and 
managed in patients with PSF. These psychological and behavioural factors are 





CHAPTER III: Development of a Psychological 
Intervention for Post-stroke Fatigue 
Section 3.1 Introduction 
In Chapter 2, I reviewed the evidence for the potential targets of a psychological 
intervention for the treatment of PSF. In brief, although PSF may be triggered by 
stroke, the persistent presence of fatigue is not necessarily associated with site or size 
of stroke lesions or the presence of neurological deficits. Psychological and 
behavioural factors probably play important roles in triggering and maintaining 
symptoms of PSF. Some of these factors, such as depressive symptoms and reduced 
physical activity, have bidirectional associations with PSF and are readily modifiable 
by psychological interventions. Interventions targeting these psychological and 
behavioural factors may be effective in reducing PSF. 
In this chapter and the next chapter, I will explain how a psychological intervention 
was developed based on the modifiable clinical correlates of PSF. Psychological 
interventions are ‘complex interventions’ that consist of multiple therapeutic 
components (Craig et al., 2013). The UK Medical Research Council (MRC) has 
proposed a phased process of developing complex interventions, with an emphasis 
on early phase development and piloting and suggesting that these early stages are 
iterative (Campbell et al., 2007). The current chapter is focused on Phase 1, which 
includes the processes of identifying evidence, developing theory, and part of the 
modelling stage (Craig et al., 2008a). The next chapter will be discussing Phase 2, 








Section 3.2 Methods 
I developed this intervention in collaboration with a stroke physician (Gillian Mead, 
GM), a stroke neurologist (Malcolm Macleod, MM), two clinical psychologists 
(Kirsten Anderson, KA and David Gillespie, DG), and a CBT psychotherapist 
(Trudie Chalder, TC). The stroke physician and the stroke neurologist (GM and MM, 
both my academic supervisors) had both clinical and research experience with stroke 
patients, as well as expertise in designing clinical trials. The clinical psychologists 
(KA and DG) had more than ten years’ experience of the psychological treatment of 
stroke patients. The psychotherapist (TC) had expertise in cognitive behavioural 
psychotherapies for chronic fatigue and clinical experience with stroke patients. I 
met these members of this multidisciplinary group (i.e. the project team) frequently 
to discuss and decide on theoretical and practical issues of this intervention, with 
perspectives from both stroke care and clinical psychology in the local health system. 
In addition, I sought service user involvement from two groups of stroke patients 
through the Stroke Research Network of the UK National Institute for Health 
Research (NIHR).  
Both qualitative and quantitative approaches were used, which complemented each 
other. Given the subjective nature of PSF, patients’ perspective is essential for the 
current study, for which qualitative approaches allow for in-depth exploration of the 
patients’ perspectives. Quantitative approaches further investigate the issues revealed 
by qualitative studies in larger samples and test the statistical significance. For 
example, the qualitative approach (e.g. focus group with stroke patients) suggested 
that psychological factors such as low mood were potentially associated with PSF, 
and the quantitative approach (e.g. meta-analysis) explored how strong these 
associations were and whether they were statistically significant. The evidence was 
accumulated through a phased but iterative process, which involved literature review 
and meta-analysis, expert opinions (by project team meetings), and service user 
feedback (by focus groups and individual consultations with stroke patients). The 
work of each stage was built on the evidence obtained from the previous stage and 
updated through the repetitive cycles of planning – identifying evidence – developing 
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intervention – reviewing evidence – refining the intervention. Figure 3.1 is the 
flowchart of the initial phase (Phase 1) of developing this psychological intervention. 
In this Chapter, I sometimes use the present or future tense to introduce this 
intervention programme, as it will be tested in the next Chapter.
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3.2.1 Proposal of a psychological intervention for PSF 
A psychological intervention 
The project team proposed a psychological intervention targeting stroke patients’ 
thoughts and behaviours to treat PSF. The choice of the intervention was based on 
stroke clinicians’ clinical observation that PSF often coexists with low mood, 
Figure 3.1 Development of a psychological intervention for post-stroke fatigue (PSF): 
identifying evidence, developing theory, and designing the intervention programme. 
Input from stroke clinicians: observation 
in stroke care that PSF often coexists with 
low mood and reduced physical activity 
Input from psychotherapist: experience in 
managing cancer-related fatigue and chronic 
fatigue syndrome by psychological interventions 
Literature review for 
understanding PSF: natural 
history and clinical correlates 
Focus group with service users: 
experience of PSF and opinions 
on the proposed intervention 
Cognitive behavioural 
model of functional 
neurological symptoms 
Draft intervention manuals (version 1.0) 
Individual consultancy with 
service users by email: 
comments on intervention 
manual and study design 
Revise intervention manuals (version 2.0) 
Input from stroke 
clinicians on study 
design 
Proposal of an individual-based psychological intervention for PSF 
Revise intervention manuals (version 2.1) 
Input from clinical 
psychologist (i.e. therapist) 
and psychotherapist on 




emotional distress and reduced physical activity, and the psychotherapist’s 
experience in managing chronic fatigue in other conditions such as cancer-related 
fatigue and chronic fatigue syndrome.  
The intervention was adapted from two fatigue management programmes that the 
psychotherapist (TC) had been involved in: the content of the intervention was 
adapted from a manualised self-management cognitive behavioural approach for 
chronic fatigue syndrome, with aims to provide fatigue education, challenge 
unhelpful thoughts, and promote physical activity (Burgess and Chalder, 2005); the 
session arrangement and delivery modes were adapted from a psychological 
intervention for cancer-related fatigue, which was an intervention programme of 
three individual, face-to-face, nurse-delivered sessions (Armes et al., 2007). We 
developed the current intervention for PSF based on these two psychological 
intervention programmes because patients with PSF share some common 
psychosocial characteristics with patients with cancer-related fatigue and chronic 
fatigue syndrome (Zedlitz et al., 2011). Also these two psychological intervention 
programmes were feasible to be administered in the UK NHS. 
Target population 
We chose to recruit patients who were at three months after stroke onset with self-
reported fatigue. The choice of this time window was based on the findings of our 
systematic review of natural history of PSF (as discussed in Chapter 2), where 
longitudinal studies indicated that in most stroke patients, if fatigue is going to 
develop, it usually develops by the first few months after stroke. Also, patients’ 
medical conditions, including fatigue status, tend to be stable after three months after 
stroke.  
Patients with severe depression would be excluded because these patients are usually 
under current treatment for depression, e.g. antidepressants and/or psychological 
interventions. The clinical psychologist (DG) suggested including patients with mild 
or moderate depressive symptoms, as in the local health system these patients usually 
do not receive treatment for depression, and psychological interventions for fatigue 
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are similar to the interventions for mood. Thus these patients with PSF might benefit 
from this psychological intervention for fatigue even though they had some 
depressive symptoms.  
Therapist 
Previous psychological interventions for PSF were group-based and delivered by 
clinical psychologists (Zedlitz et al., 2012, Clarke et al., 2012), which one could 
argue are not practical in the UK NHS because of the shortage of trained clinical 
psychologists in routine stroke care (Bowen et al., 2005). In the local health system 
in the Lothian area of Scotland, stroke patients in the community are routinely visited 
by stroke nurses at home. Thus an individual-based nurse-delivered approach may be 
more practical. In addition, symptoms of fatigue are diverse among different patients 
and their main complaint may be different, thus interventions for PSF should be 
personalised and focused on individual problems. A study in London has shown that 
the nurse-delivered individual psychological intervention was feasible in the NHS 
and effective in improving physical functioning in patients with cancer-related 
fatigue (Armes et al., 2007). Thus our intention was that the current intervention 
would ultimately be delivered by stroke nurses on an individual basis, so that it 
would be feasible and affordable in the NHS.  
In this thesis, which was related to the early development stage of the intervention, 
this psychological intervention would be delivered by a clinical psychologist (KA), 
who had more than ten years’ experience of psychological treatment of stroke 
patients. This would help to test if this intervention was comparable to psychological 
interventions normally used in clinical practice and if it was acceptable to the 
therapist from the perspective of a clinical psychologist. 
The current intervention was a ‘brief’ psychological intervention in that it did not 
require the therapist to have complex psychological expertise, as it was adapted from 
other self-management or nurse-delivered interventions. If the intervention was 
acceptable for delivery by the clinical psychologist, in future studies it will be further 
tested for the feasibility of delivery by stroke nurses. In a study investigating the 
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effect of a CBT for the treatment of chronic fatigue syndrome, there was no 
difference in the therapist effect between clinical psychologists and specialist nurses, 
given that same orientation, training and supervision were provided (Cella et al., 
2011). Thus a nurse-delivery psychological intervention for the treatment of PSF 
might be feasible. 
3.2.2 Focus group on the acceptability of the proposed intervention 
I approached a service user group at the Annual User Meeting of the Yorkshire 
Stroke Research Network (in November 2012, Bradford). Ten stroke patients (six 
men and four women) and five caregivers, who were interested in the topic on PSF, 
were invited to a round-table discussion. I held two focus groups with these users, 
each with five stroke patients and their caregivers. With each focus group, I 
introduced the proposed intervention programme and facilitated a 45 minutes’ 
discussion to elicit users’ opinions about the proposed intervention. The discussion 
also covered the topics of patients’ experiences of PSF as well as helpful and 
unhelpful strategies that they had used to manage fatigue. A co-facilitator and I took 
notes of the discussion independently. I compared the notes and analysed the 
transcripts qualitatively using the thematic content analysis (Burnard, 1991).  
The themes and categories raised by the users are summarised in Table 3.1. Users 
were satisfied with the proposed strategies to provide fatigue education, challenge 
unhelpful thoughts, and promote physical activity, as they thought that their fatigue 
was caused by the distressed mood and boredom, and also some of them found that 
regular physical activity (such as workout in the gym and doing routine housework) 
were helpful in relieving their fatigue. In addition, some users reported that sleeping 
problems contributed to their fatigue and keeping a regular sleep pattern relieved 
fatigue. This indicated the need to incorporate the strategies for developing good 
quality sleep in the current intervention. Finally, all users acknowledged that 
optimistic attitude and family support were important not only for improving fatigue 
but overall recovery of stroke. Therefore, keeping positive attitude towards fatigue 
and sharing experience with family members might help to reduce fatigue. 
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One limitation of this focus group study was that I did not take audio record, so that I 
could not report quotes of the users in Table 3.1. This annual user meeting was held 
shortly after the current intervention was conceived by our project team and we 
wanted to obtain some user feedback on the acceptability of the proposed 
intervention. I was invited to be one of the facilitators of this user meeting and so I 
organised this focus group discussing PSF and the proposed intervention. Ethical 
approval was not needed for this meeting with service users, but had I wanted to 
audio record the meeting I almost certainly would have needed ethics approval to do 
this but there was insufficient time to obtain the approval. 
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Table 3.1 Focus group’s views on their experience of and strategies for post-stroke 
fatigue 
Themes Major categories Minor categories 
Fatigue presentation Symptoms Physical exhausted 
Mental tiredness 
Sleepiness 
Timing Afternoon or end of the day 
Anytime during the day 
In the middle of an activity 
Contributing factors Biological factors Stroke  
Older age 
Family history 
Raised blood pressure 
Psychological and behavioural factors Anxiety and mental stress 
Boredom 
Sleeping problems 
Medication Multiple medication 
Antidepressants 
Helpful factors or 
strategies 
Automatically getting better with time  
Being physically active Physical activity 
Routine exercise 
Daily housework 
Taking rest  Regular rest during the day 
One day off during the week 
Regulating sleep patterns Not sleeping during the day 
Attitude Optimism of patients 
Family support and 
encouragement 
Keeping a diary to schedule things   
Fresh air  
Unhelpful strategies Antidepressants  
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3.2.3 Identifying evidence basis for the intervention 
Although both stroke-related health professionals and service users had provided 
favourable opinions on our proposed psychological intervention, further evidence 
was needed to justify the choice of the intervention in a broader context of stroke 
studies. Therefore, I conducted systematic reviews to explore the natural history and 
clinical correlates of PSF (as discussed in Chapter 2). Drawing on the evidence from 
observational studies of PSF, I developed a stroke-specific model of PSF, which 
suggested that the development of PSF was a temporal process that involved 
interactions of various biological, psychological, behavioural and environmental 
factors (see Section 2.4). Although fatigue in the first few months after stroke might 
be related to biological factors, fatigue persisting in the chronic phase of stroke might 
be more attributable to psychological (e.g. low mood and anxiety) and behavioural 
(e.g. reduced physical activity and sleep disorders) factors (see Section 2.2) (Wu et 
al., 2015b). Also, I performed meta-analyses to determine the strength of associations 
between PSF and psychological factors, which found a significant association 
between PSF and depressive symptoms, even in patients who did not meet clinical 
criteria for depression (see Section 2.3) (Wu et al., 2014b). In summary, depressive 
symptoms, anxiety, lower self-efficacy, passive coping, reduced physical activity, 
sleeping problems, and inadequate social support are important associations of PSF 
(see Section 2.4) (Wu et al., 2015b). Based on the psychotherapist’s (TC) experience 
in managing chronic fatigue, these associations could be addressed by psychological 
interventions that target people’s thoughts and behaviours (i.e. using a cognitive 
behavioural approach). By modifying these psychological and behavioural 
associations, it is possible that fatigue symptoms can be reduced. 
3.2.4 Developing rationale for the intervention 
Findings from systematic reviews and meta-analyses indicated that PSF was 
associated with depressive symptoms, anxiety, lower self-efficacy, passive coping, 
reduced physical activity, sleeping problems, and inadequate social support (Wu et 
al., 2015b). These factors can be incorporated into a cognitive behavioural model of 
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neurological functional symptoms (Williams et al., 2011), where physical symptoms 
of fatigue, patients’ thoughts, emotions, behaviours and relationships with other 
people are held both to interact with each other and perpetuate fatigue symptoms 











Psychological interventions targeting patients’ thoughts and behaviours (i.e. CBT) 
may help to break this cycle and thus reduce fatigue symptoms. The CBT has been 
widely used in mental health conditions and are effective in treating fatigue in 
patients with cancer (Armes et al., 2007), multiple sclerosis (Thomas et al., 2013), 
and chronic fatigue syndrome (White et al., 2011). In the situation of PSF, we 
hypothesised that the increase of activity will break the vicious cycle of fatigue and 
reduced physical activity, and that the increased activity will improve patients’ 
confidence in taking physical activity and thus improve their self-efficacy and mood 
distress. 
Figure 3.2 Cognitive behavioural model for post-stroke fatigue 
(adapted from (Williams et al., 2011)) 
 






efficacy, sense of control, 
and illness perceptions 
Behaviours/Activities: 
reduced physical activity, 
passive coping, and sleep 
problems 
Relationships: inadequate 
support from others  
  
92 
3.2.5 Modelling the intervention programme and outcomes 
The initial intervention programme 
The content and format of the initial intervention programme were adapted from two 
intervention programmes for fatigue in other conditions in the UK (Burgess and 
Chalder, 2005, Armes et al., 2007). In addition, information for education about PSF 
was developed from theories of PSF (based on the existing literature discussed in 
Chapter 2) and adapted from self-help materials for PSF by local stroke charities (i.e. 
Stroke Association, and Chest Heart & Stroke Scotland, CHSS). 
The programme consisted of three individual, face-to-face sessions, with two hours 
for each session and two-week intervals between sessions:  
 Session 1: introduction and education about PSF 
 Session 2: learning skills to facilitate the improvement of PSF  
 Session 3: progress assessment and making future plans 
User feedback on the initial programme 
I drafted the Participant Manual (version 1.0) to provide participants with an outline 
of the contents for each session. Another user group of five stroke patients (i.e. 
service users from the Scottish Stroke Research Network) were invited by email to 
feedback on the acceptability of the manual and the feasibility of the study design. I 
distributed the manual by email to each user, with an outline of the study and 
questions regarding the session arrangement, inclusion criteria, and mode of delivery. 
The responses of the users are summarised in Table 3.2.
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Table 3.2 Users’ feedback on the initial version of intervention manual and study 
design 
Topics Responses 
Acceptability of manual 
 Length of the manual ‘At first I thought the participant manual was a bit long and wordy 
but having looked at it a second time it’s the nature of the study and I 
cannot see how it can be reduced’ 
 More examples and 
pictures 
‘The patient would benefit from more examples and a more 
conversational tone, and use of more diagrams and pictures’ 
Arrangement of sessions 
 Three sessions, each 
two weeks apart 
‘Probably but may depend on the individual and their attention span’ 
‘I would suggest that a light touch treatment will need to take place 
over at least 1-2 years’ 
‘No, I doubt it [that three sessions would be enough]. There is a large 
amount of quite abstract materials to internalise’ 
‘For rollout in the future a maintenance group session after the 
course, say monthly, would be a good way to ensure that the lessons 





‘The final assessment should be delayed to ensure the therapy has 
had an effect and to identify whether it has persisted. The patient may 
feel obliged to be positive about the therapy because the researcher 
has spent time helping them. A postal questionnaire three months 
after completing the therapy might provide a different answer’ 
Inclusion criteria 
 Including patients at 3 
months after stroke 
‘I agree [including patients at three months after stroke]. Earlier than 
that life is in too much turmoil anyway; by 6 months the problem 
may be entrenched’ 
‘3 months is still too early to address these post stroke complications. 
The patient is still overwhelmed by the dramatic change in their 
circumstances at 3 months’  
‘This problem [fatigue] is widespread and involves those with stroke 
more than 3 months ago’ 





‘Seems fair enough’ 
‘I thoroughly approve of you including people with mild depressive 
symptoms’ 
‘Yes, strategies for addressing fatigue problems may rollover into 
other areas of life, e.g. coping with low mood’ 
Mode of delivery 
 Delivery by nurses ‘Yes, this is reasonable, but the training should be thorough’ 
‘Yes, it does. Could it also involve survivors who have beaten the 
fatigue effects?’ 
‘Probably better for the patient as I suspect that it will remove the 
additional stigma of being referred to and treated by a psychologist 
and hence probably lower anxiety levels in the patient’ 
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Revision of the intervention programme 
In response to users’ feedback, I modified the intervention manual and the study 
design as follows: a) extending three treatment sessions to six treatment sessions and 
halving the length of each session to one hour; b) adding a review session one month 
after the last treatment session to consolidate patients’ gains from the intervention; c) 
adding an assessment of clinical outcomes at three months after the last treatment 
session by postal questionnaires; and d) extending the criterion for including patients 
at three months to between three months and two years after the recent stroke. 
The revised Participant Manual (version 2.0) was discussed within the project team, 
following which the manual was modified to a more user-friendly version (e.g. 
named the current intervention as a ‘rehabilitation therapy’ in the manual) (version 
2.1). Based on this version of the Participant Manual, I developed a corresponding 
Therapist Manual to provide the therapist with detailed content of each session and 
guidance on delivery, which was discussed with and finally approved by all members 
of the project team.  
Of this final version of manuals, Sessions 1 and 6 and feedback session were 
developed by the project team (100%). Session 1 was based on the theories of PSF 
that we had developed (as discussed in Chapter 2). Session 6 and feedback session 
were based on the content delivered in the previous sessions. For sessions 2 and 5, 
introduction sections and ‘tasks to do at home’ were written by the project team 
(100%); examples and worksheets were adapted from a self-management programme 
for CFS and a nurse-delivered intervention for cancer-related fatigue (80%), of 
which some content were adjusted to the stroke-specific situations (20%). 
Defining outcome measures 
Some researchers suggested that the selection of outcome measures to assess 
functional recovery after stroke should incorporate the International Classification of 
Functioning, Disability and Health (ICF) framework (Barak and Duncan, 2006). Also 
clinical guidelines recommend that rehabilitation of stroke should target the 
individual needs of stroke patients, and aim to maximise the individual’s activity, 
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participation and quality of life, and minimise the distress to caregivers (Scottish 
Intercollegiate Guidelines Network, 2010). 
As PSF often impedes stroke rehabilitation and recovery, I considered the ICF 
framework to determine the outcome measures for the current intervention. This 
intervention primarily targeted patients’ thoughts and behaviours, with aims to 
improve how people feel physically (i.e. fatigue symptoms) and emotionally (i.e. 
mood). Thus the expected outcomes were the improvement in both fatigue and 
mood. In addition, one of the key strategies of this intervention was to promote 
physical activity in daily living, thus the participation in daily activities was assessed. 
Furthermore, the overall health-related quality of life (HRQoL) after stroke was 
assessed. In summary, the determined outcomes fit the ICF framework of recovery 
from fatigue after stroke, where fatigue and depressive symptoms relate to 
impairments, dependence in daily activities relates to limitations, and HRQoL relates 
to all three levels of impairments, limitations and restrictions (World Health 
Organization, 2001).  
To choose the measure for each outcome, I considered two criteria (Barak and 
Duncan, 2006): a) the measures should have good psychometric properties in stroke 
patients, and b) the measures should be feasible for postal delivery. The individual 
outcome measures will be discussed in the result section.
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Section 3.3 Results 
3.3.1 Theoretical issues 
Rationale of a CBT-based psychological intervention for PSF 
The premise of CBT is that changing unhelpful thoughts and behaviours would affect 
how people feel physically (physical symptoms) and emotionally (emotional 
feelings) (Beck, 2011). A CBT typically consists of two interacting therapeutic 
approaches: the cognitive approach is to help people correctly understand their 
symptoms and situations and develop correct beliefs about themselves, other people 
and the world; and the behavioural approach is to encourage people carry out 
behavioural experiments to test out the accuracy of alternative thoughts and beliefs, 
and thus adopt new ways of perceiving and acting (Grazebrook and Garland, 2005). 
Thus the key strategies of the current intervention for PSF were to reassure 
participants that the impact of PSF is reversible if factors that perpetuate fatigue are 
properly treated and to encourage them to overcome their fear of taking physical 
activity (i.e. the cognitive approach), and to promote a balance between daily 
activities, rest and sleep and then gradually increase their level of physical activity 
(i.e. the behavioural approach).  
Cognitive strategies 
Education about PSF is provided to reassure participants that fatigue is common after 
stroke and its impact on life is reversible. Firstly, PSF is potentially triggered by 
stroke, thus the expected outcome of this intervention is not to help participants go 
back to the normal life prior to stroke but to establish a new life of balance. 
Secondly, although fatigue may be triggered by stroke, the persistent presence of 
fatigue is not necessarily related to stroke lesions but associated with psychological 
and behavioural factors such as distressed mood, inactivity, and erratic sleep 
patterns. These psychological and behavioural factors are often modifiable. If these 
factors can be properly identified and managed, the impact of fatigue on these areas 
may be reduced.   
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Specific thoughts related to unpleasant emotions in the situation with fatigue are 
identified and challenged, with a particular attention paid to the fear-avoidance 
responses to fatigue. Fatigue is a common experience in chronic conditions such as 
stroke. The fear of activity-induced fatigue can lead to the avoidance of activities, 
which may in turn result in a vicious cycle of the reduced physical activity or 
inactivity – physical deconditioning – exertional fatigue – further avoidance of 
physical activity – chronic fatigue. Overcoming the fear about activity-induced 
fatigue is the starting point to break this vicious cycle. 
Behavioural strategies 
One of the key strategies of this intervention is to promote the participation in 
activities of daily living, which is also the ‘behavioural experiment’ to test out the 
theory that keeping active would break the vicious cycle of fatigue and inactivity. 
The first step is to encourage participants to develop a regular routine of daily 
activities and scheduled rests rather than act and rest in response to fatigue. This is 
because erratic activity pattern could consume more energy and thus make fatigue 
worse. After developing a routine of daily activities and scheduled rests, participants 
will be encouraged to gradually increase their daily activities (including social 
activities) and reduce the amount of rests, by a series of practice of goal setting, 
activity and rest planning, progress assessment, and goal modification.  
Sleep is another behavioural target for this intervention, as sleeping problems are 
common after stroke and often coexist with fatigue. A detailed sleep diary for the 
timing and quality of sleep is used to identify the individual sleep pattern and any 
sleeping problems that could be improved. Information about sleep hygiene is 
provided to help participants develop a regular and good quality sleep.  
Other strategies  
Information of identification and management of other potential causes for fatigue 
such as pain and certain medications is also provided in the manual, although they 
are not the key targets of this intervention. If any of these factors identified, 
participants will be suggested to consult their doctors for further advice or potential 
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treatment. In addition, because inadequate external support would confound people’s 
psychological and behavioural responses to fatigue thus worsen fatigue symptoms, 
information is provided regarding how to get help from significant others and how 
others can be of best help. Participants are encouraged to share their experience of 
fatigue with family and friends. Understanding from ‘significant others’ and their 
support are important for participants to keep positive attitude towards their fatigue. 
Structure and content of the intervention programme 
The intervention will be delivered by a therapist to individual participant through six 
face-to-face treatment sessions and one telephone-delivered review session. Table 
3.3 summarises the structure and content of the intervention programme. The 
duration of the first session is 90 minutes and the subsequent sessions are 60 minutes 
each. The extra 30 minutes in the first session would allow for the development of a 
collaborative therapeutic relationship between the participant and the therapist. There 
are two-week intervals between the sessions, during which participants will be 
encouraged to complete some home tasks (e.g. keeping a diary or increasing daily 
activities), as negotiated between the participant and the therapist during the session. 
The therapist will provide praise and encouragement throughout the intervention to 
enhance participants’ self-confidence in making changes to overcome fatigue.  
One month after the final treatment session (i.e. after Session 6), the project team 
will mail the postal questionnaires to each participant for the assessment for their 
clinical outcomes. Based on the result of this assessment, the therapist will have a 
review session (on the telephone) with each participant to discuss his/her progress 
and to negotiate plans for making further improvement in overcoming PSF. 
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Table 3.3 Structure and content of a psychological intervention for post-stroke fatigue 
(PSF) 





Education about PSF:  
To reassure the participant that impact 
of PSF is reversible 
Activity and sleep diaries:  
To identify targets to facilitate the 
improvement of PSF 






Based on the participant current 
mental and physical abilities, set goals 
to develop a balance between daily 
activities, rest and sleep 
Activity planning: 
Divide goals into small and 
manageable steps and specify 
activities to work toward the goals 







Modify goals according to the 
participant’s progress and, where 
applicable, gradually increase the 
activity level 
Activity rescheduling: 
To adjust the activity plan according 
to the new goals 




Challenging unhelpful thoughts: 
Identify thoughts about PSF that 
invoke unpleasant emotions and their 
impact on behavioural responses; 
develop alternative, more positive and 
realistic thoughts 
Acting against unhelpful thoughts: 
Foster behavioural changes 
according to the alternative thoughts 





Identifying factors that block the 
progress: 
Review the diaries and discuss 
potential factors that block the 
progress; reinforce the challenge of 
unhelpful thoughts 
Managing blocks and setbacks: 
Take action to overcome factors that 
block the progress 




Review of the learned skills; 
Summary of achieved goals; 
Making future plans 
Providing worksheets used during 
the programme to encourage the 
continue using of the learned skills 
One month’s interval 
Review session Reviewing the progress in overcoming fatigue 
Negotiating future plans to make further improvement 
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3.3.2 Practical issues 
Participants 
Inclusion criteria 
a) ≥18 years old, b) recent stroke (including minor stroke) three months to two years 
previously, c) self-reported fatigue, and d) living in the Lothian area, Scotland, UK.  
Time window after stroke 
I used three months after stroke as the lower limit for inclusion because longitudinal 
studies indicated that most patients had their fatigue developed at this early stage 
after stroke, and also there is a natural resolution of PSF in some patients in the first 
few months after stroke (as discussed in Chapter 2). This early resolution is possibly 
because that fatigue present early after stroke is associated with stroke lesions and 
thus resolves as stroke recovers (Wu et al., 2015b). Also at an early stage after stroke 
patients’ feeling of fatigue may be influenced by hospitalisation and possible lifestyle 
changes (Choi-Kwon et al., 2005). This type of transitory fatigue is not of the interest 
of this thesis, thus I only included patients who had fatigue after three months as 
beyond this time point fatigue tends to be chronic. PSF is a persistent problem in 
many patients, so I included patients up to two years after their stroke. I did not 
include patients over two years because some service users suggested that by two 
years after stroke, most patients would have adapted themselves to the life after 
stroke, thus their lifestyle might have been entrenched and difficult to change. 
Self-reported fatigue 
The presence of fatigue was screened by a single question ‘Do you feel tired all the 
time or get tired very quickly since your stroke?’ This question is part of the Greater 
Manchester Stroke Assessment Tool (GM-SAT), a structured evidence-based needs 
assessment tool that is feasible in a community setting and acceptable to stroke 
patients (Rothwell et al., 2013). I limited possible responses only to ‘yes’ or ‘no’ and 
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included patients who answered ‘yes’ to this question as it indicated that fatigue was 
a problem for the patient. 
Exclusion criteria 
a) severe depression, b) significant impairments in cognition or verbal 
communication, c) medically unstable or living in nursing home, or d) currently took 
part in other research studies that might affect fatigue or add significant burden to the 
participant (e.g. studies providing physical training). The rationale for excluding 
these people is explained in the text below.  
Severe depression 
Depression was screened by the Patient Health Questionnaire-9 (PHQ-9), which is a 
self-administered questionnaire that establishes the diagnosis of depression based on 
the fourth version of the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IV) criteria (Spitzer et al., 1999). A total PHQ-9 score less than 10 seldom 
occur in individuals with major depression whereas a score of 15 or more usually 
signifies the presence of major depression (Kroenke et al., 2001). The PHQ-9 is a 
valid screening tool for depression after stroke, of which a total score of 10 or more 
had 91% sensitivity and 89% specificity for major depression (Williams et al., 2005).  
In the current study, I used a cut-off score of 15 for exclusion. This was because a 
PHQ-9 score of 15 or more indicates at least moderately severe major depression (15 
to 19 for moderately severe depression; 20 to 27 for severe depression) (Kroenke and 
Spitzer, 2002). As suggested by a clinical psychologist (DG) in the project team, 
such patients would require for immediate medical management for depression (e.g. 
antidepressant or psychotherapy, or both), thus they were excluded from the current 
study. Patients with moderate depressive symptoms (with a PHQ-9 score between 10 
and 14) were included, because in the local health system these patients usually do 
not receive treatment for depression and the current intervention for fatigue was 
similar to the intervention for mood, thus these patients with fatigue and depressed 
mood might benefit from this intervention. For patients with moderate depression, I 
informed them that they potentially had some symptoms of depression, and 
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suggested them to either take part in the current study or consult their General 
Practitioners (GPs) for further advice on depression. 
Severe deficits in cognition and significant difficulties in verbal communication 
The current psychological intervention was delivered through therapeutic 
conversations between the therapist and the participant. This required participants to 
have adequate capability in cognition and verbal communication, so that they could 
understand the manual content and participate in the intervention. These capabilities 
were determined by my contacting with their GPs or responsible stroke clinicians, 
and by my judgement through the telephone and face-to-face conversations with each 
participant.  
Unfavourable medical conditions 
Patients with other acute or severe medical conditions were excluded because fatigue 
is a ubiquitous and common symptom in many medical conditions, and could be 
aggravated by unstable medical status. 
Other research studies 
Patients in other research studies were excluded, if by attending such studies 
participants could be overburdened or their feeling of fatigue could be affected. For 
example, a study providing physical training may have synergic effect with the 
current psychological intervention on fatigue; also a study requiring much travelling 
from home to hospital may increase the amount of physical activity thus induce 
fatigue.  
Assessment of clinical outcomes 
Outcomes were assessed four times for each participant: at baseline (i.e. before 
treatment, T0), immediately after the final treatment session (i.e. immediately after 
Session 6, T1), one month after the final treatment session (before the review 




Presence of clinically significant fatigue 
The presence of clinically significant fatigue was assessed by a case definition of 
PSF (Lynch et al., 2007). This case definition contains seven probe questions, which 
was particularly designed to identify fatigue that is clinically relevant to stroke 
patients (Lynch et al., 2007). This case definition is feasible and reliable in 
measuring fatigue in stroke survivors and has good convergent validity with the 
Fatigue Assessment Scale (FAS) (Lynch et al., 2007). 
To fulfil this case definition, the experience of fatigue should meet the following 
criteria: a) is a feeling of fatigue, lack of energy, or an increased need to rest, rather 
than sleepiness or lack of motivation; b) lasts for more than 50% of waking hours of 
the day; c) has been present every day or nearly every day for at least two weeks in 
the past month; and d) is perceived by patients as a problem and affects their 
everyday activities (Lynch et al., 2007). 
Our project team had discussed whether to use this case definition as an inclusion 
criterion and finally decided not to use it in this feasibility study. Instead, we used a 
simple screening question for fatigue in order to include a broader range of patients 
as long as they perceived fatigue as a problem for them. 
Severity of fatigue 
The severity of fatigue was assessed by the FAS (Michielsen et al., 2004). I chose 
this scale because it assesses the fatigue severity from both the patient’s subjective 
feelings of fatigue and its impact on daily life. I did not use scales that only measure 
subjective feelings, because focusing on fatigue itself might make patients feel 
worse. In addition, the FAS has good psychometric properties in measuring fatigue 
in stroke patients, in terms of face validity, feasibility, and reliability (Mead et al., 
2007). Furthermore, the FAS has good divergent validity to distinguish fatigue from 
depression (Smith et al., 2008, Michielsen et al., 2003), of which the latter is a 
common confounder of fatigue. Finally, this is a self-rating scale and is feasible for 
postal delivery (Michielsen et al., 2003). 
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The FAS has ten items asking about the frequency of different aspects of fatigue, 
with each item on a 5-point Likert rating scale from 1 = “never” and 5 = “always”. 
The total score, which was used in the current study as an index of fatigue severity, 
ranges from 10 to 50, with a higher score indicating more severe fatigue. It is 
important to note that for two items of this scale (i.e. “I have enough energy for 
everyday life” and “when I am doing something, I can concentrate quite well”), a 
higher score indicates better outcome; whilst for the other eight items (e.g. “I am 
bothered by fatigue”), a higher score indicates poorer outcome. Thus for data 
analysis, scores of these two items were converted by deducting the individual score 
from 6 (for example, a score of 1 would be transformed to 5 i.e. 6-1=5). A study 
suggested a 4-point difference on FAS as the minimal clinically important difference 
(MCID) in patients with sarcoidosis (de Kleijn et al., 2011), however, this MCID has 
not been established in stroke patients. Therefore, I used this scale as a continuous 
measure of fatigue and assessed the change of scores from before to after treatment. 
Depressive symptoms 
The depression severity was assessed by the Patient Health Questionnaire-9 (PHQ-9) 
(Kroenke et al., 2001), which was also used as the screening questionnaire for 
depression at recruitment. This scale was chosen because it was designed based on 
the nine criteria for depressive disorders of the fourth version of the DSM-IV, thus it 
could be used for both the diagnosis of depression and monitoring depression 
severity over time or in response to treatment (Kroenke et al., 2001). In addition, this 
scale has good reliability and validity in stroke patients (Williams et al., 2005, 
Janneke et al., 2012) and it is readily delivered through telephone (Pinto‐Meza et 
al., 2005). 
The PHQ-9 consists of nine items, in corresponding to the DSM-IV criteria for 
depression. Each item can be scored from 0 = “not at all” to 3 = “nearly every day”, 
with a total score ranging from 0 to 27 and a higher score indicating more severe 
symptoms. Cut-off points of 5, 10, 15 and 20 represent the thresholds for mild, 
moderate, moderately severe, and severe depression, respectively. The PHQ-9 also 
has an item in addition to the diagnostic section, which is a general rating of 
  
105 
functional impairment (Kroenke et al., 2001). It is suggested that a decline of 5 
points as the MCID on the PHQ-9 (Kroenke and Spitzer, 2002), but this has not been 
validated in stroke patients. This scale was used as a continuous measure of the 
severity of depressive symptoms in the current study. 
Participation in activities of daily living 
Independence in daily activities is an important functional outcome for stroke 
patients. Encouraging participants to take more daily activities was a key strategy of 
the current psychological intervention. Thus the Nottingham Extended Activities of 
Daily Living (NEADL) (Nouri and Lincoln, 1987) was chosen to measure the 
independence of daily life. I did not choose scales of basic ADL (e.g. Barthel Index) 
because some studies suggested that PSF was associated with instrumental activities 
of daily living (IADL) but not basic ADL (van de Port et al., 2007). Another concern 
for not using the Barthel Index is that the floor and ceiling effects are a particular 
issue of this scale in stroke trials (Quinn et al., 2011). 
The NEADL is a self-rating scale that particularly designed to assess the 
independence in activities thought to be important to stroke patients for daily living 
at home (Nouri and Lincoln, 1987). The scale contains 22 activities of four domains 
(mobility, kitchen, domestic, and leisure). Patients are asked whether they actually 
did the activity rather than if they were capable to do it, with an aim to assess the 
level of activity rather than the capacity (Nouri and Lincoln, 1987). Four answers are 
provided on a Guttmann scale for each activity (i.e. for each activity, the answers are 
arranged in an order so that the patient who agrees with a particular answer also 
agrees with all answers of lower rank-order). Patients are coded as either independent 
(scored 1) if they respond ‘on my own’ or ‘on my own with difficulty’, or dependent 
(scored 0) if they ‘need help’ or ‘did not do’ the activity (Nouri and Lincoln, 1987). 
Thus the total score ranges from 0 (very dependent) to 22 (fully independent), with a 
higher score indicating better independence. This scale is feasible for postal delivery 




Health-related quality of life 
The general health status was assessed because fatigue could affect different domains 
of life after stroke. The Stroke Impact Scale (SIS) 3.0 is a stroke-specific, self-rating 
scale that assesses different aspects of stroke recovery (Duncan et al., 2003). This 
scale was designed for repeated administration to track change over time, and has 
been recommended for assessing general changes after stroke rehabilitation, for its 
good responsiveness to changes as compared with another stroke-specific scale for 
health-related quality of life (Lin et al., 2010a). The SIS is feasible for both postal 
(Duncan et al., 2002) and telephone (Duncan et al., 2005) delivery. 
The SIS contains 59 items measuring eight domains, including physical strength, 
ADL/IADL, mobility, hand function, communication, emotion, memory and 
thinking, and participation/role function (Duncan et al., 2003). The first four of these 
domains may be combined into one physical domain, but the others must be scored 
separately. Each item can be scored from 1 to 5; for most items a higher score 
indicates a better outcome, but for three items in the emotion subscale (i.e. 3f, 3h, 
and 3i) a higher score indicates a poorer outcome. For these three items (3f, 3h, and 
3i), their individual scores are transformed by the equation: transformed score = 6 – 
individual raw score. The SIS uses the scoring algorithm of the SF-36 (Stewart and 
Ware, 1992), thus for each domain the transformed score ranges from 0 to 100 (with 
higher scores indicating better outcomes) based on the following equation: 
Score = ((actual raw score - lowest possible raw score) / possible raw score range) × 
100 
In addition, the SIS includes a question assessing the patient’s perceived overall 
recovery from stroke, with 0 indicating ‘no recovery’ and 100 indicating ‘full 
recovery’. One study suggested the MCIDs on the physical strength, ADL/IADL, 
mobility, and hand function subscales of SIS were 9.2, 5.9, 4.5 and 17.8 points, 




Section 3.4 Discussion 
This chapter has described an evidence-based process of developing a psychological 
intervention for PSF, which is related to the processes of  identifying evidence, 
developing the treatment rationale, and modelling the intervention programme and 
outcomes as described in the MRC framework (Craig et al., 2008a). The targets of 
the intervention were chosen based on the clinical observation and justified by a 
thorough, systematic review of the literature. The intervention manuals were 
developed with iterative input from stroke clinicians, psychological therapists, and 
stroke patients, considering both theoretical and practical issues in local stroke care 
and clinical psychology. In summary, a continuum of evidence was accumulated 
from three interactive strands throughout the study, which included literature review 
on mechanisms of and interventions for PSF, expert opinions from health 
professionals in stroke care and clinical psychology, and user input from stroke 
patients. 
A manualised psychological intervention has been developed. This is a complex 
intervention in that it has a number of interacting therapeutic components, involves 
multidisciplinary work, and has multiple outcome measures (Craig et al., 2013). The 
intervention is not focused on fatigue itself because paying attention to the fatigue 
may make symptoms worse, instead, this intervention aimed to reduce the impact of 
fatigue on daily life through a cognitive behavioural approach. The intervention 
challenges peoples’ fear-avoidance responses to fatigue with an aim to promote 
physical activity in daily living. This type of intervention has shown to be feasible 
and effective in treating fatigue in other chronic conditions (Armes et al., 2007, 
White et al., 2011). However, little is known about the feasibility and efficacy of this 
intervention in the context of stroke.  
Therefore, in the next chapter, I will describe a feasibility study which tests the 
acceptability of this intervention to both the stroke patients and the therapist. Also, to 
inform the design of future definitive trials, I tested the feasibility of the recruitment 
process, intervention delivery, and follow-up assessment. 
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CHAPTER IV: Feasibility Study of a Psychological 
Intervention for Post-stroke Fatigue 
Section 4.1 Introduction 
In Chapter 3, I described how a manualised psychological intervention for PSF was 
developed following the MRC framework of development and evaluation of complex 
interventions (Campbell et al., 2000, Craig et al., 2008a). I developed this 
psychological intervention in collaboration with a multidisciplinary group of stroke 
clinicians, psychological therapists, and stroke patients, considering both theoretical 
and practical issues in stroke care and clinical psychology in the local health system 
in the UK.  
In this chapter, I will introduce how this intervention was tested in a feasibility study, 
in terms of its acceptability to both the participants (stroke patients with PSF) and the 
therapist (a clinical psychologist), and the feasibility of the trial process of 
recruitment, intervention delivery, and follow-up assessment. This chapter is related 
to part of the modelling phase and part of the piloting phase of the MRC framework, 
with aims to test intervention procedures and to estimate recruitment and retention 
(Craig et al., 2008a). However, this single-arm feasibility study did not inform the 
sample size calculation, which needs to be clarified in future pilot studies with the 
randomised controlled design. 
As the clinical psychologist is not normally involved in routine health care of stroke 
patients, I also collected feedback from both the participants and the therapist for 
their opinions on our plans to deliver the intervention using approaches that are more 
affordable to the NHS, for example, delivering the intervention by stroke nurses or 
using telephone or internet. In addition, I performed the before-and-after analysis for 





Aims and objectives 
The aim of this feasibility study was to pilot a psychological intervention with stroke 
patients who had self-reported fatigue.  
The primary objectives were a) to investigate the acceptability of the intervention 
programme to both the stroke patients and the clinical psychologist, b) to assess the 
feasibility of the trial process (i.e. procedures of recruitment, intervention delivery, 
and follow-up assessments), c) to test the feasibility of questionnaires for assessing 
clinical outcomes, and d) to collect opinions from stroke patients and the clinical 
psychologist on plans to adapt the intervention for nurse-delivery, and whether 
delivery through telephone or internet would be acceptable to patients. 
The secondary objectives were to investigate whether this intervention could 
improve any of the pre-specified clinical outcomes (i.e. for fatigue, mood, 
independence in daily life, and overall health-related quality of life; measures for 
these outcomes have been discussed in Chapter 3 and will be summarised in the 
Methods section of this chapter).
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Section 4.2 Methods 
4.2.1 Study design 
This feasibility study had two stages: the screening stage and the intervention stage. 
The screening stage (including a survey for post-stroke fatigue) was to pilot the 
recruitment process and to identify potentially eligible participants for the 
intervention stage. The intervention stage (i.e. a single-arm feasibility study) was to 
test the feasibility of the intervention programme, delivery process, and follow-up 
procedures. 
4.2.2 Ethical approvals and trial registration 
Ethical approvals for this study were granted by the NHS Lothian Board, South East 
Scotland Research Ethics Committee (14/SS/0093, Appendix 3.1) and the NHS 
Lothian R&D Office (2014/0237, Appendix 3.2). Separate consent was obtained 
from participants for the survey for post-stroke fatigue and for the intervention stage. 
This feasibility study was registered at https://www.clinicaltrials.gov/ (the 
ClinicalTrials.gov Identifier NCT02131532).  
4.2.3 Participants 
Inclusion and exclusion criteria 
Rationale for the inclusion and exclusion criteria has been discussed in Chapter 3. In 
brief, patients were eligible for this study if they a) ≥ 18 years old, b) had had a 
stroke (including minor stroke) three months to two years previously, c) had self-
reported fatigue, and d) live in the Lothian area, Scotland, UK. Patients were 
excluded if they had a) severe depression, b) significant impairments in cognition or 
verbal communication, c) medically unstable or living in the nursing home, or d) 
currently took part in other research studies that might affect fatigue or add 
significant burden to the participant. 
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The eligibility was determined through a multi-stage process (details of the 
recruitment process will be discussed shortly in this section): 
 Screening the discharge summary of stroke patients stored in the TRAK 
system (which is the electronic database of the NHS that holds medical 
information of patients, e.g. for age, home address, time since stroke, current 
medical conditions, and whether deceased) 
 Contacting GPs of the potential participant to determine the presence of 
current depression, communication capacity, medical stability, unfavourable 
conditions, and whether in other research studies. 
 Reviewing the result of survey questionnaires completed by the potential 
participant (i.e. questionnaires for post-stroke fatigue and depression) 
 Telephone conversations and face-to-face meetings with the potential 
participant (e.g. for capacity of cognition and verbal communication) 
Sample size 
Sample size calculation is not normally required for feasibility or pilot studies (Arain 
et al., 2010). Some researchers suggested that a sample of 10 or fewer would be 
sufficient for studies assessing acceptability of formatting or ease of administration 
of an instrument (Hertzog, 2008). Such a small group of participants had been used 
in the development and preliminary evaluation of a cognitive behavioural approach 
to manage fatigue in patients with multiple sclerosis (Thomas et al., 2010), which 
successfully informed the design of a multi-centre RCT (Thomas et al., 2013). Thus I 
pre-specified a sample size of 12 for this feasibility study to allow for two dropouts. 
This sample size was anticipated to be achievable in the limited time (three to four 
months) available for the recruitment in this feasibility study. 
  
112 
4.2.4 Study process 
4.2.4.1 Screening stage 
The recruitment process is presented in Figure 4.1. Potential participants were 
identified through three approaches, i.e. from the Stroke Clinic of Western General 
Hospital in Edinburgh, from the Stroke Unit of Royal Infirmary of Edinburgh, and 
through the Chest Heart & Stroke Scotland (CHSS, which is a health charity 
organisation that supports stroke nurses routinely visit stroke patients in the 
community). The recruitment processes through these three approaches were similar, 
with the main difference lying in the personnel who initially identified and contacted 
the potential participants; that is, colleagues who were members of the medical care 
team of stroke patients at each of these three sites identified potential participants for 
this study. In the text below, I will explain in detail how participants were recruited 
from the Stroke Unit and summarise the difference in the recruitment from the Stroke 
Clinic and by the CHSS. 
1) Initial screening of eligibility before contacting potential participants 
The Scottish Stroke Research Network nurses (Seona Burgess, Katrina McCormack 
and Ruth Paulton), who were part of the clinical team, helped with the recruitment. 
The nurses obtained discharge summaries from the ward secretary of all stroke 
patients discharged from the Royal Infirmary of Edinburgh in the past two years. 
They screened these discharge summarises to identify adult patients (18 years or 
over) who had their stroke three months to two years previously and currently lived 
in the Lothian area. Then the nurses contacted GPs of these patients to check that 
they did not meet any exclusion criteria. 
In the Stroke Clinic, the above process was conducted by the responsible stroke 
consultant (Martin Dennis and his clinical secretary Maggie Scott). In the CHSS, the 
Stroke nurses (Audrey Bruce, Thomas Jones, Fiona Ryan and Kay Walkinshaw) 
identified potential participants (i.e. those who potentially had fatigue) during their 






















For patients who 
completed and returned 
the consent form and the 
questionnaire 
For patients who did not 
return the consent form 
or the questionnaire 
Retrieved a name list of patients who met all of the following criteria:  
1) Over 18 years old, 2) Had a stroke in the past three months to two years 3) Live in local area of Lothian 
Stroke Unit: the stroke 
research nurses reviewed the 
discharge summary and 
contacted GPs to assess if the 
patient met any exclusion 
criteria 
Stroke Unit of RIE, by the stroke 
research nurses in the ward 
Stroke Clinic of WGH, by the 
responsible stroke consultant  
CHSS, by the CHSS 
stroke nurses 
No further contact 
from the project 
team 
Stroke Clinic: the stroke 
consultant sent an invitation 
pack to each potential 
participant  
 
(The invitation pack included 
a survey questionnaire for 
fatigue and depression, an 
invitation letter, an 
information sheet about the 
survey, and a consent form) 
The stroke research nurses 
sent the invitation pack to 
each potential participant 
CHSS: the CHSS stroke 
nurses assessed if the 
patient met any exclusion 
criteria, and asked for 
permission from potential 
participants to be contacted 
by the project team 
 
The project team sent the 
invitation pack to each 
potential participant 
Patients decided whether to take part in the survey 
The project team sent letters to 
both the participants and their 
GPs to inform them of the 
individual result of the survey 
For participants from 
the Stroke Clinic: the 
project team reviewed 
their medical 
information and 
contacted their GPs to 
ensure that they did 




Figure 4.1 Flowchart of the recruitment for a feasibility study of a psychological 
intervention for post-stroke fatigue. 
  
Stroke patients with self-reported fatigue and without severe depression or any other exclusion 
criteria were eligible for further assessment 
One week later 
For patients interested in taking part 
The project team contacted the patient by telephone to invite them to take part in the intervention 
stage and to answer their questions about this study  
The project team invited the patient to a face-to-face meeting with the researcher, where the 
researcher further assessed the eligibility of the patient. 
If the patient was eligible for the study and willing to take part, they were asked to: 
 Sign a consent form for participating the intervention stage 
 Complete questionnaires for the baseline assessment of clinical outcomes 
The project team sent the second set of invitation letter and information sheet to invite the 




2) A survey for post-stroke fatigue and depression 
For patients from the Stroke Unit who appeared eligible during the initial screening, 
the Stroke Research Network nurses mailed an invitation pack (see Appendix 4) to 
invite them to complete a survey for post-stroke fatigue and depression. For patients 
from the Stroke Clinic, the invitation letters were mailed out by their responsible 
stroke consultant in the clinic; for patients identified by the CHSS nurses, the 
invitation letters were mailed out by me. This questionnaire pack contained an 
invitation letter (signed by the stroke consultants who had been responsible for the 
patient’s clinical care, see Appendix 4.1), an information sheet about the survey (see 
Appendix 4.2), a consent form (see Appendix 4.3), and a survey questionnaire for 
post-stroke fatigue and depression (see Appendix 4.4). By signing the consent form, 
the patient gave his/her consent a) to complete the survey, b) to receive further 
contact from the project team, c) for the project team to access his/her medical 
information held by the NHS, and d) for his/her GP to be informed of his/her 
participation in and the result of this survey. A stamped addressed envelope was 
enclosed in the questionnaire pack for each patient to return the signed consent form 
and the completed survey questionnaire to me. 
The survey questionnaire contained a single question for post-stroke fatigue ‘Do you 
feel tired all the time or get tired very quickly since your stroke?’ (this question is 
part of the Greater Manchester Stroke Assessment Tool, GM-SAT, which is a 
feasible tool to identify unmet needs of stroke patients in community (Rothwell et al., 
2013)) and the Patient Health Questionnaire-9 (PHQ-9, a valid screening tool for 
depression in stroke patients (Williams et al., 2005)).  
For patients who completed and returned the questionnaire, I assessed their eligibility 
following the criteria as listed in Table 4.1 and sent a written report with individual 
results to each patient and their GPs. In brief, stroke patients who answered ‘yes’ to 
the fatigue question and had a PHQ-9 score of 14 or less were eligible for further 
assessment, to whom I mailed another set of invitation letter (Appendix 5.1) and 
information sheet (Appendix 5.2) to invite them to take part in the intervention stage. 
For patients who had a PHQ-9 score between 10 and 14, I explained in the report that 
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they might have some symptoms that we commonly see in patients with depression, 
and provided them with the choice of either taking part in this study or consulting 
their GPs about possible depression. I excluded patients who had a total PHQ-9 score 
of 15 or more, as this score indicated the presence of at least moderately severe 
depression (Kroenke and Spitzer, 2002). For these ‘ineligible’ patients, I wrote a 
letter (Appendix 5.3) explaining why this intervention was not suitable for them and 
recommending that they should seek advice from their GPs for further assessment 
and treatment for possible depression (Figure 4.2). 
 
Table 4.1 Screening criteria for post-stroke fatigue and depression 
Question 
for fatigue 
Total score of PHQ-9 Eligibility for 
further assessment 
‘Yes’ 9 or less (no or mild depression) Eligible 
Between 10 and 14 (moderate depression) Eligible 
15 or more (at least moderately severe depression) Ineligible 
‘No’ 9 or less (no or mild depression) Ineligible 
10 or more (at least moderate depression) Ineligible 
  











Figure 4.2 Flowchart of the survey for post-stroke fatigue and depression. 
Invited the 
patient to take 




For patients with self-reported fatigue For patients without self-reported fatigue 
 







With at least moderately 
severe depression, or other 
exclusion criteria (PHQ-9 15 
or more) 
Without or with 
mild depression 
(PHQ-9 0-9) 
With at least moderate 
depression, or other 
exclusion criteria (PHQ-9 




take part in the 
intervention 
stage or see 
their GPs for 
possible 
depression 
Sent a letter to explain why 
this intervention is not 
suitable for them 
 
Suggested the patient see 
their GPs for depression or 
other problems 




not suitable for 
them 
Patients signed the consent form for survey and returned it with the completed survey questionnaire 
Sent a letter to explain 
why this intervention is 
not suitable for them 
 
Suggested the patient 
see their GPs for 




3) Final assessment and consent for participating the intervention stage 
One week after sending out the invitation letter to potentially eligible patients, I 
contacted each patient by telephone a) to check if they had received the invitation 
letter, b) to answer their questions about this study, and c) to invite them to take part 
in the intervention stage. For patients who agreed to take part, I invited them to 
attend a one-to-one, face-to-face meeting with me at the Clinical Research Facility 
(CRF) of the Royal Infirmary of Edinburgh. This meeting had three aims: a) to 
confirm eligibility of the patient; b) to obtain written consent from the eligible 
patient; and c) to conduct the baseline assessment of clinical outcomes for each 
participant. 
At the beginning of the meeting, I explained the study process to the patient and 
answered any questions that the patient had. Then I asked the patient when their 
fatigue started; only those who stated that their fatigue occurred or became evident 
after their recent stroke (i.e. in the past three months to two years) were eligible for 
this study. A CRF research nurse (Audrey Kuchnowski or Liz Fraser) helped to 
check if the patient had adequate capacity in cognition and verbal communication to 
take part in this study (this would identify a few patients who were not eligible for 
the study. For those patients, I would explain why this intervention was not suitable 
for them and thanks for their participation so far). Only if both the CRF nurse and I 
agreed that the patient was eligible for the study, I invited the patient to take part in 
the intervention stage.  
After the patient gave the written consent (Appendix 6) for participating the 
intervention stage, I assigned a unique participant number (from S001 to S012) to 
him/her. This participant number was used in all questionnaires for clinical outcomes 
(including baseline assessment and all post-treatment assessments), to allow for 
anonymised assessment of outcomes by researchers. I conducted the baseline 
assessment for the participant using four questionnaires: a case definition of PSF, the 
FAS, the NEADL, and the SIS (these questionnaires have been introduced in detail 
in Chapter 3). In case the participant had uncertainty in giving the answer to any item 
of the questionnaires, I gave explanations or examples to help them understand the 
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question. The result of the PHQ-9 that the participant completed during the survey 
stage was used as the result of the baseline assessment for mood. 
4.2.4.2 Intervention stage 
Setting 
This single-arm feasibility study was conducted at a single site at the Department of 
Clinical Psychology of Astley Ainslie Hospital, a rehabilitation hospital in 
Edinburgh. The project team reimbursed participants their expenses on travelling 
between home and hospital (e.g. bus tickets, parking fees, taxi fees, or petroleum). 
Intervention programme 
The intervention programme has been introduced in detail in Chapter 3. In brief, the 
intervention was delivered by the a clinical psychologist (KA) to each participant 
individually, which consisted of six face-to-face treatment sessions over a period of 
12 weeks, followed by one telephone-delivered review session one month later. At 
the first treatment session, the dates and time for the subsequent treatment sessions 
were agreed between the participant and the therapist and logged into an Outline of 
Sessions (see Appendix 7), of which the participant and the therapist each kept a 
copy as a reminder of the appointment. Participants were required to inform the 
project team by telephone if they could not attend the appointment, of which this 
process was co-ordinated by the administrative secretary (Maureen Harding) of the 
Department of Geriatric Medicine of Royal Infirmary of Edinburgh (where my office 
was based).  
Each treatment session had a therapeutic theme (as covered by each session in the 
Participant Manual), from the general introduction of this intervention and education 
about PSF to specific strategies to challenge participants’ behaviours and thoughts:  
 Session 1: Introduction and fatigue education 
 Session 2: Goal setting and activity planning 
 Session 3: Progress assessment and goal modification 
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 Session 4: Cognitive restructuring 
 Session 5: Dealing with blocks and setbacks 
 Session 6: Overview and future planning 
Immediately after the final treatment session (i.e. Session 6), the therapist gave a set 
of five questionnaires to the participant to complete at home, which included the four 
questionnaires used for baseline assessment plus the PHQ-9. One month after 
Session 6, I mailed the same set of five questionnaires to each participant. Together 
with the questionnaires, I provided a stamped addressed envelope for the participant 
to return the questionnaires to me. After receiving the completed questionnaires, I 
sent a copy of all questionnaires to the therapist (KA) and worked with her on a 
written report of the individual result for each participant.  
One week after sending out the report of the individual result of one-month 
assessment to the participant, I contacted the participant by telephone to check if s/he 
had received the report and to negotiate a date and time for the review session. The 
review session was delivered by the therapist over the telephone to each participant, 
which was about 30 minutes on average. The main aim of the review session was to 
consolidate the learned skills and to reinforce the improvement. During the review 
session, the therapist discussed with the participant his/her progress in overcoming 
fatigue and plans for making further improvement. 
Intervention manuals 
The structure and content of the intervention manuals have been introduced in 
Chapter 3. The Participant Manual was distributed to each participant in the format 
of small leaflets, each of which outlined the content that would be discussed in the 
forthcoming session. I gave the leaflet for the first session to each participant at the 
consenting meeting. For the subsequent sessions, the leaflet was given by the 
therapist by the end of the previous session. A matching Therapist Manual was used 
by the therapist, which provided detailed content of each session and instructions for 
the therapist to follow. 
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4.2.5 Outcome measures 
4.2.5.1 Feasibility outcomes 
Data collection 
Feasibility data were collected throughout the study process, from both the 
participants and the therapist and including both quantitative and qualitative data. 
Outcome measures and data analysis 
Recruitment 
I recorded the numbers of patients eligible at each stage of recruitment and reasons 
for ineligibility. 
Acceptability of intervention programme 
Acceptability of the intervention to participants was determined by participants’ 
attendance, feedback questionnaires, and a feedback meeting. Attendance to each 
session and reasons for rescheduling or non-attending were recorded. I recorded the 
number of dropouts and reasons for withdrawal. Through the feedback 
questionnaires and the feedback meeting I asked both general and specific questions 
to participants about their opinions on the acceptability of the intervention 
programme and the study design. 
Feasibility of clinical outcome assessment  
I recorded the number of participants completing and returning questionnaires on 
time at each assessment, as well as reasons for delayed completing or non-returning. 
I also recorded items of each questionnaire that participants did not complete or did 
not give an adequate answer. 
Participant feedback 
After all participants (those who retained in the study) completed their review 
sessions, they were invited to a focus group feedback meeting. At this meeting, they 
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were asked to complete an anonymised, semi-structured feedback questionnaire, 
which contained 14 questions assessing the usefulness of the intervention strategies, 
adequacy of the intervention content, arrangement of intervention sessions, 
acceptability of outcome questionnaires, and arrangement of follow-up assessments 
(see Appendix 8). I also discussed with participants their opinions on the 
acceptability of delivering this intervention by stroke nurses, through telephone, or 
online. Participants who were unable to attend the focus group were invited to give 
feedback over the telephone. 
Therapist feedback 
After completing all treatment and review sessions, the therapist provided a written 
report regarding a) adequacy of the intervention programme, b) feasibility of the 
delivery process, c) suggestions to improve this intervention, and d) feasibility of 
delivering the intervention by stroke nurses. 
4.2.5.2 Clinical outcomes 
Data collection 
With the participants’ consent, I accessed their demographic and clinical information 
in the NHS TRAK system, which included age, sex, incident or recurrent stroke, time 
since the last stroke onset, psychological history, and cardiopulmonary 
comorbidities.  
Baseline assessment of clinical outcomes was conducted by me with each participant 
at the meeting for recruitment (T0). Three post-treatment assessments (T1: 
immediately after Session 6; T2: one month later; and T3: three months later) were 
conducted by postal questionnaires and completed by the participant at home. 
Clinical outcome measures 
 A case definition of post-stroke fatigue (Lynch et al., 2007) 
 Fatigue Assessment Scale (FAS) (Michielsen et al., 2004) 
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 Patient Health Questionnaire-9 (PHQ-9) (Kroenke et al., 2001) 
 Nottingham Extended Activities of Daily Living (NEADL) (Nouri and 
Lincoln, 1987) 
 Stroke Impact Scale 3.0 (SIS, 9 subscales) (Duncan et al., 2003) 
Data analysis 
Data analyses were performed in IBM SPSS (version 21). For the comparisons 
between participants who completed all sessions and those who dropped out, the 
independent t-test was used for continuous variables and the Fisher’s exact test for 
dichotomous variables with a significance level of 5% (2-tailed). For participants 
who completed all treatment and review sessions, results of each outcome before-
and-after treatment were compared using the paired t-test for continuous outcomes 
and the McNemar test for dichotomous outcomes.  
Considering the correction for multiple comparisons (13 measures and 3 post-
treatment assessments), the critical level of significance would drop from 0.05 to 
0.001 (2-tailed). However, there might be interactions between some measures (for 
example the case definition and the FAS, and the PHQ-9 and the emotional subscale 
of SIS) and the results of three post-treatment assessments were not independent of 
each other, thus the appropriate adjusted critical significance level might be 
somewhere between 0.001 and 0.05, but the exact value is unknown. Therefore, I 




Section 4.3 Results 
Figure 4.3 is the flowchart of this feasibility study. 



















Figure 4.3 Flowchart of the feasibility study for a psychological intervention for 
post-stroke fatigue. 
20 patients eligible for the intervention 
12 patients consented to take part and 
completed baseline assessment  
8 participants completed all 6 treatment 
sessions 
4 participants dropped out: 2 for falling at 
home; 1 reported her life was not 
significantly affected by fatigue; 1 did not 
attend any session and gave no reason 
Post-treatment assessment for clinical outcomes: immediately after Session 6 (n = 8) 
Telephone-delivered review session (n = 8) 
Feedback from participants: 5 attended feedback meeting; 3 feedback by telephone 
Revise intervention manuals (version 3.0) 
and study design 
Therapist feedback 
120 stroke patients were invited to the survey:  
49 replied the questionnaire 
29 patients ineligible: 
18 did not have fatigue 
11 severely depressed  
One-month assessment for clinical outcomes: one month after Session 6 (n = 8) 
Three-month assessment for clinical outcomes: three months after Session 6 (n = 8) 
421 stroke patients were screened, from the Stroke Unit, Stroke Clinic and CHSS 
8 patients declined: 1 full-time job; 1 too 
much travel; 1 on depression treatment; 1 
severe illness; 1 sick family member; 1 
not good at keeping diaries; 2 no interest  
Minor modifications in format and language (version 3.4) Iterative input from 




The recruitment was started in July 2014, when 341 patients from the Stroke Unit 
and 80 patients from the Stroke Clinic (who had their stroke in the past two years) 
were screened. Of these patients, 116 patients (66 from the Stroke Unit and 50 from 
the Stroke Clinic) were invited to complete the survey for post-stroke fatigue and 
depression. The other 305 patients were excluded for the following reasons: not 
stroke but transient ischaemic attack (TIA) or other mimic conditions, medically 
unstable, homebound or in nursing home, in other research studies, deceased, or 
living out of the Lothian area. The CHSS stroke nurses normally visited about 15 
stroke patients each week, and in total they referred four potentially eligible patients 
to me. However, the total number of patients screened by these CHSS stroke nurses 
is unknown. The recruitment was finished in October 2014, when the pre-specified 
sample size of 12 participants was achieved.  
In summary, from July 2014 to October 2014, we approached 120 stroke patients 
with the intention of securing the engagement of 12 eligible participants (Table 4.2). 
49 stroke patients (41%) completed and returned the survey questionnaire, of whom 
31 (63%) reported fatigue and the other 18 did not. Of the 31 fatigued patients, 11 
patients (35%) had a total PHQ-9 score of 15 or more (indicating at least moderately 
severe depression) thus were excluded; the remaining 20 patients were eligible for 




Table 4.2 Numbers of patients at each stage of recruitment 
No. of patients Stroke Clinic  Stroke Unit  CHSS Total 
Initial screening 80 341 Unknown 421 
Invited to the survey 50 66 4 120 
Replied to the survey 23 24 2 49 
Eligible for the intervention 12 7 1 20 
Consented to the intervention 7 5 0 12 
 
Of the 20 patients who were eligible for the intervention stage, eight declined to take 
part during my telephone invitation. Their reasons for not participating included a) 
full-time job (n=1), b) too much travel from home to hospital (n=1), c) currently on a 
therapy for depression (n=1), d) severely ill in bed (n=1), e) sick family member 
(n=1), f) not good at keeping diaries (n=1), and g) simply no interest (n=2). The other 
twelve patients agreed to take part in the intervention stage and attended the 
consenting meeting with me at the Clinical Research Facility (CRF) of Royal 
Infirmary of Edinburgh. None of them were excluded by the CRF nurse and myself 
at this stage (i.e. they all had adequate capacity in cognition and verbal 
communication) and all gave the written consent to take part in this feasibility study. 
4.3.2 Participant characteristics 
Of the 12 participants, five were women and seven were men, and they had a mean 
age of 63 years (SD = 13, range 47 to 85 years). Eight participants had had their first-
ever stroke and the other four participants had had a recurrent stroke in the previous 
two years, and all were ischaemic stroke. The mean time from the onset of the recent 
stroke to recruitment was 16 months (SD = 6, range 5 to 23 months). Five 
participants had cardiopulmonary comorbidities, two participants had psychological 
conditions, and the other five participants did not have any cardiopulmonary or 
psychological comorbidities. For the two participants with current psychological 
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conditions, either the therapist or I talked to their GPs or clinical psychologists 
before recruiting the participants to the study.  
4.3.3 Feasibility outcomes 
Attendance and retention 
Four participants (33%) dropped out: one participant did not attend any session and 
gave no reasons, another participant withdrew after the first session as she reported 
her life was not significantly affected by fatigue and this intervention was not 
suitable for her, and the other two participants withdrew because they had fallen and 
therefore were unable to attend sessions in hospital (one had attended one session 
and the other had attended two sessions).  
The other eight participants (67%) completed all six treatment sessions as well as the 
review session. Of these participants, seven participants attended all face-to-face 
treatment sessions as planned and the other participant had one session rearranged 
due to his busy schedule during the Christmas season. For the telephone-delivered 
review sessions, only one participant attended the session on the agreed date and 
time, whilst the other seven participants rescheduled their sessions due to their delay 
of completing one-month assessment questionnaires (n = 2) or forgetting about the 
appointment for the review session (n = 5). 
Questionnaires for clinical outcomes 
Completion of questionnaires 
The baseline assessment was completed by 12 participants at the meeting for signing 
the consent form. Some patients asked questions about items that they thought were 
irrelevant to them, for example, items relating to driving and gardening in the 
NEADL for patients who did not drive or those who did not have a garden, and also 
the item relating to religious activities in the SIS for patients who did not have 
religious beliefs. For these questions, I explained to the patient that according the 
scale guidance these items should be marked as ‘not at all’ or ‘none of the time’. 
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The subsequent assessments were completed by the eight participants who had 
completed all the treatment sessions, by postal questionnaires. Most participants gave 
consistent and adequate answers to the questions, whilst one participant gave some 
obviously different answers from his answers at baseline assessment. Those 
questions included two questions in the FAS and three questions in the mood 
subscale of the SIS, in each case the answers were scored in the opposite direction 
(i.e. higher scores representing more or less fatigue) as compared with other 
questions in the same questionnaire. I contacted this participant by telephone and 
clarified with him the answers to these questions. 
Timing of returning postal questionnaires 
For the post-treatment assessment, five participants completed and returned 
questionnaires in time (i.e. within one week after the final treatment session), one 
participant returned in the second week (i.e. delayed for one week), another 
participant in the third week (i.e. delayed for two weeks), and the other participant in 
the fourth week (i.e. delayed for three weeks, around the time for one-month 
assessment). For this last participant, I did not send questionnaires to him for one-
month assessment; instead, I used his results of post-treatment assessment as the 
results of both the post-treatment assessment and the one-month assessment for data 
analysis.  
I sent questionnaires to the other seven participants for the one-month assessment, of 
whom five participants returned the completed questionnaires by mail within one 
week, another participant returned by mail in the second week, and the other 
participant completed the questionnaires by telephone in the second week.  
For the three-month assessment, six participants returned the completed 
questionnaires by mail within one week and the other two participants completed the 




Five participants attended the feedback meeting and the other three participants 
provided their feedback by telephone.  
Usefulness of intervention 
Of eight participants who completed all sessions, seven (87.5%) rated the 
intervention ‘very useful’ or ‘somewhat useful’ in improving their fatigue (Table 
4.3). Three participants reported that they had not used the strategies for sleep 
regulating or thought challenging, as they considered that these problems were not 
relevant to them. For the strategy for sleep regulating, the rating of usefulness varied 
among participants who had used it. Regarding the other strategies, each was rated as 
‘very useful’ by more than 70% of the participants (Table 4.3). In addition, one 
participant said that the survey for post-stroke fatigue was useful, as the 
identification of fatigue enabled him to recognise it as a problem and thus take action 
working against it. One participant thought that this intervention was targeting his 
mood but he did not have any depression problems, thus he rated this intervention 
was ‘not useful at all’ in general, including the strategies for regulating sleep and for 
the review session. Though interestingly his fatigue score improved.  
Table 4.3 Participants’ rating of the usefulness of the intervention in improving their 
post-stroke fatigue 
Intervention strategies Participants 
who used 
the strategy 
Numbers of participants 








General rating of 
intervention 
8  
1 (12.5%) 0 2 (25.0%) 5 (62.5%) 
Fatigue education 8  0 0 1 (12.5%) 7 (87.5%) 
Activity and sleep 
diaries 
8  
0 1 (12.5%) 1 (12.5%) 6 (75.0%) 
Planning activities 8  0 2 (25.0%) 0 6 (75.0%) 
Regulating sleep 5  1 (20.0%) 1 (20.0%) 1 (20.0%) 2 (40.0%) 
Challenging thoughts 5  0 0 1 (20.0%) 4 (80.0%) 
Overcoming blocks 7  0 0 2 (28.6%) 5 (71.4%) 
Review session 8  1 (12.5%) 1 (12.5%) 0 6 (75.0%) 
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Difficulty in completing home tasks 
Most participants (60% or more) rated all home tasks as being ‘not difficult’ or ‘a 
little difficult’ (Table 4.4). Some participants found that keeping diaries, increasing 
daily activity, and regulating sleep were difficult. Nevertheless, they commented that 
despite the difficulties, they were able to make changes in daily life to overcome 
fatigue by completing these tasks.  
Table 4.4 Participants’ rating of the difficulty in completing home tasks 
Home tasks Participants 
who used 
the task 









Keeping diaries 8 4 (50.0%) 1 (12.5%) 3 (37.5%) 0 
Making plans 8 5 (62.5%) 2 (25.0%) 1 (12.5%) 0 
Increasing activities 8 4 (50.0%) 1 (12.5%) 3 (37.5%) 0 
Challenging thoughts 5 2 (40.0%) 3 (60.0%) 0 0 
Regulating sleep 5 3 (60.0%) 0 0 2 (40.0%) 
 
Session arrangement 
All eight participants were satisfied with the arrangement of six treatment sessions 
over a period of 12 weeks. Five participants rated the content of all sessions as being 
‘of the right amount’, whilst two participants thought Session 1 was ‘too much’ and 
another participant thought Session 6 was ‘too little’. 
Feedback on follow-up assessments 
One participant rated the three-month follow-up and three assessments after 
treatment ‘too many’ (this was the participant who rated this intervention as ‘not 
useful at all’). The other seven participants stated that three assessments over three 
months after treatment were acceptable in terms of the amount and the length of 
interval. Two participants also suggested having a longer follow-up assessment so 
that it could act as an incentive for them to continue making progress. 
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Feedback on questionnaires for clinical outcomes 
Most participants stated that the questionnaires were easy to complete. But two 
participants indicated ‘a little difficulty’ in completing the SIS, in terms of its length 
(60 items in total). One of these participant also commented that there were some 
duplicating items between different questionnaires, for example the SIS and the 
NEADL, which he felt ‘annoying’. 
Plans of delivering the intervention by stroke nurses 
Some participants had concerns about our future plans for nursing staff to deliver 
psychological interventions, regarding their lack of psychological expertise. 
Nevertheless, after I explained that nursing therapists would be specifically trained 
for this intervention and supervised by experienced psychologists, these participants 
agreed that the nurse-delivery approach would be acceptable. 
Preferences for delivery in person, by telephone, or online 
All participants suggested that treatment sessions should be delivered face to face. 
They felt that they would be taken more seriously when meeting the therapist in 
person, and this would result in them being more committed in the sessions. Based 
on their experience of telephone-delivered review sessions, they had difficulty in 
attending such appointment and were easily distracted by their environment during 
the session. Participants suggested that they would not wish to undertake a therapy 
online, because they would not take information on the internet seriously. 
They commented that ‘in face-to-face session, you feel like being treated as a 
person’, ‘it is awkward to receive a therapy over telephone’, ‘when talking over 
telephone, it is easily distracted by your kids around’, ‘I would not take things on the 
internet seriously’ and ‘It is hardly to lie to a therapist in person; but if over 





The intervention manual 
The therapist, who was a clinical psychologist with rich experience in delivering 
CBT and working with stroke patients, commented that this intervention ‘has been 
carefully designed on the basis of standard CBT literature’ and ‘the chapters have 
been clearly laid out’. However, she suggested a more even distribution of materials 
between sessions, because there was too much information in Session 1 and 
insufficient materials in Session 6 for some participants. This feedback was 
consistent with feedback from some participants. 
Sleep/Activity diaries 
A Sleep Diary and an Activity Diary were used in this study, to record details of 
sleep patterns, physical activities and extent of social interaction. The therapist 
suggested that these diaries were too arduous for the participant to complete every 
day. She suggested these diaries to be used only following the initial session and for 
the final session as an overall assessment of improvement during the intervention, 
rather than as a daily monitoring. 
Review session over telephone 
The therapist suggested that the telephone-delivered review session could have been 
improved if questionnaires for one-month assessment had been timeously returned 
and mutually appropriate arrangements had been made for telephone calls. However, 
seven out of eight participants had their review sessions rearranged due to the delay 
of returning one-month assessment questionnaires or participants’ forgetting about 
the appointment. Delivering the review session person-to-person might be a better 
delivery approach, because this may be an incentive for participants to return the 
questionnaires in time and also participants may be more likely to be committed to 




Potential challenges for delivery by stroke nurses 
The therapist suggested that as the CBT model of PSF presented thoughts and 
emotions in a conceptual way, which would be unfamiliar for both inexperienced 
therapist and patients. People are usually aware of their emotions in the first instance 
before attempting to analyse their thoughts that actually precede the emotions. Thus 
it is important to acknowledge this to both the therapist and patients. For 
inexperienced nursing staff, it would require rehearsal and repetition to familiarise 
them with the CBT. For example, the specialist training for nursing staff should be 
provided by an experienced CBT therapist, which include introduction of basic CBT 
principles, familiarisation with both the Therapist Manual and the Participant 
Manual, and practicing administration of the intervention between nursing staff. 
4.3.4 Clinical outcomes 
Baseline characteristics 
Clinical characteristics of participants (n = 12) who completed baseline assessment 
are summarised in Table 4.5. Those who dropped out had more women and poorer 
physical strength than participants who completed all sessions. There was no 
difference between these two groups in other demographic or baseline clinical 
outcomes. 
Of the eight participants who completed all sessions, five fulfilled the case definition 
of PSF at baseline, whilst the other three did not fulfil it as their fatigue did not 
present every day or did not occupy most of their daytime. The two participants with 
psychological conditions at recruitment were under relevant treatment and their 
psychological conditions were stable (with a total PHQ-9 score less than 15). All 
eight participants were very independent in daily activities, with a total score of the 
NEADL ranging from 20 to 22 (out of a maximal possible score of 22); and the lost 
scores were mainly due to that the participant did not drive or not have a garden. 








all sessions (n = 8) 
Participants dropping 
out (n = 4) 
p values 
Female/Male 1/7 4/0 0.01* 
Mean age (years) 62.0 (SD = 14.7) 64.5 (SD = 8.8) 0.76 
First/Recurrent stroke 6/2 2/2 0.55 
Mean time since 
recent stroke 
(months) 




5 (62.5%) 3 (75.0%) 1.00 
Fatigue Assessment 
Scale 
26.5 (SD = 8.0) 24.5 (SD = 5.2) 0.66 
Patient Health 
Questionnaire-9 
7.6 (SD = 4.3) 6.3 (SD = 3.0) 0.59 
Nottingham Extended 
Activities of Daily 
Living 
20.8 (SD = 0.9) 18.0 (SD = 2.6) 0.12 
SIS General 
Recovery 
74.8 (SD = 16.7) 80.0 (SD = 8.2) 0.57 
SIS Physical Strength 89.1 (SD = 9.9) 73.4 (SD = 10.7) 0.03* 
SIS Memory and 
Thinking 
75.4 (SD = 21.3) 77.7 (SD = 22.7) 0.88 
SIS Emotion 66.0 (SD = 26.1) 81.9 (SD = 13.9) 0.20 
SIS Communication 80.4 (SD = 23.3) 93.8 (SD = 7.9) 0.18 
SIS Daily Activities 93.4 (SD = 6.54) 90.0 (SD = 4.1) 0.37 
SIS Mobility 87.5 (SD = 15.1) 86.8 (SD = 11.4) 0.94 
SIS Hand Function 93.8 (SD = 9.5) 81.3 (SD = 17.0) 0.13 
SIS Social Activity 67.8 (SD = 24.5) 59.4 (SD = 35.1) 0.63 
*p value < 0.05. SIS: Stroke Impact Scale. 
Intervention effects on clinical outcomes 
Table 4.6 presents clinical outcomes at each assessment and the difference between 
baseline assessment and each of the subsequent assessment.
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Post-treatment assessment  One-month assessment  Three-month assessment 
Mean  
(SD) 
Mean difference   
(95% CI)**; p values 
 Mean  
(SD) 
Mean difference  
(95% CI)**; p values 
 Mean  
(SD) 
Mean difference  




62.5% 25.0% p=0.25  25.0% p=0.25  12.5% p=0.13 
FAS 
 
26.5 (8.0) 21.8 (7.4) 4.8 (-2.1, 11.6); p=0.15  19.5 (8.4) 7.0 (-0.8, 14.8); p=0.07  17.3 (8.6) 9.3 (1.4, 17.1); p=0.03* 
PHQ-9 
 
7.6 (4.4) 4.8 (4.9) 2.9 (-0.002, 5.8); p=0.05  4.5 (5.1) 3.1 (0.2, 6.1); p=0.04*  5.0 (6.3) 2.6 (-0.7, 5.9); p=0.10 
NEADL 
 












75.5 (21.3) 79.9 (23.3) -4.5 (-10.2, 1.2); p=0.11  82.0 (24.4) -6.6 (-15.3, 2.2); p=0.12  87.1 (18.0) -11.6 (-19.2, -4.0); p=0.009* 
SIS Emotion 
 








93.4 (6.5) 92.5 (10.2) 0.9 (-4.4, 6.3); p=0.69  92.8 (8.3) 0.6 (-4.7, 5.9); p=0.79  95.9 (5.3) -2.5 (-5.5, 0.5); p=0.09 
SIS Mobility 
 




93.8 (9.5) 93.8 (11.6) 0.0 (-4.5, 4.5); p=1.00  92.5 (11.0) 1.3 (-2.5, 5.0); p=0.45  95.6 (8.6) -1.9 (-9.6, 5.8); p=0.58 
SIS Social 
Activity 
67.9 (24.6) 86.3 (14.5) -18.5 (-29.4, -7.6); 
p=0.005* 
 82.8 (24.3) -15.0 (-26.7, -3.2); 
p=0.02* 
 82.4 (19.9) -14.6 (-23.3, -5.8);  
p=0.006* 
*p value < 0.05. **Mean of the difference in scores or proportions between the baseline assessment and the assessment after treatment, i.e. the result of baseline 
assessment minus the result of post-treatment assessment. FAS: Fatigue Assessment Scale; PHQ-9: Patient Health Questionnaire-9; NEADL: Nottingham Extended 
Activities of Daily Living; SIS: Stroke Impact Scale. Of FAS and PHQ-9, higher scores indicate worse outcomes and the positive value of MD indicates improvement; of 
NEADL and SIS subscales, higher scores indicate better outcomes and the negative value of MD indicates improvement. 
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Presence of clinically significant fatigue 
Numbers of participants fulfilling the case definition of PSF decreased from five 
(62.5%) at T0 to two (25.0%) at T1, and further decreased to one (12.5%) at T3, 
although this decrease in proportions was not statistically significant (Table 4.6). 
Fatigue Assessment Scale (FAS) 
Means scores of FAS decreased over time across four assessments (Figure 4.4). The 
decrease was most evident between T0 and T1 (by a mean score of 4.8 points, p = 
0.15), and continued between T1 and T2 (by a further 2.2 points, p = 0.05) and 
between T2 and T3 (by a further 2.3 points, p = 0.11). Overall, the FAS score 
decreased significantly from baseline to the three-month assessment (by a mean 












Baseline Post-treatment 1 month 3 months
Fatigue Assessment Scale
 
Figure 4.4 Scores of the Fatigue Assessment Scale (FAS) at baseline and at three 
assessments after treatment. The horizontal axis is the time of assessment. The 
vertical axis is the FAS scores. Error bars represent the 95% confidence interval of the 





Patient Health Questionnaire-9 (PHQ-9) 
The PHQ-9 scores decreased from T0 to T1 (p = 0.05) and maintained stable at 
follow up (Figure 4.5). There was no significant difference between T1 and T2 (p = 









Baseline Post-treatment 1 month 3 months
Patient Health Questionnaire-9
 
Figure 4.5 Scores of the Patient Health Quesitonnaire-9 (PHQ-9) at baseline and at 
three assessments after treatment. The horizontal axis is the time of assessment. The 
vertical axis is the PHQ-9 scores. Error bars represent the 95% confidence interval of 










Nottingham Extended Activities of Daily Living (NEADL) 
All participants had good independence in activities of daily living, with a mean 
score of NEADL of 20.8 (SD = 0.9, out of a possible maximal score of 22 for full 
independence) at T0. The level of independence was stable over time (Figure 4.6) 
and there was no significant difference in NEADL scores between T0 and any of the 
follow-up assessments (Table 4.6). Also there was no difference between T1 and T2 
(p = 0.20), or between T2 and T3 (p = 0.35). 
 
 
Figure 4.6 Scores of the Nottingham Extended Activities of Daily Living (NEADL) at 
baseline and at three assessments after treatment. The horizontal axis is the time of 
assessment. The vertical axis is the NEADL scores. Error bars represent the 95% 






Stroke Impact Scale (SIS) 3.0 
Self-rating on recovery 
For participants’ self-rating of their recovery from stroke (Figure 4.7), there was a 
marginally significant increase of scores from baseline to immediately post-treatment 
(p = 0.05), a relatively stable status from immediately after treatment to one-month 
assessment (p = 0.82), and a marginally significant increase from one-month to 
three-month assessments (p = 0.05). Overall, the self-rating of recovery was 
improved significantly from baseline to three-month assessment (Table 4.6). 
 
 
Figure 4.7 Scores of the general recovery by the Stroke Impact Scale (SIS-recovery) at 
baseline and at three assessments after treatment. The horizontal axis is the time of 
assessment. The vertical axis is the SIS-recovery scores. Error bars represent the 
95% confidence interval of the mean SIS-recovery scores at each assessment.   
 
Other subscales of SIS 
Scores of eight subscales of SIS are summarised in Table 4.6 and illustrated in Figure 
4.8. The most evident improvement was in the self-reported of participation in social 
activity, of which the score improved significantly from baseline to immediately 
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post-treatment (p = 0.005); this improvement was stable afterwards, with no 
significant difference between post-treatment and one-month assessments (p = 0.40) 
or between one-month and three-month assessments (p = 0.93). 
Significant improvement from baseline to three-month assessments was also present 
in self-reported mobility, memory and thinking, and emotion (Table 4.6). The 
mobility scores improved significantly from baseline to post-treatment (p = 0.005) 
and kept stable between post-treatment and one-month assessments (p = 0.69) and 
between one-month and three-month assessments (p = 1.00). For both the memory 
and thinking subscale and emotion subscale, scores increased over time but did not 
reach a significant level until at three-month assessment (Table 4.6).  
For the other four subscales (i.e. physical strength, communication, daily activities, 
and hand function), there was no significant difference between baseline scores and 
those at any follow-up assessment (Table 4.6, Figure 4.8).  
Figure 4.8 Scores of eight subscales of the Stroke Impact Scale (SIS) at baseline and 
three assessments after treatment. The horizontal axis is the time of assessment. The 
vertical axis is the mean score of each subscale of SIS. 
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Section 4.4 Discussion 
This chapter has described a feasibility study to test the acceptability and feasibility 
of a psychological intervention for the treatment of PSF. The intervention was well 
received by the stroke patients in terms of the adherence to the intervention 
programme. Also most participants rated this intervention very useful in helping 
them overcome PSF. According to the feedback from participants and therapist, a 
number of changes could be incorporated to improve the study design and 
intervention programme, as discussed in this section. 
4.4.1 Feasibility of study design 
Recruitment 
The recruitment process was feasible in the local health system in the Lothian area of 
Scotland with a recruitment rate of 10% of initially approached stroke patients. 
About 41% of the invited patients replied to the survey questionnaires for post-stroke 
fatigue and depression; and 63% of those who replied had fatigue. To ensure a good 
response rate to the survey, I had used the strategies reported previously to be 
effective in increasing response rates of postal questionnaires, for example using 
short and colour printed questionnaires and providing stamped return envelops 
(Edwards et al., 2002). However, the response rate in the current study was lower 
than that in previous studies. In a Norwegian study, which mailed the FSS to patients 
who were discharged from the Stroke Unit at least six months previously, 58% of 
patients returned the questionnaire and 42% of those who replied had PSF (Naess et 
al., 2012). A Dutch study sent postal questionnaires to community patients who had 
stroke more than one year ago, asking whether fatigue was their main complaint 
(yes/no), 65% of patients returned the questionnaire and 50% of them indicated that 
fatigue was their main complaint (van der Werf et al., 2001).  
One possible reason for the lower response rate in the current study is that the target 
population was different from other studies. For example, the Norwegian study had 
used a wider inclusion criteria than the current study, which included patients with 
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either stroke or TIA (Naess et al., 2012). Another possible explanation is that the 
previous studies were purely surveys for fatigue, whilst in the current study I had 
provided information for patients that if the result of the survey indicated that they 
had fatigue I would further invite them to take part in an intervention study. This 
might require more initiative for the patients to take part in the current study, that is, 
patients who were more interested in PSF (e.g. they perceived fatigue as a problem 
for them) were more likely to take part in the current study. This may explain our 
lower response rate but a higher proportion of responding patients had PSF. 
The outpatient Stroke Clinic is an important resource of potential participants. In the 
current study, 14% of stroke patients approached from the Stroke Clinic were 
recruited, compared with 8% approached from the Stroke Unit and 0% from the 
CHSS. Compared to patients discharged from the Stroke Unit, those from the Stroke 
Clinic usually have less severe stroke. It is possible that patients with less severe 
stroke are more likely to take part in the research study for fatigue, as for these 
patients fatigue could be a prominent problem whilst for patients with more severe 
stroke fatigue is a less severe problem for them as compared to other disabling 
complications. This hypothesis may be partly supported by the findings that all our 
participants had good independence in daily activities at recruitment. This was 
similar in another pilot trial for the treatment of PSF, where the mean score of the 
baseline Barthel Index of all participants was 92.5 (out of a maximal possible score 
of 100, indicating full independence) (Clarke et al., 2012).  
Attrition and reasons for withdrawal 
The dropout rate (n = 4, 33%) was higher than expected. In a previous longitudinal 
study on PSF in the same general population, 13% of the consenting participants did 
not attend any assessment and another 18% withdrew after the one-month assessment 
(Duncan et al., 2015). In a trial for PSF in the Netherlands, 16% of the randomised 
participants discontinued the treatment for various reasons (Zedlitz et al., 2012). 
In the current study, one participant withdrew after attending the first session as she 
reported that she had coped well with her fatigue, so that she did not need an 
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intervention. To screen for patients with PSF, I had adapted a single question ‘do you 
feel tired all the time or get tired very quickly since your stroke’ from the GM-SAT 
(Rothwell et al., 2013) and provided a simple answer of ‘yes’ or ‘no’. Learning from 
this participant, in future we may need to ask an additional question to identify those 
who have fatigue and also would like extra help for their fatigue. For example, it may 
be better to expand the answers to ‘yes and I would like additional help and support’, 
‘yes but I am receiving enough help and support’, or ‘no’, which are the original 
answers developed in the GM-SAT for this question (Rothwell et al., 2013). Another 
two participants withdrew due to the falling at home thus were unable to travel to 
hospital. I offered to deliver the sessions to them on the telephone, but both 
participants declined as they thought it would be too difficult to continue a research 
study when their mobility impaired. Falling is common in stroke patients. In a study 
following 108 stroke patients for six months after their discharge from hospital, 73% 
of patients had least one falling during this period (Forster and Young, 1995). 
Another study reported that the incidence of falling in stroke patients was more than 
twice of the incidence in age and sex matched people (Jørgensen et al., 2002). Stroke 
patients are usually elder people and vulnerable to many other medical conditions, 
which may affect their attendance in research studies. The final participant withdrew 
without attending any session and did not give any reason. 
Although a case definition had been specifically designed for PSF, our project 
decided not to use it to screen for PSF. Instead, we used a simple screening question 
for PSF, with an aim to include a broader range of patients as long as they perceived 
fatigue as a problem for them. Of the eight participants who completed all their 
treatment sessions, three did not fulfil this case definition at recruitment, because 
their fatigue did not present every day or did not occupy most of their daytime. This 
suggests that the case definition may be too strict to be used as a screening question. 
Therefore, I would suggest using the simple question rather than the case definition 
to screen for PSF in future studies.  
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Attendance and delivery modes 
Participants had very good adherence to attending face-to-face treatment sessions, 
given the dates and time had been agreed in advance between the participant and the 
therapist at the initial session. But for the telephone-delivered review session, some 
participants gave different excuses to delay the session or simply forgot the 
appointment. This is in contrary to a previous study, which reported that patients 
with depression had better adherence to the telephone-delivered psychotherapy than 
to the face-to-face approach (Mohr et al., 2012). In the current study, the face-to-face 
meetings with the therapist were greatly appreciated by the participants, and they 
expressed unfavourable opinions about the potential for online or telephone-delivery 
approaches. Similarly, in a feasibility study that delivered a mindfulness-based 
intervention for mental fatigue in patients with traumatic brain injury (n = 16) or 
stroke (n = 18), seven out of 34 participants (20%) did not accept to attend the 
internet-based intervention (Johansson et al., 2015). Thus, although online 
psychotherapies have been frequently used for patients with mental conditions 
(Fischer et al., 2015, Rooksby et al., 2015), its acceptability to stroke patients is 
unclear and the low acceptance may affect patients’ adherence to the intervention. 
When discussing our plan of delivering this intervention by stroke nurses, 
participants were concerned about the expertise of the nursing staff in delivering 
psychological interventions. Adequate training and supervision will be needed for 
nurses to deliver psychological interventions. A study of psychotherapy for chronic 
fatigue syndrome reported no therapist effect (between clinical psychologists and 
specialist nurses) on the fatigue outcome (Cella et al., 2011). Strategies used in this 
study of chronic fatigue syndrome to minimise the therapist effect included the 
manualised therapy, standardised training, and supervision by experienced 
psychotherapists (Cella et al., 2011). One thing that should be pointed out is that in 
the above study of therapist effect, the specialist nurses had completed a postgraduate 
diploma in cognitive behavioural psychotherapy (Cella et al., 2011), which is not 
practical to be provided for nurses in routine stroke care. However, the 
psychotherapist (TC) in our project team, who was also an investigator in the above 
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study on therapist effect, suggested that a short-term training with a few sessions of 
introduction and practice would be sufficient to train nurses to deliver brief 
psychological interventions. 
Follow-up assessment for outcome measures 
The completion of post-treatment assessment was delayed in a number of 
participants, and some of them returned the questionnaires around the time for one-
month assessment. There is not much difference to be expected between the two 
assessments. Thus, in future it may be better to conduct one instead of two 
assessments between the final treatment session and the review session. That is, after 
the final treatment session, participants will be given the questionnaires to complete 
at home and then return to the therapist by post before they attend the review session. 
This arrangement may have some advantages over the current arrangement. Firstly, 
this will give the participant one month’s time to complete one set of questionnaires 
rather than two sets, of which the latter had been hardly achieved by some 
participants in the current study. Secondly, this will allow participants have some 
time to reflect on their participation in the study. Finally, the review session will be 
an incentive to encourage participants to return questionnaires, as the discussion 
during the review session will be based on the result of these questionnaires.  
As some participants suggested a longer follow-up than the current three months and 
also because PSF is a chronic problem, in future we would consider extend the three-
month follow-up to six months or even longer after the end of treatment. 
4.4.2 Improvement of clinical outcomes 
I analysed data of the eight participants who completed all their treatment sessions 
and found significant improvement in fatigue severity, mood, self-reported mobility 
and participation in social activity from baseline to three months after the end of 
treatment. I had considered also including data of the four participants who dropped 
out in the data analysis, i.e. using their baseline data as the post-treatment results. 
Thus I consulted a medical statistician (Niall Anderson), who suggested that I should 
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not include the dropout data. This is because for the current feasibility study with a 
small sample size of 12 participants, the dropout of four participants took up a 
significant proportion (33%) of the whole sample size. If these dropouts were 
included in the analysis, this would inevitably comprise the reported improvement.  
It is relevant to note that only one participate dropped out because of the intervention 
itself (she felt that she did not actually need the intervention), whilst for the other 
three participants their dropouts were not directly related to the current intervention 
(one did not attend any session and the other two withdrew because they had fallen at 
home and could therefore not attend further sessions). Also the current feasibility 
study did not aim to investigate the intervention efficacy on PSF. Therefore, I did not 
include the data of the dropped out participants in the analysis. The efficacy of the 
intervention should be investigated in future trials with the randomised controlled 
design and larger sample sizes. Also, an intention-to-treat analysis will need to be 
used to control for the attrition bias. 
4.4.3 Plans for future adaptation of the intervention manuals 
Revision of intervention manuals 
According to the feedback from participants and therapist, I revised the intervention 
manuals for future use. Please see Appendix 9 for the final version of the Participant 
Manual (version 3.4) and Appendix 10 for the corresponding Therapist Manual 
(version 3.2). 
Session arrangement 
In a future trial, some information from the participant manual in Session 1 will be 
removed and be given to the participant to read at home prior to attending the initial 
treatment session. Also Session 6 will be combined with Session 5, as this last 
session does not provide any new skills but just a review of previous sessions. These 
changes will ensure a more even distribution of content between sessions. The 





The strategies that were most useful to participants included the education about PSF 
and using diaries to record and plan for activities. These strategies will be retained as 
the main strategies in the revised Participant Manual.  
For other strategies, including regulating sleep patterns, challenging unhelpful 
thoughts, sharing fatigue experience with others, and overcoming ‘blocks’, some 
participants reported that they did not use them as they did not have these problems. 
Thus the implementation of these strategies should be individualised for each 
participant. The revised manuals will still contain information of these strategies, but 
only participants who have relevant problems will be recommended to use relevant 
strategies. 
Section 4.5 Conclusions 
This psychological intervention was well received by stroke patients and the clinical 
psychologist, and the study process of recruitment, intervention delivery, and follow 
up was generally feasible in the local health system. Although the statistical power of 
this study was limited, there were statistically significant improvements in several 
aspects of life including fatigue severity. Based on these promising results, an 
exploratory randomised controlled trial would be a useful next stage for the 
intervention development, to further pilot other issues of the study design such as the 
nurse-delivery approach and the randomised controlled design. 
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CHAPTER V: Interventions for Post-stroke Fatigue – 
an Updated Systematic Review 
Section 5.1 Introduction 
In previous chapters, I described the theoretical (Chapter 2), modelling (Chapter 3) 
and part of the piloting (Chapter 4) stages of developing a psychological intervention 
for PSF. The MRC framework suggests that these three early stages of the 
intervention development should be considered as part of a larger iterative activity 
rather than as sequential stages (Campbell et al., 2007). Thus, I have updated the 
evidence and refined the intervention with input from three interactive strands: 
literature review, expert opinions from stroke clinicians and psychotherapists, and 
user input from stroke patients.  
This framework also suggests that the results of intervention development and 
evaluation should be presented in the context of an updated systematic review of 
similar interventions (Craig et al., 2008b). A previous Cochrane review of 
interventions for PSF (published in 2009) concluded that there was insufficient 
evidence to inform the treatment of PSF (McGeough et al., 2009). Based on this 
review and the knowledge that psychological interventions are effective in reducing 
fatigue in conditions other than stroke, I developed the current psychological 
intervention for PSF. While developing this intervention, I became aware that several 
new interventions had been tested for PSF since 2009. Therefore, I decided to update 
this Cochrane review, in the hope of providing some new evidence that could be 
included in future studies.  
I did not conduct this updated review before developing the current psychological 
intervention, because there would have then been insufficient time for me to develop 
and deliver the intervention within my three-year PhD study period. Also the 
intervention development is an iterative process and this thesis only covers the early 
development stages, thus the intervention needs to be refined by data from other 
subsequent studies before testing in a larger definitive trial. Therefore, this updated 
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review did not only focus on psychological interventions but reviewed any 
intervention that had been tested to treat or prevent fatigue in stroke patients, in order 
to identify any evidence that could inform the development of novel interventions for 
PSF in the future. 
Updating a systematic review is to search for new evidence to incorporate into a 
previously completed systematic review, using the originally formulated protocol 
that may be modified or extended (Moher and Tsertsvadze, 2006). Thus I used the 
same protocol for the evidence search and study selection as used in the previous 
review. The previous review was only able to include three trials that tested different 
interventions and reported diverse outcome measures, making it difficult to perform 
summary statistical analysis. Over the last decade, more researchers and clinicians 
became interested in PSF, thus it was anticipated that this updated review would 
identify more studies to allow for statistical analyses. Therefore, I modified the 
protocol to provide methods for statistical analysis and the modification had been 
discussed with and agreed by all review authors before the updated search was 
conducted (for details of the differences between the previous protocol in 2008 and 
the current review, please see Appendices for this thesis, Appendix 1.3 the full 
publication of this updated Cochrane review, pages 101-102). The current review 
was updated by trials identified by searches in May 2014 and published in the 
Cochrane Database of Systematic Reviews 2015, Issue 7 (Wu et al., 2015a). 
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Section 5.2 Abstract 
Background 
Post-stroke fatigue (PSF) is a common and distressing problem after stroke. The best 
ways to prevent or treat PSF are uncertain. Several different interventions can be 
argued to have a rational basis. The aim of this review was to determine whether 
there was any evidence that any intervention reduces the fatigue severity or the 
proportion of stroke patients with fatigue, or both; and to determine the effect of 
intervention on health-related quality of life, disability, dependency and death, and 
whether such intervention is cost effective. 
Methods 
The search was up-to-date in May 2014. We searched the Cochrane Stroke Group 
Trials Register, Cochrane Central Register of Controlled Trials, MEDLINE, 
EMBASE, CINAHL, AMED, PsycINFO, Digital Dissertations, British Nursing 
Index, PEDro and PsycBITE. We also searched four ongoing trials registries, 
scanned reference lists, performed citation tracking of included trials and contacted 
experts. 
Two review authors independently scrutinised all titles and abstracts and excluded 
obviously irrelevant studies. We obtained the full texts for potentially relevant 
studies and three review authors independently applied the inclusion criteria. We 
included randomised controlled trials (RCTs) that compared an intervention with a 
control, or compared different interventions for PSF. 
Two review authors independently extracted data and assessed risk of bias for each 
included trial. The primary outcomes were severity of fatigue, or proportion of 
patients with fatigue after treatment. We performed separate analyses for trials 
primarily investigating the intervention efficacy in treating PSF, trials primarily 
investigating the intervention efficacy in preventing PSF, and trials primarily 
investigating the intervention efficacy on symptoms other than fatigue in stroke 
patients but reported fatigue as an outcome. We pooled results from trials that had a 
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control arm. For trials that compared different potentially active interventions 
without a control arm, we performed analyses for individual trials without pooling. 
We calculated standardised mean difference (SMD) as the effect size for continuous 
outcomes and risk ratio (RR) for dichotomous outcomes. We pooled the results using 
a random-effects model and assessed heterogeneity using the I2 statistic. We 
performed separate subgroup analyses for pharmacological and non-pharmacological 
interventions. We also performed sensitivity analyses to assess the influence of 
methodological quality on effect sizes.  
Results 
We retrieved 12,490 citations, obtained full texts for 58 studies and included 12 trials 
(three from the 2008 search and nine from the 2014 search) with 703 patients. Eight 
trials were specifically designed to treat PSF, and each tested a different intervention. 
Of these eight trials, six trials with seven comparisons provided data suitable for 
meta-analysis (five pharmacological interventions: fluoxetine, enerion, (-)-OSU6162, 
citicoline and a combination of Chinese herbs; and two non-pharmacological 
interventions: a fatigue education programme and a mindfulness-based stress 
reduction programme). The fatigue severity was lower in the intervention groups 
than in the control groups (244 patients, pooled SMD = -1.07, 95% confidence 
interval (95% CI) -1.93 to -0.21), with significant heterogeneity between trials (I2 = 
87%, degrees of freedom (df) = 6, p < 0.0001). The beneficial effect was not seen in 
trials that had used adequate allocation concealment (two trials, 89 patients, SMD = -
0.38, 95% CI -0.80 to 0.04) or trials that had used adequate blinding of outcome 
assessors (four trials, 198 patients, SMD = -1.10, 95% CI -2.31 to 0.11). No trial 
primarily investigated the efficacy of any intervention in preventing PSF. Four trials 
(248 patients) were primarily designed to treat symptoms after stroke other than 
fatigue, but reported PSF as an outcome. They tested antidepressants, tirilazad 
mesylate, continuous positive airway pressure (CPAP) for sleep apnoea, and a self-





There was insufficient evidence on the efficacy of any intervention to treat or prevent 
fatigue after stroke. Trials to date have been small and heterogeneous, and some have 
had a high risk of bias. Some of the interventions described were feasible in people 
with stroke, but their efficacy should be investigated in RCTs with a more robust 
study design and adequate sample size. 
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Section 5.3 Background 
In Chapters 1 and 2 I have provided the background and rationale for this Cochrane 
review. In brief, fatigue is common and persistent and is a priority for research in 
stroke patients. Its aetiologies and mechanisms are not well understood. A myriad of 
biological, psychosocial, and behavioural factors might be associated with PSF (Wu 
et al., 2015b).  
Since PSF may have several causative or maintaining factors (Wu et al., 2015b), 
there are a number of potential interventions, in combination or alone, that may be 
helpful. Possible interventions include pharmacological interventions (e.g. 
antidepressants, wakefulness stimulants), psychological interventions (e.g. CBT, 
educational programme), and physical training (e.g. graded physical training, aerobic 
exercise). Nevertheless, due to our lack of knowledge of the exact aetiologies or 
mechanisms of PSF, it is unclear which approach may be effective.  
Therefore, we performed this systematic review using broad inclusion criteria with 
the aim of identifying any intervention that might prevent or improve PSF (even if 
the intervention was not primarily designed to manage PSF). The objectives of this 
review were to determine whether, among stroke patients, any intervention reduces 
the proportion or severity of fatigue, or both; and to determine the effect of 
intervention on health-related quality of life, disability, dependency, and death; and 
whether such intervention is cost effective. 
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Section 5.4 Methods 
5.4.1 Search strategies 
With the help of the Cochrane Stroke Group Co-ordinators (Hazel Fraser and Brenda 
Thomas), we performed updated searches of the following electronic databases and 
trial registers from the previous searches in 2008 to May 2014: Cochrane Stroke 
Trial Register, Cochrane Central Register of Controlled Trials, MEDLINE, 
EMBASE, CINAHL, AMED, PsycINFO, ProQuest Dissertation and Theses 
Database, British Nursing Index, PEDro (www.pedro.fhs.usyd.edu.au), PsycBITE 
(www.psycbite.com), ISRCTN (www.isrcn.com), Trials Central 
(www.trialscentral.org), Stroke Trials Registry (www.strokecenter.org/trials), and 
Health Service Research Projects in Progress 
(wwwcf.nlm.nih.gov/hsr_project/home_proj.cfm). (For details of the searches 
performed in 2008, please see the previous review (McGeough et al., 2009)) 
In order to further identify the published, unpublished and ongoing trials, we checked 
the reference lists of the included trials, used the Web of Science Cited Reference 
Search for forward tracking of included trials, and contacted relevant researchers in 
the field of PSF. We searched for trials in all languages and arranged translation of 
relevant papers published in languages other than English.  
5.4.2 Study selection 
5.4.2.1 Selection process 
I scrutinised all titles and abstracts retrieved from the electronic searches (published 
between February 2008 and May 2014) for relevance. Four other review authors 
(Ho-Yan Chun, HYC; Eileen Cowey, EC; Mansur Kutlubaev, MK; Gillian Mead, 
GM) scrutinised these titles and abstracts independently from me: HYC screened 
studies from MEDLINE, EMBASE, PsycINFO, AMED, CINAHL, CENTRAL, 
ProQuest Dissertations and Theses Database, PEDrom and British Nursing Index; 
EC screened studies from PsycBITE, ISRCTN, Stroke Trials Registry and Health 
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Service Research Projects in Progress; MK screened studies from Trials Central; and 
GM screened studies from the Cochrane Stroke Trial Register. We excluded 
obviously irrelevant citations and obtained full references for potentially relevant 
studies. I together with two other review authors (HYC and MK) each independently 
read all full texts and determined whether the study fulfilled the inclusion criteria. 
We resolved any discrepancies about whether or not a study fulfilled the inclusion 
criteria through discussion. 
5.4.2.2 Inclusion criteria 
Types of studies 
We included randomised controlled trials (RCTs) in patients with a clinical diagnosis 
of stroke, where the interventions were used to treat or prevent PSF. This included 
three groups of trials: 
 Trials primarily intended to treat PSF: the aim of the intervention was to treat 
fatigue (as stated by the trial investigators), which required patients to have 
fatigue at recruitment. 
 Trials primarily intended to prevent PSF: the aim of the intervention was to 
prevent fatigue (as stated by the trial investigators) in stroke patients who did 
not have fatigue at recruitment. 
 Trials not primarily intended to treat or prevent PSF but which reported 
fatigue as an outcome: the aim of the intervention was to improve health 
status or other symptoms after stroke, and fatigue was pre-specified as an 
outcome. These trials usually did not specify whether the patients had to have 
fatigue at recruitment or not. 
We excluded trials that used fatigue as a measure to assess whether the intervention 
was tolerable in patients (i.e. whether the intervention had induced intolerable 
tiredness during treatment) rather than a measure to assess the therapeutic effect. For 
trials using a cross-over design, we only included data from the first phase, that is, 
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before crossing over the treatment. We included trials irrespective of their 
publication status and publication language. 
Participants 
We included adult patients (aged 18 years or over), both men and women, with a 
clinical diagnosis of stroke. We included all pathological subtypes of stroke, 
including ischaemic stroke, haemorrhagic stroke, and subarachnoid haemorrhage. 
We included any methods of diagnosis or assessment of PSF, but it was not 
necessary for patients to have fatigue at recruitment. For trials reporting mixed 
populations of patients (e.g. a group of patients with either stroke or brain injury), we 
included them only if more than 75% of the patients had had a stroke, or if separate 
data for the stroke patients were reported by or were later obtained from trial 
investigators. 
Interventions 
We included any pharmacological interventions and non-pharmacological 
interventions, in combination or alone. We included trials that attempted to evaluate 
the following comparisons: 
 A comparison between an intervention and a control (where the control was 
either placebo, usual medical care, attention control, or wait-list). 
 A comparison between two or more different interventions, with or without a 
control. 
 A comparison between different doses or intensity of the same type of 
intervention, with or without a control. 
Outcome measures 
The primary outcome was fatigue at the end of treatment, measured as either the 
proportion of patients with fatigue or the mean severity of fatigue, or both. Examples 
of possible outcome measures included, but were not limited to: the Fatigue Severity 
Scale (FSS) (Krupp et al., 1989), the Visual Analogue Scale for fatigue severity, and 
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the energy/fatigue scale from the Medical Outcomes Study (i.e. the vitality subscale 
of the Short Form-36, SF-36). 
If a trial had used a number of different tools to assess fatigue, we included the main 
outcome measure as specified by trial investigators. For instances where trial 
investigators had not specified the main one, we specified our main outcome measure 
in order of preference based on the following criteria:  
a) A measure of fatigue specifically designed for stroke patients (e.g. the case 
definition of post-stroke fatigue);  
b) A generic measure of fatigue that has been tested in stroke patients (e.g. the 
Fatigue Assessment Scale, FAS); 
c) A generic measure for fatigue that has not been previously tested in stroke 
patients.  
If the scales were in the same category according to the above criteria, we specified 
the main outcome measure from most commonly used scales (e.g. FSS) to less 
commonly used scales in the publications identified in this review. 
Our pre-specified secondary outcomes included health-related quality of life (e.g. 
SF-36), disability (e.g. modified Rankin scale), dependence (e.g. Barthel Index 
score), death, and cost effectiveness. 
5.4.3 Data extraction and analysis  
The second review author (HYC) and I independently extracted data from the 
included trials and recorded the information on a data extraction form. Another 
review author (MK) extracted the data for one trial published in Russian. We 
collected information about the study setting, the methodological design 
(randomisation; allocation concealment; blinding of patients, researchers and 
outcome assessors; and intention-to-treat analysis), the numbers of patients at 
recruitment and at the end of the study, the characteristics of patients (age, sex, time 
since stroke onset, pathological subtypes, and severity of stroke), the treatment and 
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control interventions (type of intervention, dose/intensity, frequency and duration), 
the primary and secondary outcome measures (methods and time of assessment), the 
criteria and assessment methods of fatigue at baseline and follow-up, and the results 
of each assessment. We contacted trial investigators to request for additional 
information that we thought relevant but which had not been reported in the 
publication. 
5.4.3.1 Assessment of risk of bias 
Two review authors (HYC and I) independently documented the methodological 
quality of the included trials for the following quality criteria: allocation 
concealment, blinding of outcome assessors, and intention-to-treat analysis. This was 
done by another review author (MK) for the trial published in Russian. We used the 
Cochrane criteria and the ‘Risk of bias’ tool to assess the methodological quality 
(Higgins and Green, 2011).  
5.4.3.2 Measures of treatment effect 
I calculated standardised mean differences (SMDs) and relevant 95% confidence 
intervals (CIs) for continuous outcomes (i.e. fatigue scores) and risk ratios (RRs) and 
relevant 95% CI for dichotomous outcomes (i.e. presence or absence of fatigue). If 
there were fatigue scales where the score decreases as fatigue increases, I multiplied 
scores of these scales by -1. For trials reporting both dichotomous and continuous 
outcomes of fatigue, I collected data for both types of measures. 
5.4.3.3 Assessment of heterogeneity 
I assessed heterogeneity between trials and between pre-specified subgroups, using 
the statistic with Chi2 distribution with k – 1 degrees of freedom (df; where k was the 
number of trials or number of subgroups) to determine the statistical significance of 
heterogeneity. I quantified heterogeneity using the I2 statistic, which describes the 
proportion of total variance across trials that is attributed to heterogeneity. 
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5.4.3.4 Assessment of reporting bias 
I had intended to explore publication bias using a funnel plot. However, this was not 
done because, according to the Cochrane Handbook for Systematic Reviews of 
Interventions (Higgins and Green, 2011), “tests for funnel plot asymmetry should be 
used only when there are at least 10 studies included in the meta-analysis”. In the 
current review, there were only six trials in the meta-analysis. 
5.4.3.5 Data synthesis 
I performed separate analyses for trials primarily intended to treat PSF, for trials 
primarily intended to prevent PSF, and for trials not primarily targeting PSF but 
other symptoms after stroke, because the key characteristic of their patients (i.e. 
whether they had fatigue at recruitment) was different. 
Trials primarily intended to treat post-stroke fatigue 
I performed separate analyses for trials that compared the intervention(s) with a 
control (where placebo, usual medical care, attention control or wait-list was used as 
control) and for trials that compared different potentially active interventions without 
a control. 
For trials with a control arm, I performed separate analyses for continuous outcomes 
and for dichotomous outcomes of fatigue. For either type of outcome, where data 
were suitable, I performed the meta-analysis using a random-effects model in 
Review Manager 5 (RevMan, 2014). If a trial assessed outcomes at multiple time 
points (e.g. immediately after treatment and at six-month follow-up), I performed 
separate analyses for outcomes assessed at each time points. 
For trials without a control arm, I did not perform the meta-analysis because no two 
trials compared a same pair of interventions; instead, I calculated individual mean 
difference (MD) or RR for each trial, which would indicate the comparative efficacy 
of one intervention over the other. Here I used MD rather than SMD for continuous 
outcomes because SMD was used for the pooling of results from trials using different 
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scales for the same outcome, but for individual trials MD was preferable because it 
was more interpretable. 
Trials primarily intended to prevent post-stroke fatigue 
I had intended to perform the same analyses for this group of trials as I did for the 
trials primarily intended to treat PSF, but no trials were eligible for inclusion in this 
group. 
Trials not primarily intended to treat or prevent post-stroke fatigue 
I had intended to perform the same analyses for this group of trials as I did for the 
trials primarily intended to treat PSF. However, the data were too diverse across 
trials to be pooled, as they were different in all four aspects of the studied 
populations, treatment interventions, control interventions, and outcome measures 
(i.e. PICO). Therefore, I calculated the MD or RR for each trial and reported them 
individually. 
Subgroup analysis 
I had intended to perform the subgroup analysis for different types of interventions. 
However, trials in the meta-analysis each had tested a different intervention. Thus, I 
could only broadly categorise these interventions into ‘pharmacological 
interventions’ and ‘non-pharmacological interventions’ and performed a subgroup 
analysis to investigate whether one group of interventions was superior to the other. I 
did not perform other pre-specified subgroup analyses, i.e. for the source of patients, 
time since stroke, and amount of treatment. This was because these subgroups were 
pre-specified to investigate the contribution of these clinical characteristics to 
heterogeneity under the same type of intervention (e.g. antidepressants, CBT, or 
physical exercise), but trials included in the meta-analysis had each used a different 
intervention, thus, I could not perform further subgroup analyses under the individual 




I explored methodological heterogeneity by sensitivity analyses for allocation 
concealment (with analysis limited to the trials with adequate allocation 
concealment), blinding of outcome assessors (with analysis limited to the trials with 
blinding of outcome assessors), and intention-to-treat analysis (with analysis limited 
to the trials with intention-to-treat analysis). I performed post-hoc sensitivity 
analyses a) by excluding one trial in which the baseline fatigue scores were not 
comparable between groups, and b) by excluding one comparison that was a visual 
outlier in the forest plot. For each sensitivity analysis, I compared the pooled effect 
size with the summary effect size of all included trials, using a Z-test (Borenstein et 
al., 2009). 
Section 5.5 Results 
5.5.1 Results of search 
Figure 5.1 summarises the process for electronic searches and study selection in the 
previous and current reviews.  
For the current review, we identified 6839 unique citations from electronic databases 
and 909 records from ongoing trials registers. We obtained full texts for 29 published 
studies and relevant information for nine ongoing trials. We included nine new trials 
(of which two were ongoing trials in the 2008 review) and nine new ongoing trials 
that met the inclusion criteria. Together with the three trials identified in the 2008 
search (McGeough et al., 2009), we included 12 completed trials (Brown et al., 2013, 
Choi-Kwon et al., 2007, Clarke et al., 2012, Guo et al., 2012, Gurak and Parfenov, 
2005, Johansson et al., 2012a, Johansson et al., 2012b, Karaiskos et al., 2012, Lorig 
et al., 2001, Ogden et al., 1998, Zedlitz et al., 2012, Zhou et al., 2010) and nine 
ongoing trials (Hackett, 2013, Chuang, 2013, Laska et al., 2014, Mead, 2012, Liu, 






















Figure 5.1 Flowchart of electronic search and study selection for a systematic 
review of interventions for post-stroke fatigue. 
Search in 2008 
6839 references from 
electronic databases 
4742 references 
Search in 2014 
909 records from 
trials registers 
29 full texts 29 full texts 9 ongoing trials met 
inclusion criteria 
9 completed trials met 
inclusion criteria 
3 completed trials 
and 2 ongoing trials 
met inclusion criteria 
9 completed trials (2 were ongoing trials included 
in the 2008 review) and 9 ongoing trials were 
included 
21 trials eligible to be analysed in the current review 
 12 completed trials (3 from the 2008 search and 9 from the 2014 search) 
 9 ongoing trials (all from the 2014 search) 
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5.5.1.1 Included studies 
Completed trials 
Among the 12 included trials (703 patients), eight trials (455 patients) were primarily 
intended to treat PSF (Choi-Kwon et al., 2007, Clarke et al., 2012, Guo et al., 2012, 
Gurak and Parfenov, 2005, Johansson et al., 2012a, Johansson et al., 2012b, Zedlitz 
et al., 2012, Zhou et al., 2010), no trial was primarily intended to prevent fatigue 
after stroke, and the other four trials (248 patients) did not primarily target PSF but 
other symptoms after stroke, but reported fatigue as an outcome (Brown et al., 2013, 
Karaiskos et al., 2012, Lorig et al., 2001, Ogden et al., 1998). 
Trials primarily intended to treat post-stroke fatigue 
Characteristics of the study design of each individual trials is presented in Table 5.1 
and summarised in the text below. 
Participant characteristics: all eight trials (455 patients) recruited adult patients of 
both sexes with the male proportion ranging from 33% (Gurak and Parfenov, 2005) 
to 80% (Choi-Kwon et al., 2007) and the mean age ranging from 50 years (Johansson 
et al., 2012b) to 72 years (Clarke et al., 2012), except for one trial, which recruited 
mixed populations of patients with stroke (16 patients) or traumatic brain injury (10 
patients) but did not separately report these demographics for the subgroup of stroke 
patients (Johansson et al., 2012a). Five trials recruited patients with ischaemic stroke 
and haemorrhagic stroke, and the other three trials recruited only patients with 
ischaemic stroke. Six trials recruited community-dwelling patients, one trial recruited 
inpatients, and one trial recruited both inpatients and outpatients. Three trials 
recruited patients who were at least three months after stroke onset, one trial more 
than four months after stroke, two trials more than one year after stroke, one trial 
within six months of stroke, and one trial with patients at a mean of six months and 
no more than three years after stroke.  
Definition of post-stroke fatigue: different diagnostic criteria of fatigue were used at 
recruitment, which included the self-reported experience of fatigue by patients (Choi-
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Kwon et al., 2007), a mean score of the FSS of 4 or more (Clarke et al., 2012), the 
Traditional Chinese Medicine (TCM) diagnostic criteria for Qi-deficiency (i.e. 
“fatigue” in Chinese culture) (Guo et al., 2012), a score of the Multidimensional 
Fatigue Inventory-20 (MFI-20, cut-off score not reported) (Gurak and Parfenov, 
2005), a total score of the Mental Fatigue Scale (MFS) of 10 or more (Johansson et 
al., 2012a, Johansson et al., 2012b), a total score of the Checklist Individual 
Strength-fatigue subscale of 40 or more (Zedlitz et al., 2012), and a total score of the 
energy subscale of the Stroke Specific Quality of Life (SSQOL-energy) of 12 or less 
(Zhou et al., 2010). 
Treatment and control interventions: four trials investigated pharmacological 
interventions and the other four trials investigated non-pharmacological 
interventions. Six trials used placebo, usual medical care, attention control or wait-
list as the control and the other two studies compared different potentially active 
interventions. 
Outcome assessment: all eight trials assessed fatigue outcomes immediately after the 
end of treatment: eight trials reported fatigue scores in each group (continuous 
outcomes of fatigue); two trials also reported the numbers/proportions of stroke 
patients with PSF (dichotomous outcomes of fatigue). In addition, four trials assessed 
the presence or severity of fatigue at a later follow-up point.  
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Table 5.1 Summary of trials primarily intended to treat post-stroke fatigue: participants, treatment and control interventions, and outcomes (PICO) 
Studies Participant 
characteristics 
Numbers of participants Treatment interventions Control 
interventions 









et al., 2007) 
Community-dwelling 
patients; 
At least 3 months after 




End of treatment: n=78 
Completion of follow-up: 
n=78 
 
Fluoxetine (a selective 
serotonin reuptake inhibitor, 
20 mg, daily, 3 months) 
Placebo (20 mg, 









Guo 2012  
(Guo et al., 
2012) 
Inpatients; 




Recruitment: n=90  
End of treatment: n=90 
Group 1: oral Chinese herbs 
(100 mL, twice daily, 4 weeks) 
plus intravenous Chinese herbs 
(250 mL, daily, 14 days) 
Group 2: placebo oral Chinese 
herbs (100 mL, twice daily, 4 
weeks)  plus intravenous 
citicoline (500 mg/250 mL, 
daily, 14 days) 
 
Placebo oral Chinese 
herbs (100 mL, twice 
daily, 4 weeks) plus 
intravenous saline 
(250 mL, daily, 14 
days) 







At least 3 months after 
ischaemic stroke 
 
Recruitment: n=30  
End of treatment: n=30 
 
Enerion (a synthetic derivative 
of vitamin B1, 200 mg, twice 















At least 12 months after 
ischaemic or haemorrhagic 
stroke 
Recruitment: n=6  
End of treatment: n=6 
 
(-)-OSU6162 (a 
monoaminergic stabiliser, 15 
to 45 mg, twice daily, 4 weeks) 
Placebo (15 to 45 mg, 
twice daily, 4 weeks) 
MFS scores Not applicable 
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3 to 18 months after 
ischaemic or 
haemorrhagic stroke; 





End of treatment: 
n=16 
Fatigue Group Education therapy (6 weekly group 
sessions, 60 minutes for each session) 
General Group 
Education therapy 
(6 weekly group 
sessions, 60 
minutes for each 
session) 
 
FSS scores  FSS scores at 3  
months after 













End of treatment: 
n=16 
Mindfulness-based stress reduction therapy (8 
weekly group sessions, 2.5 hours for each session 
plus 45 minutes home practice for 6 days a week) 
 
Wait-list MFS scores Not applicable 
Zedlitz 2012 













Group 1: cognitive behavioural therapy (12 weekly 
cognitive treatment sessions, 2 hours for each 
session) 
Group 2: cognitive behavioural therapy plus graded 
activity training (treadmill walking and strength 
training for 2 hours, twice a week, 12 weeks) 
 




SOL-f scores at 
6 months after 
the end of 
treatment 
Zhou 2010 
(Zhou et al., 
2010) 
Inpatients and outpatients; 








Group 1: electro-acupuncture (30 minutes per day, 
10 days as 1 cycle, for 3 cycles with 2-day intervals 
between cycles) plus cupping at back (10 minutes, 
once every 2 days, 5 weeks) 
Group 2: sertraline (50 mg, daily, 5 weeks) plus 
compound aminobutyric acid and vitamin E 
capsules (2 capsules, 3 times per day, 5 weeks) and 
magnesium gluconate solution (100 mg/10 mL, 











with PSF at 2 
months after 
the end of 
treatment 
CIS-f: Checklist Individual Strength – fatigue subscale; FSS: Fatigue Severity Scale; MFI-20: Multidimensional Fatigue Inventory – 20; MFS: Mental Fatigue Scale; n: 
number of participants; PSF: post-stroke fatigue; RCT: randomised controlled trial; SOL-f: Self-observation List – fatigue subscale; SSQOL-energy: Energy subscale of 
Stroke-specific Quality of Life; TCM: Traditional Chinese Medicine.
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Trials primarily intended to prevent post-stroke fatigue 
We identified no trial primarily intended to prevent PSF. 
Trials not primarily intended to treat or prevent post-stroke fatigue 
Four trials (248 patients) did not primarily target PSF but primarily intended to 
investigate the efficacy of interventions on treating other symptoms after stroke. 
These trials reported fatigue as a secondary outcome. 
Brown et al. (Brown et al., 2013) assessed the feasibility of a continuous positive 
airway pressure (CPAP) therapy for sleep apnoea in patients with ischaemic stroke. 
Thirty-two stroke patients who had a positive result on the test for sleep apnoea were 
randomised to either the active CPAP group or the sham CPAP group, where patients 
were given an active or sham device for the CPAP for home use, respectively. 
Nineteen patients completed the three-month treatment. The primary outcome was 
the self-reported usage of the device by patients. Fatigue was measured by the FSS as 
a secondary outcome at the end of the three-month treatment. I calculated the MD for 
post-treatment fatigue scores between the active and the sham CPAP groups. 
Lorig et al. (Lorig et al., 2001) evaluated a Chronic Disease Self-management 
Programme (CDSMP) on health status, healthcare utilisation, and self-efficacy 
outcomes in patients with stroke, heart disease, lung disease, or arthritis. In total, 
1140 community-dwelling patients were recruited, of which 125 had stroke. Of these 
125 stroke patients, 67 were allocated to the treatment group and 58 to the wait-list 
control group. Patients in the treatment group were immediately offered a manual of 
programme content and received seven consecutive weekly sessions (peer-taught 
sessions, 2.5 hours for each session). Participants in the wait-list group were offered 
the manual and the intervention six months after randomisation. Primary outcomes 
were health behaviours, health status, and health service utilisation. Fatigue was 
measured using the energy/fatigue scale from the long-form Medical Outcomes 
Study as a secondary outcome. Outcomes were collected at baseline, six months, one 
year, and two years after randomisation. The trial investigators did not report results 
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separately for the different diseases, but they provided unpublished data for the 
subgroup of 125 stroke patients at six-month follow-up. However, the investigators 
did not provide data of post-treatment scores but only the changes of scores from 
baseline to after treatment. I calculated the MD for the changes of scores between the 
treatment group and the wait-list group. 
Ogden et al. (Ogden et al., 1998) assessed the efficacy of tirilazad mesylate (a 
hypothesised neuroprotective agent) on recovery following subarachnoid 
haemorrhage. Thirty-one women were randomised to receive either tirilazad 
mesylate (150 mg/100 mL) or placebo (100 mL) for 10 consecutive days after the 
onset of subarachnoid haemorrhage. Eighteen women were interviewed three months 
later and were asked whether they had experienced fatigue that was much worse than 
prior to their subarachnoid haemorrhage. If patients answered ‘yes’ then the 
interviewer explored this with further questioning and patients were asked to provide 
specific examples. Patients’ responses to questioning were analysed as a ‘yes’ or ‘no’ 
to debilitating fatigue based on the subjective opinion of the interviewer. I calculated 
the RR for the risk of patients having fatigue after treatment between the tirilazad 
group and the placebo group. 
Karaiskos et al. (Karaiskos et al., 2012) investigated the efficacy of three 
antidepressants for treating depression in patients with ischaemic or haemorrhagic 
stroke. Sixty patients with a clinical diagnosis of depression after stroke were 
randomised to one of three groups for anti-depressive treatment (20 patients in each 
group): duloxetine (60 to 120 mg/day, for three months), citalopram (20 to 40 
mg/day, for three months), or sertraline (50 to 200 mg/day, for three months). The 
primary aim of this trial was to investigate the effects of these antidepressants on 
depression and anxiety. Fatigue was measured using the FSS as a secondary outcome 
at one month, two months, and three months after the start of treatment. I calculated 
the MDs for the FSS at the end of three-month treatment between the duloxetine 
group and the citalopram group, between the duloxetine group and the sertraline 





The two ongoing trials (Brown et al., 2013, Zedlitz et al., 2012) identified in the 
previous review (McGeough et al., 2009) were completed and published by the time 
of current search in 2014 and are discussed in the previous section for ‘completed 
trials’. We identified a further nine ongoing trials in the current search. 
Three trials are primarily intended to treat PSF. Chuang et al. (Chuang, 2013) 
(estimated enrolment: 160 patients) is investigating the efficacy of a combined 
therapy of functional electrical stimulation and graded treadmill training (one hour 
daily, three days per week for four weeks) versus conventional rehabilitation on 
fatigue and shoulder pain after stroke. The inclusion criteria require patients to be at 
least six months after stroke and have both hemiplegic shoulder pain and PSF within 
the past seven days before assessment. The primary outcome is a vertical numerical 
rating scale with a face rating scale for fatigue and pain at the end of treatment. Liu 
et al. (Liu, 2012) (90 patients) is investigating the efficacy of astragalus 
membranaceus (a Chinese herb, 2.8 g three time per day, treatment duration 
unknown) versus placebo (2.8 g three time per day, treatment duration unknown) on 
PSF. The inclusion criteria require patients to be at least three months after stroke 
and have fatigue based on a screening scale (methods unknown). The primary 
outcome is the Brief Fatigue Inventory at two years after treatment. Overgaard et al. 
(Overgaard and Poulsen, 2012) is investigating efficacy of modafinil (a wakefulness 
promoting agent, 400 mg once daily for three months) versus placebo (400 mg once 
daily for three months) on PSF. The inclusion criteria require patients to be within 14 
days of stroke onset and have fatigue according to the MFI-20. The primary outcome 
is the total score of MFI-20 at the end of the three-month treatment period.  
Three trials are investigating the efficacy of physical training on functional outcomes 
of stroke, where fatigue is measured as a secondary outcome. MacKay-Lyons et al. 
(MacKay-Lyons, 2012) (20 patients) is investigating the efficacy of aerobic exercise 
or cognitive training, or both, on cognition after stroke. Patients who are at least six 
months after stroke are randomised to one of the four arms for a six-week treatment: 
aerobic training group, cognitive training group, aerobic plus cognitive training 
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group, and control group. Fatigue is assessed using the FSS at ten-week follow-up. 
Michael et al. (Michael, 2008) (54 patients) is investigating the efficacy of adaptive 
physical activity (APA) on physical fitness and quality of life of stroke patients. 
Patients who are at least six months after stroke and with residual hemiparetic gait 
deficits are randomised to one of the three arms for a six-month treatment: APA 
group, APA plus progressive treadmill walking group, and home exercise group. 
Fatigue is assessed by psychosocial questionnaires as a secondary outcome at 
baseline, three months, six months, and nine months after the beginning of the 
treatment. Vanroy et al. (Vanroy, 2010) (50 patients) is investigating the efficacy of 
aerobic exercise on aerobic capacity and daily functioning in stroke patients. Patients 
who are within six weeks after stroke onset are randomised to either an aerobic 
exercise group or a passive mobilisation group for a 12-week treatment. Fatigue is 
assessed at baseline, after 12 weeks’ treatment, six months, one year, and two years 
after baseline (assessment methods unknown). This trial has been completed but is 
not yet published. 
Three parallel trials are investigating the efficacy of fluoxetine on recovery of stroke 
and assess fatigue as a secondary outcome: FOCUS trial (estimated enrolment: 3000 
patients) (Mead, 2012), AFFINITY trial (1600 patients) (Hackett, 2013), and 
EFFECTS trial (1500 patients) (Laska et al., 2014). These three trials share the same 
core protocol, which are recruiting patients who are between two and 15 days after 
stroke onset and randomise them to either the fluoxetine group (20 mg daily, orally, 
for six months) or the placebo group (20 mg daily, orally, for six months). The 
primary outcome is the modified Rankin Scale at six months after recruitment. 
Fatigue is a secondary outcome assessed by the vitality subscale of SF-36 at six 
months and 12 months after recruitment. 
5.5.1.2 Excluded studies 
In the search in 2008, we excluded two trials because one had non fatigue-related 
outcomes (Allison and Dennett, 2007), and in the other fatigue was not a measure for 
therapeutic effect (Underwood et al., 2006). We identified nine trials but excluded 
them after full-text screening: three ongoing trials were specifically targeting PSF but 
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were excluded because they had only a single treatment group without a control arm 
(Feys and Maris, 2013, Kirkevold, 2012, Wu, 2014), of which the feasibility study 
described in this thesis was included in this group; two trials measured fatigue as to 
assess whether patients were too tired after using the intervention rather than to test 
the therapeutic effect on fatigue (Cruz, 2013, Lin, 2013); two trials did not use 
randomisation (Kim, 2012, Sianni, 2008); one trial compared patients with multiple 
sclerosis with patients with stroke but did not have a control group for stroke patients 
(Brioschi et al., 2009); and one trial recruited mixed populations of patients but did 
not report data for the subgroup of stroke patients and we could not obtain these data 
from trial investigators (Robinson et al., 2003). 
5.5.2 Risk of bias in included studies 
Figures 5.2 and 5.3 summarise the risk of bias of all included trials, irrespective of 
whether they were primarily intended to treat or prevent PSF. In the text below, I 
separately summarise the risk of bias of the eight trials primarily intended to treat 






Figure 5.2 Review authors' judgements about each risk of bias item presented as 
percentages across all included studies. 
 




5.5.2.1 Selection bias (allocation concealment) 
Of the eight trials primarily intended to treat PSF, two trials used the placebo with 
identical appearance of the tested drug and a ‘double-blind’ procedure and thus had a 
low risk of selection bias (Choi-Kwon et al., 2007, Johansson et al., 2012b), one trial 
reported the use of ‘placebo’ but did not report details of allocation concealment thus 
its risk of bias was unclear (Guo et al., 2012), and the other five trials had a high risk 
of bias because they did not use adequate allocation concealment (Clarke et al., 2012, 
Gurak and Parfenov, 2005, Johansson et al., 2012a, Zedlitz et al., 2012, Zhou et al., 
2010). 
Of the four trials not primarily intended to treat or prevent PSF, two trials had a low 
risk of selection bias (Brown et al., 2013, Ogden et al., 1998), and the other two trials 
had a high risk of selection bias (Karaiskos et al., 2012, Lorig et al., 2001). 
5.5.2.2 Detection bias (blinding of outcome assessors) 
Of the eight trials primarily intended to treat PSF, five trials used adequate strategies 
to blind the outcome assessors and thus had a low risk of detection bias (Choi-Kwon 
et al., 2007, Clarke et al., 2012, Guo et al., 2012, Johansson et al., 2012b, Zedlitz et 
al., 2012), and the other three trials did not report sufficient information to permit 
this judgement thus the risk was unclear (Gurak and Parfenov, 2005, Johansson et al., 
2012a, Zhou et al., 2010). 
Of the four trials not primarily intended to treat or prevent PSF, two trials had a low 
risk of detection bias (Brown et al., 2013, Ogden et al., 1998), and the risk in other 
two trials was unclear (Karaiskos et al., 2012, Lorig et al., 2001). 
5.5.2.3 Attrition bias (Intention-to-treat analysis) 
Of the eight trials primarily intended to treat PSF, two trials performed intention-to-
treat analysis (low risk) (Choi-Kwon et al., 2007, Zedlitz et al., 2012), three trials had 
the same numbers of patients at the end of trials as that at randomisation (low risk) 
(Guo et al., 2012, Gurak and Parfenov, 2005, Zhou et al., 2010), and the other three 
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trials had drop-outs and used the available-case analysis (high risk) (Clarke et al., 
2012, Johansson et al., 2012a, Johansson et al., 2012b). 
Of the four trials not primarily intended to treat or prevent PSF, one trial had the 
same number of patients at the end of trial as that at randomisation (low risk) 
(Karaiskos et al., 2012), and the other three trials had drop-outs and used the 
available-case analysis (high risk) (Brown et al., 2013, Lorig et al., 2001, Ogden et 
al., 1998). 
5.5.3 Effect of interventions 
5.5.3.1 Trials primarily intended to treat post-stroke fatigue 
Eight trials (455 patients) were primarily intended to treat PSF, of which six trials 
compared the interventions(s) with control (where the control was placebo, usual 
medical care, attention control or wait-list) (Choi-Kwon et al., 2007, Clarke et al., 
2012, Guo et al., 2012, Gurak and Parfenov, 2005, Johansson et al., 2012a, 
Johansson et al., 2012b), and the other two trials compared different potentially 
active interventions without a control arm (Zedlitz et al., 2012, Zhou et al., 2010) 
(details of interventions see Table 5.1). 
5.5.3.1.1 Trials with a control arm (interventions versus control) 
Of the six trials (244 patients) that had a control arm (Choi-Kwon et al., 2007, Clarke 
et al., 2012, Guo et al., 2012, Gurak and Parfenov, 2005, Johansson et al., 2012a, 
Johansson et al., 2012b), one trial compared two potentially active interventions with 
a control (Guo et al., 2012). For this trial, I divided the number of patients in the 
control group to two equal-size groups so that there were two comparisons each with 








Summary meta-analysis  
All of these six trials (seven comparisons with 244 patients) reported continuous 
measures of fatigue after treatment. Fatigue severity was lower in the intervention 
group compared with the control group (pooled SMD = -1.07, 95% CI -1.93 to -
0.21), with significant heterogeneity between trials (I2 = 87%, df = 6, p < 0.0001 for 




Study ID Number of 
participants 
Treatment interventions Standardised Mean Difference 
(95% confidence interval) 
                             Forest plot 
 
Outcomes at the end of treatment  
Guo 2012a 45 Citicoline -0.21 (-0.83, 0.41)  
Johansson 2012a 6 (-)-OSU6162 -0.27 (-1.99, 1.44)  
Choi-Kwon 2007 83 Fluoxetine -0.38 (-0.82, 0.05)  
Gurak 2005 30 Enerion -1.07 (-1.85, -0.30)  
Guo 2012b 45 Chinese herbs -4.35 (-5.48, -3.22)  
Subtotal 209 Pharmacological 
interventions 
-1.23 (-2.40, -0.06)  
                                                        Heterogeneity: Chi2 = 45.84, df = 4 (p < 0.00001); I2 = 91% 
 
 
Clarke 2012 19 Fatigue Group Education  -0.43 (-1.35, 0.50)  
Johansson 2012b 83 Mindfulness-based 
Stress Reduction 
-1.01 (-2.08, 0.06)  
Subtotal 35 Non-pharmacological 
interventions 
-0.68 (-1.37, 0.02)  
                                                         Heterogeneity: Chi2 = 0.66, df = 1 (p = 0.42); I2 = 0%  
Total 244 All interventions -1.07 (-1.93, -0.21)  
                                                         Heterogeneity: Chi2 = 46.52, df = 6 (p < 0.0001); I2 = 87% 
                                                         Test for subgroup differences: Chi2 = 0.64, df = 1 (p = 0.42); I2 = 0% 
 
     
Outcomes at three months after the end of treatment  
Clarke 2012 19 Fatigue Group Education  -0.10 (-1.09, 0.89)  
Choi-Kwon 2007 83 Fluoxetine -0.37 (-0.81, 0.06)  
 
                                                                                                                                                Favours interventions              Favours control 




There was no significant heterogeneity between the subgroup of pharmacological 
interventions and the subgroup of non-pharmacological interventions (Figure 5.4). 
Pharmacological interventions showed a marginally significant effect on reducing 
PSF (five comparisons, 209 patients), whilst non-pharmacological interventions 
showed no statistically significant effect (two comparisons, 35 patients) (Figure 5.4).  
Sensitivity analysis 
Two trials (two comparisons, 89 patients) reported adequate strategies for allocation 
concealment (Choi-Kwon et al., 2007, Johansson et al., 2012b), of which 
interventions showed no significant effect on PSF (pooled SMD = -0.38, 95% CI -
0.80 to 0.04; with no significant heterogeneity: I2 = 0%, df = 1, p = 0.90). 
Four trials (five comparisons, 198 patients) reported the use of adequate strategies for 
blinding the outcome assessors (Choi-Kwon et al., 2007, Clarke et al., 2012, Guo et 
al., 2012, Johansson et al., 2012b), of which interventions showed no significant 
effect on PSF (pooled SMD = -1.10, 95% CI -2.31 to 0.11; with significant 
heterogeneity: I2 = 91%, df = 4, p < 0.00001). 
Three trials (four comparisons, 203 patients) used intention-to-treat analysis or had 
no patient lost to follow-up (Choi-Kwon et al., 2007, Guo et al., 2012, Gurak and 
Parfenov, 2005), of which interventions showed a beneficial effect over the control 
(pooled SMD = -1.41, 95% CI -2.73 to -0.09; with significant heterogeneity: I2 = 
93%, df = 3, p < 0.00001). This pooled SMD was not significantly different (p = 
0.67) from the summary SMD of all seven comparisons (pooled SMD = -1.07, 95% 
CI -1.93 to -0.21). 
Fatigue scores at baseline in one trial were significantly higher in the control group 
than the treatment group (Choi-Kwon et al., 2007), so I performed a post-hoc 
sensitivity analysis by excluding this trial. The pooled SMD of the remaining five 
trials (six comparisons, 161 patients) was -1.22 (95% CI -2.34 to -0.09; with 
significant heterogeneity: I2 = 88%, df = 5, p < 0.00001), which was not significantly 
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different (p = 0.84) from the summary SMD of all seven comparisons (pooled SMD 
= -1.07, 95% CI -1.93 to -0.21). 
One included comparison (Guo et al., 2012), a combination of oral and intravenous 
Chinese herbs versus placebo Chinese herbs (SMD = -4.35, 95% CI -5.48 to -3.22), 
appeared as an outlier in the forest plot (Figure 5.4). After excluding this comparison 
(45 patients), the pooled SMD of the remaining six comparisons (199 patients) was -
0.49 (95% CI -0.78 to -0.20; with no significant heterogeneity: I2 = 0%, df = 5, p = 
0.52), which was not significantly different (p = 0.21) from the summary SMD of all 
seven comparisons (pooled SMD = -1.07, 95% CI -1.93 to -0.21). 
Outcomes at three-month follow-up 
Two trials that assessed fatigue at three months after the end of treatment. I 
calculated the SMDs for each trial, which indicate that neither intervention had a 
significant effect on fatigue at three-month follow-up (Figure 5.4). 
Dichotomous outcomes 
Of the six trials (seven comparisons) that compared the intervention with the control, 
only one trial (83 patients) reported the number/proportion of patients with PSF after 
treatment (dichotomous outcomes of fatigue) (Choi-Kwon et al., 2007). There was 
no significant difference in proportions of patients with PSF between the fluoxetine 
group and the placebo group at baseline (100% versus 100%), at the end of treatment 
(82% versus 93%, RR = 0.89, 95% CI 0.75 to 1.05), or at three months after the end 
of treatment (85% versus 93%, RR = 0.91, 95% CI 0.78 to 1.07). 
5.5.3.1.2 Trials without a control arm (comparison between different 
interventions) 
Two trials compared different potentially active interventions without a control arm. 
Because these two pairs of comparisons were different (also because they reported 
different types of outcomes), we did not perform a meta-analysis, but calculated 
individual MD or RR for each trial. 
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Zedlitz et al. (Zedlitz et al., 2012) (83 patients) reported the continuous outcomes of 
fatigue after treatment. Fatigue scores were not significantly different between the 
Cognitive and Graded Activity Training (COGRAT) group and the cognitive therapy 
group either at the end of treatment (for CIS-f: MD = 0.80, 95% CI -3.63 to 5.23; for 
SOL-f: MD = -0.30, 95% CI -1.35 to 0.75) or at six months after the end of treatment 
(for CIS-f: MD = -2.00, 95% CI -6.74 to 2.74; for SOL-f: MD = -0.50, 95% CI -1.64 
to 0.64). 
Zhou et al. (Zhou et al., 2010) (128 patients) reported both continuous outcomes and 
dichotomous outcomes of fatigue after treatment. Trial investigators reported that 
scores of SSQOL-energy after treatment were significantly higher (indicating better 
outcome) in the electro-acupuncture plus cupping (a traditional Chinese therapy in 
which heated glass cups are applied to the skin along the back of the body) group 
than the medication group (p < 0.05). These scores were presented graphically but 
raw data were not reported and we could not obtain these data from trial 
investigators, thus I did not calculate an MD for this trial. Twenty-two patients in the 
electro-acupuncture plus cupping group and 41 patients in the medication group had 
PSF at the end of treatment (34% versus 64%, RR = 0.54, 95% CI 0.37 to 0.79), and 
30 patients in the electro-acupuncture plus cupping group and 52 patients in the 
medication group had PSF at two months after the end of treatment (47% versus 
81%, RR = 0.58, 95% CI 0.43 to 0.77). 
5.5.3.1.3 Secondary outcomes 
Three trials assessed health-related quality of life (Clarke et al., 2012, Guo et al., 
2012, Zedlitz et al., 2012), and one trial assessed disability and dependence (Clarke 
et al., 2012). No trial reported death or cost-effectiveness. Here I present the results 
of these outcomes as reported by the trial investigators. 
Clarke et al. (Clarke et al., 2012) reported a significant improvement in the social 
functioning subscale of the SF-36 for both groups (p = 0.03) but there was no 
difference between groups (p = 0.20). There was no significant change from baseline 
to post-treatment assessment in other subscales of the SF-36, the Barthel Index, or 
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the modified Rankin Scale, and none of the changes were significantly different 
between groups. 
Guo et al. (Guo et al., 2012) reported that the total score of the SSQOL after 
treatment was significantly higher in the TCM (a combination of Chinese herbs) 
group than that in the citicoline group (p < 0.01) and the placebo group (p < 0.01). 
Zedlitz et al. (Zedlitz et al., 2012) reported a significant reduction of scores of the 
Stroke-adapted Sickness Impact Profile – 30 from baseline to post-treatment 
assessment (p = 0.002), but this change was not significant between groups (p > 0.1). 
5.5.3.2 Trials primarily intended to prevent post-stroke fatigue 
We identified no trial that was primarily intended to prevent PSF. 
5.5.3.3 Trials not primarily intended to treat or prevent post-stroke fatigue 
We identified four trials that were not primarily intended to treat or prevent PSF. 
Three trials reported continuous outcomes and one reported dichotomous outcomes 
of fatigue after treatment. I did not pool results from these trials because they had 
substantial differences in the studied populations, treatment and control 
interventions, and outcome measures. Instead, I calculated effect sizes for each of 
these trials and present the individual results in Table 5.2. In summary, none of these 
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Table 5.2 Summary of trials not primarily targeting post-stroke fatigue: participants, treatment and control interventions, and outcomes (PICO) 
Studies Participants Interventions Measures of fatigue and 
results (reported by trial 
investigators) 
Effect size on fatigue 










Control: sham CPAP 
Duration: 3 months 
Scores of FSS at the end of 
treatment 
Active CPAP: mean score 
3.11, SD 1.30 
Sham CPAP: mean score 2.66, 
SD 1.69 
MD 0.45, 95% CI -0.59 
to 1.49 
Trial investigators only provided data for the 19 
participants who completed the trial. They found 
no between-group difference of scores of either 
sleep apnoea (Epworth Sleepiness Scale) or 
fatigue after treatment 






Duration: 7 weeks 
Changes of scores of 
energy/fatigue scale from the 
long form Medical Outcomes 
Study 
CDSMP: mean decrease of 
energy score 0.087, SD 0.988 
Wait-list: mean decrease of 
energy score 0.246, SD 0.600 
MD -0.16, 95% -0.44 
to 0.12 
Higher energy score indicates lower fatigue 
severity; decrease of energy score indicates 
increase of fatigue severity; the greater decrease 








Group 1: duloxetine 
Group 2: citalopram 
Group 3: sertraline 
No control 
Duration: 3 months 
Scores of FSS at the end of 
treatment 
Duloxetine: mean score 3.7, 
SD 1.1 
Citalopram: mean score 3.9, 
SD 1.3 
Sertraline: mean score 4.0, SD 
1.4 
Duloxetine versus 
citalopram: MD -0.20, 
95% CI -0.95 to 0.55 
Duloxetine versus 
sertraline: MD -0.30, 
95% CI -1.08 to 0.48 
Citalopram versus 
sertraline: MD -0.10, 
95% CI -0.94 to 0.74 
Trial investigators found significant improvement 
of depression and anxiety after treatment in each 
of the three groups, but no significant change of 
fatigue scores during the treatment in any group 
Dichotomous outcomes 







Duration: 3 months 
Self-report of debilitating 
fatigue by participants 
Tirilazad: 4 participants 
Control: 9 participants 
RR 0.42, 95% CI 0.16 
to 1.07 
Trial investigators only provided data for the 18 
participants who completed the trial. They found 
no between-group difference in either Glasgow 
Outcome Scale scores or cognitive impairment, 
but concentration, sustained attention, 
psychomotor speed, and debilitating fatigue were 
worse in placebo group 
CDSMP: Chronic Disease Self-management Programme; CI: confidence interval; CPAP: continuous positive airway pressure; MD: mean difference; RR: risk ratio; SD: 
standard deviation. 1 I calculated the effect size using the intention-to-treat analysis: based on the number of participants and their grouping at recruitment. 
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Section 5.6 Discussion 
5.6.1 Summary of main results 
We included 12 completed trials (703 patients) and identified nine ongoing trials 
meeting our inclusion criteria. Of the 12 completed trials, eight trials were primarily 
intended to treat PSF, none was primarily intended to prevent PSF, and the other four 
trials did not primarily target PSF but reported fatigue as an outcome. 
Of the eight trials primarily intended to treat PSF, four trials investigated 
pharmacological interventions and the other four investigated non-pharmacological 
interventions. The wide range of different interventions identified in the current 
review reflect the uncertainty and complexity of the aetiologies and mechanisms of 
PSF. Meta-analysis indicated that the overall effect of these interventions on treating 
PSF was statistically significant. However, the identified trials were small and 
heterogeneous, and the benefit was not seen in trials with low risks of 
methodological bias. Of the four trials not primarily intended to treat or prevent PSF, 
none showed an effect on reducing fatigue in stroke patients. In summary, there are 
insufficient data to draw any firm conclusions about whether or not these 
interventions were effective, either to treat or prevent PSF.  
Antidepressants and other psychostimulants 
Our previous systematic review found that PSF was associated with depressive 
symptoms and this association existed even in stroke patients who did not meet 
criteria for depression (Wu et al., 2014b). In addition, a small study found that PSF 
was associated with serotonin synthesis (Ormstad et al., 2014). Thus, it is plausible 
that treatment for depression may reduce PSF. Potential efficacy of psychostimulants 
in the management of PSF was shown in non-randomised trials (Brioschi et al., 
2009). However, RCTs identified in the current review found no beneficial effects of 
any antidepressants (Choi-Kwon et al., 2007, Karaiskos et al., 2012), or other 
psychostimulants (Johansson et al., 2012b), on PSF. It is important to note that these 
trials were small, thus may lack of power to detect the effect. A number of larger 
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trials are ongoing, which may provide further evidence on the efficacy of 
psychostimulants on PSF (Hackett, 2013, Laska et al., 2014, Mead, 2012, Overgaard 
and Poulsen, 2012).  
Psychological interventions 
Although PSF is associated with depressive symptoms and neuroendocrine changes, 
RCTs to date provided no evidence on the efficacy of psychostimulants. One 
possible explanation is that PSF is a complex phenomenon influenced by a mixture 
of biological, physical, psychological, and behavioural factors and there are 
interactions between these factors (Wu et al., 2015b). Psychological interventions 
(e.g. CBT) targeting patients’ perceptions and behaviours are effective in treating 
fatigue in conditions other than stroke, such as cancer (Armes et al., 2007) and 
chronic fatigue syndrome (White et al., 2011). Furthermore, the psychological profile 
of patients with PSF is comparable to that of patients with other chronic conditions 
(Zedlitz et al., 2011). Therefore, psychological interventions effective for fatigue in 
other conditions are promising interventions to treat fatigue in stroke patients. 
However, the existing studies, including the feasibility study described in this thesis 
(Wu, 2014), have only informed the feasibility of psychological interventions for 
PSF in stroke patients, but their efficacy on PSF is unknown due to the limitations of 
study design in these trials (Clarke et al., 2012, Johansson et al., 2012a, Lorig et al., 
2001, Zedlitz et al., 2012). The current psychological intervention described in this 
thesis was excluded in this Cochrane review, because it was still at an early 
development stage, where a single-arm feasibility study could not provide 
information of its efficacy on PSF. Future studies are expected to investigate the 
efficacy of psychological interventions specially designed for PSF in RCTs with 
adequate sample sizes and controlled with usual medical care. 
Physical training 
Small studies found that PSF was associated with reduced physical fitness (Lewis et 
al., 2011) and lower levels of physical activity (Duncan et al., 2015). Furthermore, 
one study found that PSF was related to the reduced excitability of the motor cortex 
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(Kuppuswamy et al., 2015). Physical training after stroke may improve physical 
fitness and stimulate cortical excitability, which may help to reduce fatigue. In the 
current review, we identified one trial that reported that CBT plus graded activity 
training was more effective in reducing PSF than CBT alone (Zedlitz et al., 2012). 
However, from this trial we do not know whether the reduction of fatigue was a 
result of the physical training alone or a combination effect of physical training and 
CBT. This question may be answered by some ongoing trials that compare physical 
training, cognitive training, or both, with a sham or usual medical care control 
(Chuang, 2013, MacKay-Lyons, 2012, Michael, 2008, Vanroy, 2010), which have 
fatigue as an outcome. 
Other interventions 
Traditional Chinese therapies (including medicine and physical therapy) showed 
promising effects on PSF, but the components of each therapy were complicated and 
the study quality was poor (Guo et al., 2012, Zhou et al., 2010). Some other 
interventions showed efficacy on PSF in single small trials, for example enerion (a 
synthetic derivative of vitamin B1) (Gurak and Parfenov, 2005) and tirilazad 
mesylate (a hypothesised neuroprotective agent) (Ogden et al., 1998). These were 
small trials and the efficacy of these drugs should be investigated in future RCTs 
with an adequate sample size and a robust study design. The CPAP, with was 
designed for sleep apnoea after stroke, was of no benefit on reducing either fatigue or 
sleep apnoea (Brown et al., 2013). This trial was very small and had significant drop-
outs. In addition, we do not know if other interventions, if effective for sleep 
disorders, are helpful to reduce PSF. 
5.6.2 Quality of the evidence 
There was considerable heterogeneity in the study design of the included trials. 
Firstly, the heterogeneity might be attributed to the different interventions used in 
different trials. Although we stratified heterogeneity by grouping trials into 
pharmacological interventions and non-pharmacological interventions, significant 
heterogeneity remained within the subgroup of pharmacological interventions, where 
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no two trials used a same type of drug. This means each type of intervention has only 
been evaluated in one trial, which limits the generalisability of the findings. 
Secondly, heterogeneity might also be attributed to the differences in patient 
characteristics, with many different criteria used for diagnosis of fatigue and also the 
time window from stroke onset to randomisation ranging from within first few 
months to several years after stroke. Given different factors may contribute to fatigue 
at different stages of its natural history (Wu et al., 2015b), the efficacy of a specific 
intervention may be different for patients with different characteristics. 
Another important aspect of study design is the sample size required to detect a 
clinically significant therapeutic effect. Of the 12 included trials, only six trials 
(50%) had a sample size of over 50 patients, and the largest sample was 128 patients. 
The other six trials each had no more than 30 patients who completed the trial and 
were primarily aimed to test the feasibility of the interventions rather than to 
investigate efficacy. In addition, none of these 12 trials reported how the sample size 
was determined. The small sample size might have limited the power to detect the 
clinically significant effect. 
In summary, the included trials were small and heterogeneous, and some of them had 
a high risk of bias. It is difficult to interpret the significance of outcomes when there 
is inadequate concealment of allocation, non-blind assessment, or significant drop-
outs in several of the included trials. Although the interventions showed an overall 
significant effect on treating PSF, the sensitivity analyses indicated that, in trials with 
a low risk of bias, this effect was no longer significant. In summary, there was no 
robust evidence to inform the prevention or treatment of PSF. The efficacy of 
interventions should be investigated in future RCTs with a more robust design. 
5.6.3 Potential bias in the review process 
The inclusion criteria of this review were deliberately broad with an aim to inform 
future research. We sought to include trials that fatigue was a secondary as well as a 
primary outcome and the patients in the included trials did not necessarily have 
fatigue at baseline to be eligible for inclusion, because identifying strategies to 
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prevent (as well as treat) fatigue is important. However, the identification of all 
relevant trials might have been confounded by a number of factors. We did not 
search any non-English databases, thus we only had access to trials that published 
their abstracts in English. In addition, for trials measuring fatigue as a secondary 
outcome, trial investigators might not have reported the results of fatigue in the 
abstract or coded it as a keyword identifiable for electronic searches. Furthermore, 
some trials had used scales that part of the scale is the valid tool for assessing PSF 
(e.g. SF-36 vitality subscale); for these trials, if fatigue was not a specific target of 
the intervention, ‘fatigue’ or its synonyms might not appear in the report, thus we 
could not identify such trials. To minimise the risk of missing relevant studies, we 
used extensive search strategies and contacted experts in the field for relevant 
studies. We would appreciate if other researchers who have noticed any relevant 
studies missing from this review could inform us, so that we can update our review. 
5.6.4 Agreement and disagreement with other studies or reviews 
As far as we know, there are no other systematic review of interventions for PSF. 
Our review identified a mixture of pharmacological and non-pharmacological 
interventions. Non-pharmacological interventions identified in our review were 
similar to those identified in a Cochrane Overview of reviews of interventions for 
fatigue in adults with advanced progressive illness (e.g. cancer, motor neuron 
diseases, and chronic pulmonary diseases), which include aerobic exercise, physical 
training, education programmes, and psychological interventions (Payne et al., 
2012). However, in the Cochrane Overview, the pharmacological interventions (e.g. 
amantadine and carnitine) were different from the pharmacological interventions 
identified in our review (e.g. antidepressants and neuroendocrine regulators). A 
possible explanation is that the choice of drugs might be relevant or specific to 
fundamental diseases. Furthermore, we found that psychological interventions or 
physical training, or both, for fatigue were feasible in stroke patients, although their 
efficacy on PSF should be further investigated. This is consistent with a systematic 
review of interventions for chronic fatigue syndrome, where the review authors 
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concluded that CBT and graded exercise therapy were promising treatment strategies 
for fatigue (Whiting et al., 2001). 
Section 5.7 Conclusions 
There was insufficient evidence on the efficacy of any intervention for the treatment 
or prevention of PSF. The identified interventions included antidepressants and 
psychostimulants, psychological interventions, physical training, traditional Chinese 
herbs, and vitamin B supplementation. Although some interventions showed a 
significant benefit for PSF, they had been tested in small trials which had some 
methodological limitations. Therefore, larger randomised trials are needed to confirm 
whether these interventions are really effective. Other interventions showed no 
evidence of efficacy, but this does not mean that these interventions are useless. This 
is because all the trials were very small and heterogeneous, and some have had a 
high risk of bias. Given the high prevalence and distressing consequences of fatigue 
following stroke, more research is urgently needed to identify effective interventions 




CHAPTER VI: Thesis Discussion 
Section 6.1 Summary of my thesis 
The purpose of this thesis was to develop a psychological intervention for the 
treatment of PSF. This section is a summary of the work that I have done for the 
intervention development, which was based on the theoretical phase, modelling 
phase and part of the piloting phase of the MRC framework for developing and 
evaluating complex interventions (Craig et al., 2008a). In the following sections, I 
will discuss the clinical implications of the current work and directions for future 
research. 
The first stage of this thesis was to identify the evidence to justify the choice of a 
psychological intervention for PSF and to determine its therapeutic components 
(Chapter 2). I systematically reviewed the literature on natural history of PSF, which 
suggested that fatigue is common at an early stage after stroke and often persist to the 
chronic stage. This justified the need for interventions for PSF. In addition, 
longitudinal studies indicated that PSF is often a persistent problem but if it does 
resolve naturally, this tends to occur in the first few months after stroke. These 
findings imply that the chronic stage (e.g. three months after stroke onset) is the best 
timing for implementing interventions for PSF, as at this stage we will be able to 
distinguish persistent fatigue from a transitory phenomenon. The mechanisms of PSF 
are elusive and our understanding is mainly based on cross-sectional associations 
rather than causal relationships. To identify potential targets for treatment, I 
conducted a systematic review to investigate clinical factors associated with PSF. 
Drawing on the literature, I proposed a conceptual model for understanding PSF. 
This model illustrates a temporal process of the development of ongoing fatigue, 
which involves a mixture of biological, psychological, behavioural and 
environmental factors that predispose, trigger, or perpetuate fatigue at different 
stages in relation to stroke onset. There is limited evidence regarding the 
predisposing factors and triggers of PSF, whilst co-existing psychological and 
behavioural factors are commonly reported in observational studies of PSF. Some of 
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these factors have bidirectional associations with PSF and are usually modifiable, 
which include depressive symptoms, anxiety, lower self-efficacy, and reduced 
physical activity. Interventions targeting these associations may help to reduce PSF. 
Other comorbidities (e.g. sleeping problems and pain) and some medications (e.g. 
antidepressants and anti-hypertensive drugs), which are commonly used in stroke 
patients, may also cause fatigue, thus should be considered in patients with PSF. 
The second stage was to develop treatment rationale of the intervention (Chapter 3). 
As there was insufficient evidence to recommend any treatment for PSF, I learnt 
from interventions for fatigue in conditions other than stroke. The psychological and 
behavioural factors that I identified as being associated with PSF can be addressed by 
CBT, a type of psychological interventions. Individual-based CBT is effective in 
treating cancer-related fatigue and chronic fatigue syndrome (which share some 
psychosocial characteristics with PSF). The premise of CBT is that changing 
unhelpful thoughts and behaviours would affect how people feel physically and 
emotionally. In the situation of PSF, a hypothesis is that fatigue is perpetuated by a 
vicious cycle of fatigue, physical deconditioning and reduced physical activity, and 
this cycle may be reinforced by distressed mood and low self-efficacy. The cognitive 
approach of CBT to improve patients’ self-efficacy for taking physical activity and 
the behavioural approach to directly promote physical activity may break this vicious 
cycle and thus improve fatigue (symptoms) and mood (emotional feelings). As a 
complex intervention, this intervention also included strategies to improve sleep and 
to identify other possible causes of fatigue (e.g. pain and some medications). 
The next stage was to develop the intervention programme (Chapter 3). By adapting 
from a nurse-delivered intervention programme for cancer-related fatigue and a self-
management programme for chronic fatigue syndrome, I developed the intervention 
in collaboration with stroke clinicians, clinical psychologists, and a psychotherapist, 
all of whom had both clinical and research experience with stroke patients. The 
psychotherapist had expertise in managing chronic fatigue in conditions other than 
stroke. I also incorporated input from service users (i.e. stroke patients and their 
caregivers) by focus groups and individual consultations. The current intervention 
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consisted of six face-to-face treatment sessions at two-week intervals over a period 
of 12 weeks, followed by a telephone-delivered review session one month later. The 
key aim of the intervention was to encourage participants to gradually increase their 
physical activity, by strategies such as planning and recording daily activities and 
challenging their negative thoughts. Also for participants with sleeping problems, the 
intervention provided information of sleep hygiene and a sleep diary to facilitate 
reconstruction of sleep patterns.  
The fourth stage was to model the intervention process and to pilot the trial 
procedures (Chapter 4). I used a multi-stage process to determine the eligibility of 
participants, which included screening their clinical records, contacting their GPs, 
survey questionnaires for fatigue and depression, and telephone conversations and 
face-to-face meetings with potential participants. I recruited 12 participants over a 
period of four months from a single NHS site (i.e. in the NHS Lothian, from a Stroke 
Unit, an outpatient Stroke Clinic, and the community stroke service). The 
intervention was delivered by a clinical psychologist (i.e. the therapist) who had 
expertise in delivering CBT and more than ten years’ experience of working with 
stroke patients. The recruitment was feasible in the local health system in the Lothian 
area, Scotland. Participants were satisfied with the format and contents of the 
intervention and reported that it was helpful in improving their fatigue. In response to 
the feedback from the participants and the therapist, I refined the intervention 
programme by combining sessions 5 and 6 into a single session and simplifying 
some contents of the Participant Manual for future studies. Also I would suggest that, 
in future trials for this intervention, it is better to deliver the review session in person 
rather than by telephone and have a longer follow-up period than the current three 
months. The final version of the Participant Manual (version 3.4, Appendix 9) and 
the Therapist Manual (version 3.2, Appendix 10) are provided in the Appendices of 
this thesis for future use. 
A Cochrane review of interventions for PSF, published in 2009, concluded that there 
was insufficient evidence to inform the treatment of PSF. Based on this review and 
the knowledge that psychological interventions are effective in reducing fatigue in 
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conditions other than stroke, I developed the current psychological intervention for 
PSF. Whilst reviewing the literature on PSF and conducting the feasibility study of 
this intervention, I became aware that several new interventions had been tested for 
PSF since 2009. So I updated this Cochrane review (Chapter 5), in the hope of 
providing some new evidence on the management of PSF that could be included in 
future studies. I identified 12 trials, of which each tested a different intervention for 
PSF. These included antidepressants and other psychostimulants, psychological 
interventions, physical training, traditional Chinese medicine, and vitamin 
supplementation. There was insufficient evidence to recommend the use of any 
specific intervention for the management of PSF. However, this does not mean that 
the identified interventions are ineffective. The frequent lack of significant effects 
that I observed in the existing studies could arise from the small sample sizes, the 
limitations in study design, and the diversity of interventions. More research is 
needed to address the methodological issues and provide further evidence for the 
management of PSF. The diversity of existing interventions reflects the 
multidimensional nature of PSF, which involves interactions of various biological, 
psychological, behavioural and environmental factors. The current psychological 
intervention was excluded from this review because of its single-arm design, but it is 
one of the promising interventions for PSF worth being investigated in future studies.  
In summary, this thesis has presented a phased and evidence-based process of 
developing a psychological intervention for PSF. The intervention was developed 
based on the current theories about the mechanisms of PSF and was refined by 
iterative input from stroke clinicians, psychological therapists, and stroke patients. 
After the intervention was approved by the ethics committee, it was tested in a small 
group of stroke patients and further refined by incorporating feedback from the 
participants and the therapist. Given that the intervention had multiple therapeutic 
targets, the expected improvement was not only in fatigue but also mood and 
physical activity, which was reflected in the clinical results of the current feasibility 
study. Therefore, this is a complex intervention not only in its multiple therapeutic 
components but also in multidisciplinary personnel it had involved and multiple 
expected outcomes.  
  
191 
This is also a brief psychological intervention as it was a short-term intervention 
programme over 12 weeks and did not require the therapist to have complex 
psychological skills. The programme was developed based on a nurse-delivered 
programme for cancer-related fatigue and a self-management programme for chronic 
fatigue syndrome. In the current study the intervention was delivered by a clinical 
psychologist in order to test whether this intervention was comparable to 
psychological interventions normally used in clinical practice and if it was acceptable 
to the therapist from the perspective of a clinical psychologist. The therapist was 
required to strictly adhere to the intervention manual and to avoid using any 
additional psychological skills. The intervention was designed to be ultimately 
delivered by stroke nurses so that it would be affordable in the NHS. The feasibility 
of the nurse-delivery of this intervention will be tested in future studies. 
A limitation of this study was that I did not have recordings or direct observation of 
the intervention delivery during sessions, as the therapist reported uncomfortable to 
be recorded or observed. To ensure that key therapeutic components be delivered to 
the participant, I had provided a checklist of key therapeutic components of each 
session for the therapist to read before the session and to complete after the session 
(i.e. the therapist was asked to tick the component if she had delivered it during the 
session). The therapist reported in the checklist for each participant that all key 
therapeutic components had been delivered. However, this checklist was unable to 
reflect the therapy enthusiasm of the therapist, which is important for psychological 
interventions that are delivered through interactions between the therapist and the 
participant. Also the adherence reported in this checklist might have been biased as it 
was reported by the therapist rather than be observed by a third person. In addition, 
although inter-therapist diversity is not a concern for this single-site study, in future 
multi-centre trials it is important to record and supervise the intervention delivery 
processes, in order to ensure the core element of intervention has been delivered in 
the same pattern by all therapists across sites.
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Section 6.2 Implications for clinical practice 
Although currently there is insufficient evidence to recommend the use of any 
specific intervention for the treatment or prevention of PSF, findings from this thesis 
contribute towards a growing knowledge of PSF to inform its clinical management.  
In Chapter 2, I have systematically reviewed the literature and proposed a model for 
PSF (Wu et al., 2015b). In qualitative studies exploring patients’ views of PSF, one 
of the major concerns of the patients was that they felt unprepared for, and 
uneducated about their fatigue (Flinn and Stube, 2010, White et al., 2012). In general 
stroke care, there is evidence that providing information about stroke improves 
patients and carers’ knowledge of stroke and reduces patients’ depression scores, 
although the best way to provide information is unclear (Forster et al., 2012). As 
fatigue is a common problem and is often present immediately after stroke, 
information about the potential of PSF and its impact on daily lives need to be 
provided for stroke patients and their families at an early stage after stroke (e.g. 
during acute stroke hospitalisation) as part of the general information about stroke. 
Knowing that PSF is a legitimate symptom and being prepared for it, patients may be 
less distressed when PSF occurs and be less anxious to seek validation for their 
symptoms. Currently in the Lothian area, the health service routinely provides stroke 
patients with an information pack for stroke education, which includes a leaflet about 
‘coping with tiredness’. In future, this leaflet may be improved by introducing PSF as 
a specific problem after stroke and providing information about possible impacts of 
PSF on daily lives. 
PSF tends to be a persistent problem but if it does resolve naturally, this tends to 
occur in the first few months after stroke, which may reflect the influence of stroke 
recovery or lifestyle changes during hospitalisation. In clinical practice, persistent 
fatigue is probably more important to identify than a transitory fatigue. Given that 
fatigue is so common after stroke, arguably clinicians should screen for it. Clinicians 
may be more interested in screening PSF in medically stable patients and in the 
chronic stage (i.e. three or six months after stroke onset, probably during the routine 
follow-up of stroke patients) rather than in the acute phase of stroke, in order to 
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distinguish persistent fatigue from a transitory phenomenon. One of our participants 
commented that the screening questionnaire for PSF was very useful, because it 
helped him to identify fatigue as a problem thus he could take action to work against 
it. In the current study, we used a single question from the GM-SAT to screen for 
PSF, as it is a brief and feasible tool in stroke patients. In future studies, we will need 
to investigate the sensitivity and specificity of this single fatigue question in 
identifying clinically significant fatigue in stroke patients as against the standard 
criteria for PSF (e.g. the case definition of PSF). 
However, if any patients report PSF at an early stage (e.g. within three months after 
stroke onset), clinicians need to provide further fatigue education to help patients 
understand and manage their fatigue. Patients who report PSF should be educated 
about potential mechanisms of PSF. The key message is that the persistent presence 
of PSF is associated with many different factors after stroke and some of these 
factors, such as low mood and reduced physical activity, are manageable and 
reversible. If these associated factors are properly identified and treated, it may help 
to reduce PSF. In the current feasibility study, seven out of eight participants rated 
the fatigue education as ‘very useful’ in helping them overcome fatigue and the other 
one rated it as ‘somewhat useful’. Based on the fatigue education, patients will be 
encouraged to keep physically active in their daily life. Although the best way to 
promote physical activity in stroke patients is still uncertain, being active in daily 
living may be an easy starting point. Other medical issues that could cause fatigue, 
such as depression, pain, sleep disorders and medication, should be screened for and 
managed in fatigued patients.  
Although the power of this small study was limited (n = 8), the decrease of fatigue 
scores from baseline to three months after treatment (mean FAS scores decreased by 
9 points out of a possible range from 10 to 50) was statistically significant. But it is 
important to note that there was no control group in the current study, so we cannot 
exclude the possibility that fatigue scores might have fallen spontaneously. I 
recruited patients who were at least three months after their stroke onset, with a mean 
time of 16 months (range 5 to 23 months). Previous longitudinal studies reported no 
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significant change of fatigue scores over time in the chronic stage after stroke (as 
discussed in Chapter 2). For example, in a longitudinal study recruiting stroke 
patients from the same sources of the current study (i.e. from the Stroke Unit and 
outpatient Stroke Clinics in Lothian), the majority of patients (51%) did not have a 
change in the FAS scores by more than 4 points from six months to 12 months after 
their stroke, and in the remaining patients who had the FAS scores changed by more 
than 4 points, half of them had a decrease and the other half had an increase (Duncan 
et al., 2014). This suggests that the participants attending the current study were 
more likely to experience a reduction in their fatigue than the general stroke 
population. However, the stroke populations were not identical in these two studies, 
that is, the current study only recruited patients who answered ‘yes’ to the fatigue 
screening question but the previous longitudinal study did not require patients to 
have fatigue to be recruited. Therefore, the efficacy of this intervention on PSF 
should be investigated in well-designed RCTs, where these non-interventional 
factors will be controlled for. 
In the current study, participants’ self-reporting of fatigue severity, mood, mobility, 
and participation in social activities seemed to improve immediately after the end of 
treatment and this improvement was sustained to the three-month follow-up. 
Whether the intervention has long-lasting changes to behaviours should be 
investigated in future RCTs. Follow-up is necessary to determine the stability of 
improvements over a period of time. In addition, some of our participants reported 
that knowing about the upcoming assessment was the motivation for them to keep 
working on this intervention, and they suggested using a longer follow-up than the 
current three months. Therefore, I would suggest using a longer follow-up (e.g. six 
months or longer) in future trials for this intervention. Also to ensure the continued 
improvement over time, a review session may be provided during the follow-up, for 
example, in the middle between the end of treatment and the end of follow-up, just as 





Section 6.3 Implications for research and future directions 
Research of PSF is still in its infancy but there is increasing interest in this area. 
Taking my systematic review of psychological associations of PSF as an example, I 
identified 31 studies that had investigated the association between PSF and 
depression, which were published before October 2012 and the earliest one was 
published in 1999 (i.e. 2.2 papers per year on average) (Wu et al., 2014b). Through a 
recent updated search, I identified 11 new studies published between October 2012 
and August 2015 (3.7 papers per year on average). The increasing number of 
research studies indicates an increase of interest in PSF by researchers and clinicians. 
Although our current knowledge of PSF is mainly about its psychological and 
behavioural factors, some researchers have started to explore its biological 
mechanisms such as inflammation (Becker et al., 2015), neuroendocrine (Ormstad et 
al., 2014) and cortical excitability (Kuppuswamy et al., 2015). However, these are 
single small studies, of which the results should be confirmed in future studies. Also 
in my Cochrane review of interventions for PSF, although the existing 12 trials 
provided insufficient evidence to inform the clinical management of PSF, there are 
nine ongoing RCTs which may provide new evidence in the near future (Wu et al., 
2015a). The current psychological intervention is a potential treatment for PSF, but 
whether it is effective on PSF should be investigated in future trials. 
RCTs are the gold standard for determining intervention efficacy and effectiveness. 
However, evaluations are often undermined by problems of acceptability, 
compliance, delivery of the intervention, recruitment and retention, or smaller-than-
expected effect sizes (Craig et al., 2008a). Therefore, the MRC framework suggests 
that a series of pilot studies are required to estimate these uncertainties and to refine 
the study design, before embarking on a definitive RCT (Craig et al., 2008a). The 
current feasibility study was the initial stage of piloting, which tested acceptability of 
intervention procedures, estimated the likely rates of recruitment and retention of 
participants. The results showed that the intervention was well accepted to both 
stroke patients and the clinical psychologist, and the procedures for recruitment, 
intervention delivery and follow up were feasible in the local health system. 
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According to the MRC framework, the next step will be an exploratory RCT to 
further test the feasibility of the intervention and issues of study design that had not 
been investigated in the current study, for example, testing a randomised controlled 
design (Craig et al., 2008b). In this section, I will discuss issues to be considered for 
planning a future exploratory RCT (a grant application for this future study is in 
progress), which include optimal intervention, choice of control, outcome evaluation, 
determining sample size, and improving recruitment. I will also discuss whether this 
intervention could be adapted to a wider population of stroke patients with fatigue, 
low mood, or anxiety symptoms, as these symptoms often coexist in stroke patients 
and in the general population interventions to treat these symptoms are similar. 
Optimal intervention 
At this early development stage in this thesis, the intervention was delivered by a 
clinical psychologist (KA) to test whether the intervention was comparable to 
psychological interventions normally used in clinical practice and whether the 
intervention was acceptable to the therapist from the perspective of a clinical 
psychologist. However, one could argue that the psychologist-delivered approach is 
not practical in the NHS, because of the shortage of trained psychologists in stroke 
care (Bowen et al., 2005). Therefore, at the commencement of this study, our project 
team decided that this intervention should be designed to be suitable for nurse 
delivery in the longer term, so that it could be affordable in the NHS.  
To ensure that the current intervention does not require the therapist to have complex 
psychological expertise, we adapted it from a nurse-delivered psychological 
intervention for cancer-related fatigue (Armes et al., 2007) and a self-management 
psychological intervention for chronic fatigue syndrome (Burgess and Chalder, 
2005). In addition, the psychotherapist (TC) in the project team had been involved in 
the above two studies for non-stroke fatigue and several other nurse-led 
psychological interventions (Kennedy et al., 2006, Maissi et al., 2011, Reme et al., 
2011), who provided advice in developing this brief psychological intervention in the 
current study. Furthermore, the therapist (KA) was required to strictly adhere to the 
intervention manuals without using any additional psychological skills. By the end of 
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this feasibility study, we had refined the intervention manuals according to the 
feedback from the participants and therapist, and are now seeking to have these 
manuals published. To move forward to the next stage of the development of this 
intervention, we will conduct an exploratory trial to test if the nurse-delivery 
approach is acceptable to the patients and nursing therapists, and whether it is 
feasible and affordable in the NHS. 
To ensure that the nursing therapists correctly understand the intervention and adhere 
to the manuals, they will receive the specialist training in CBT prior to delivering the 
intervention to the patient. The training will be provided by experienced CBT 
therapists, starting with one or two introduction sessions to introduce basic CBT 
principles and the intervention manuals, followed by practical sessions for nursing 
staff to rehearse the administration of the intervention with one another. Based on the 
experience of the psychotherapist (TC) and the clinical psychologist (KA) in working 
with and training nursing staff, this short-term specialist training will allow the 
nurses to acquire essential skills for delivering a CBT. During the intervention 
delivery, the experienced CBT therapists will also provide supervision to nursing 
therapists on a monthly basis. This ‘light touch’ supervision would allow the 
intervention to be deliverable in routine stroke care. 
PSF is a common and chronic problem. Therefore, after short-term, intensive, 
specialist care by stroke physicians, clinical psychologists, or stroke nurses, more 
cost-effective health service is needed to provide patients with long-term care. If this 
intervention shows to be feasible to be delivered by stroke nurses who do not have 
psychological background, delivery by community health service (e.g. by general 
practitioners, physiotherapists or occupational therapists) will be tested in future so 
that the intervention can be generalised to a wider range of stroke patients and for 
longer term. Furthermore, given the chronic nature of PSF, patients and their families 
take the primary roles in health care. Thus ‘expert patients’, i.e. patients who have 
been benefit from this intervention, and their families who have been involved in the 




Although some previous trials for PSF used group-based psychological interventions 
(Clarke et al., 2012, Zedlitz et al., 2012), in the current study we used an individual-
based approach. CBT is a complex intervention, which may work best if 
individualised and tailored to local context (Craig et al., 2013). The individual-based 
approach would allow the intervention to be flexible and individualised; for example, 
for patients who do not have sleep problems, the strategies for sleep hygiene will not 
be introduced to them. Also, participants in the same group will be expected to 
progress at the same pace during the study, which would be difficult to achieve 
because participants may have different main complaints and their ability of learning 
may be different. In addition, in the NHS Lothian, stroke nurses routinely visit 
community-dwelling stroke patients at home, which would provide the occasion for 
individual delivery; whilst group-based interventions will require participants to 
travel to the same venue, which may increase the burden to participants as well as the 
travelling cost. Therefore, in the next stage, we will test the feasibility of delivering 
this CBT by stroke nurses on a one-to-one basis to patients with PSF.  
Choice of control group for a future trial 
The current study did not have a control group, which is an essential part of RCTs to 
ensure the internal validity of the treatment effect. In RCTs, the efficacy or 
effectiveness of an experimental intervention is determined relative to a control 
condition. There are three commonly used control conditions for psychological 
interventions: a) strategies that are defined by and under the control of investigators, 
b) strategies that are provided in routine clinical care and are not in the control of 
investigators, and c) no treatment (Mohr et al., 2009).  
An example of the investigator-defined control is used in a previous RCT that 
compared two potentially active interventions, CBT alone and CBT plus graded 
activity training, for the treatment of PSF (Zedlitz et al., 2012). This study reported 
that the combination therapy was better than CBT alone, but whether CBT or graded 
exercise training alone was effective on PSF is unclear. Another pilot RCT used a 
stroke group education therapy as the control for a fatigue group psychoeducation 
therapy for PSF (Clarke et al., 2012). This type of control is known as the ‘attention 
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control’, which aims to provide participants in the control group with additional 
‘attention’ (e.g. contact with the project team and interaction with the therapist) as 
comparable to the ‘attention’ provided for participants in the treatment group. Some 
researchers suggest using the attention control to balance the ‘placebo effect’ that 
could be caused by factors such as additional care and attention given to participants 
(Lindquist et al., 2007). However, for psychological interventions, this type of 
control is not analogous to the placebo control in drug trials. This is because the 
interaction with therapists is an integral part of the intervention that is not provided 
in routine care, and that participants’ motivation and emotions thought to be affected 
by the ‘placebo effect’ are managed through the interaction with therapists. 
Psychological interventions are complex interventions that we cannot really tell 
which part of the interaction with therapists is therapeutic and which is not. Thus I 
would suggest not using the attention control in future trials for the current 
psychological intervention, because it may contain some active therapeutic 
components and it would also increase the cost of a future trial.  
For the current intervention, we are interested in whether any intervention as a whole 
offers an improvement over current clinical practice. In clinical practice there is no 
specific treatment for PSF, thus routine medical care for stroke patients means no 
treatment for PSF. Therefore, routine medical care is the optimal control for the 
current intervention. To standardise the routine care provided for each participant (i.e. 
the standardised routine medical care), we will provide information for education 
about PSF and general advice to encourage participants to increase their level of 
activity, but without providing any cognitive restructuring approaches. 
However, we should be aware that when using (standardised) routine medical care as 
control, it is difficult to blind participants and therapists to the allocation. Some 
researchers stated that participants’ awareness that they are not receiving treatment 
would have negative effects on outcomes (Walach et al., 2008). Because the clinical 
outcomes in this study were all measured by the self-report questionnaires by the 
participants, bias from the non-blinding of participants needs to be considered when 




This intervention was aimed to improve patients’ feelings and emotions in the 
situation of PSF, by challenging their thoughts and behaviours. Thus the expected 
outcomes were the improvement in fatigue and mood. In addition, health-related 
quality of different domains of life after stroke was assessed. In the current study, 
postal questionnaires (FAS, PSF case definition, PHQ-9 and SIS) were used to 
measure these clinical outcomes. Most of our participants returned questionnaires in 
time; for those who had difficulty in returning the questionnaire, completing 
questionnaires over telephone was a feasible alternative. These scales will be used in 
future trials for this intervention. The preliminary data obtained in the current study 
showed that for some measures the beneficial effect was sustained to three months 
after the end of treatment. Also fatigue is a chronic problem that is not expected to be 
solved by a ‘quick fix’, so the optimal follow-up period needs to be six months or 
longer (as discussed in the previous section). 
Fatigue will be the primary outcome because the current intervention was 
specifically designed to reduce PSF. We measured both the presence (using a case 
definition specially designed for PSF) and severity (using the FAS) of PSF. A 
previous study conducted a meta-analytic comparison between continuous and 
dichotomous outcomes in studies of psychotherapy for depression, reporting that the 
two types of outcomes resulted in comparable pooled effect sizes (Cuijpers et al., 
2010). However, other researchers suggested that of small RCTs (50 participants or 
less), studies that reported continuous outcomes had a significant higher mean power 
than those that reported dichotomous outcomes (Bhandari et al., 2002). Given the 
low rate of recruitment in the current study (12 participants recruited from 421 
initially screened stroke patients), I would expect a small sample size for future 
studies thus will use fatigue severity as the primary outcome.  
One of the key strategies of this intervention was to promote physical activity in 
daily living, thus the participation in daily activities was assessed by the NEADL. 
The lack of effect on this measure as well as on the Daily Activities subscale of the 
SIS might be due to the high-functioning sample in this study, of whom the mean 
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NEADL score at baseline was 20.8 (SD = 0.9, out of a possible maximal score of 22, 
indicating full independence). Some researchers suggested that this lack of effect was 
common in trials of exercise after stroke, as current measures of disability were not 
sufficiently sensitive for high-functioning stroke patients (Saunders, 2009). In 
addition, some participants in the current study pointed out that some items in the 
NEADL were duplicated with the Daily Activities subscale of the SIS. Therefore, I 
suggest not using the NEADL in future trials for this intervention, as it is does not 
sensitive enough to provide information of the efficacy on daily activities but adds 
burdens to participants. 
In addition, although not assessed in the current study, in future studies I would 
suggest assessing participants’ illness beliefs and coping behaviours prior to and after 
the intervention programme. This will help us to better understand if this intervention 
has taken the effect through a cognitive behavioural approach. 
Sample size 
A major reason for conducting an exploratory trial (a further pilot study) in the future 
is to obtain data for sample size calculation for the definitive trial (Lancaster et al., 
2004). The essential components required for sample size calculations include the 
alpha for type I error, the beta for type II error (or, the power=1-beta), variance of the 
primary outcome measure, and the minimal clinically important difference (MCID) 
(Noordzij et al., 2010). The alpha and the power are usually pre-specified by 
researchers, where an alpha at 0.05 means that the researcher expects a <5% change 
of drawing a false-positive conclusion and a power at 0.9 means that the researcher 
desires a 90% probability of correctly rejecting null hypothesis. The sample size 
calculation is based on using the population variance of the primary outcome, which 
is estimated by means of the sample standard deviation (SD, in case of a continuous 
outcome, e.g. the FAS).  
If using the FAS as the primary outcome, a change of four points or more has been 
considered to represent a clinically relevant change in fatigue status in patients with 
sarcoidosis (de Kleijn et al., 2011); however, the MCID of the FAS has not been 
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established in stroke patients. Therefore, future exploratory studies are needed to 
provide some preliminary data on the difference between the groups, to help 
researchers determine a difference that is biologically plausible and clinically 
relevant in the studied population (Noordzij et al., 2010). Estimates of clinical 
important difference or effect size based on small samples will be positively biased 
(i.e. too large) (Hertzog, 2008). Hertzog et al. suggested that studies with a total 
sample size between 30 and 40 could give bias-corrected estimates for medium to 
large effect sizes, but for small effect sizes even a sample size of 80 would be 
insufficient (Hertzog, 2008). 
The sample size of the exploratory trial is important because it also influences the 
accuracy of the variance estimate. For example, the standard deviation in a small 
sample tends to be negatively biased, thus if used to estimate population variance for 
sample size calculation it is likely to result in an underpowered study (Hertzog, 
2008). Kieser et al. suggested that pilot RCTs with sample sizes between 30 and 50 
in total would be sufficient to derive a later definitive trial with a sample size 
between 150 and 400 with 80% power (Kieser and Wassmer, 1996). This was based 
on Browne’s theory that using the upper limit of the 100 (1-γ)% confidence interval 
of the estimate of population variance for the sample size calculation would 
guarantee a planned power with at least 100 (1-γ)% probability (i.e. 80% in Kieser’s 
simulation) (Browne, 1995).  
The 4-point difference on the FAS was used as a clinically significant difference of 
fatigue severity in an observational study for PSF (Duncan et al., 2014), in which the 
mean FAS score was 24.24 and SD was 8.06 (unpublished, obtained by personal 
communication). If these findings are consistent with future exploratory trials, when 
using a difference of four points as the MCID of the FAS for the current intervention, 
future definitive RCTs for intervention efficacy would require a minimal sample size 
of 86 participants in each group (total n = 172) to provide a power of 0.9 to detect 
this MCID at a critical significance level of 0.05 (Florey, 1993). As discussed in the 
previous paragraph, an exploratory trial with a sample size of 50 will be sufficient to 
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provide accurate estimates to derive a later definitive trial with a sample size of 172 
with adequate power. 
In summary, considering practical issues in the recruitment and to control for biases 
in estimating effect sizes and variance, a total sample size of 50 or more may be 
sufficient for the next stage exploratory RCTs to provide accurate estimates for 
future definitive trials. 
Improving recruitment 
We approached 120 stroke patients and recruited 12 participants from a single NHS 
site (NHS Lothian) over a period of four months. To recruit an adequate sample size 
for a definitive RCT (which would require a few hundred of participants or even 
more), we will need to involve multiple recruiting centres in the future. In the current 
study, we only retrospectively screened for patients who had had a stroke between 
the past three months to two years, from a single site, due to the limited recruiting 
time. If the recruitment period could be longer (e.g. six months or one year), we 
could also recruit participants prospectively; for example, we could identify potential 
participants while they are in hospital and consent them for subsequent fatigue 
screening, and then send them screening  questionnaires at three months after their 
stroke. In a previous RCT investigating strategies to improve medication adherence 
in stroke patients, which used this two-stage prospective recruitment, the researchers 
identified potential participants at their discharge from the stroke clinic or stroke unit 
and sent postal questionnaires to 407 participants when they were at three months 
after stroke. Of these,  355 (87%) of them completed and returned questionnaires 
(O’Carroll et al., 2013). This response rate is more than twice of that in the current 
study (41%). Thus, consenting patients at discharge and contacting them at three 
months to screen for fatigue may improve the recruitment for this intervention in 
future trials. A central randomisation system would be needed to provide 
randomisation and allocation for all participating centres. This could be an online 
randomisation system or a telephone-served system. The feasibility of this central 
randomisation system will need to be tested in the exploratory RCT. 
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Adapting to a wider population with fatigue, low mood, and anxiety 
symptoms after stroke? 
My systematic reviews have revealed significant associations between fatigue, 
depression and anxiety in stroke patients. Also in clinical practice, we have observed 
that fatigue, low mood, and anxiety symptoms often coexist in stroke patients, even 
in those who do not meet clinical criteria for depression or anxiety. Given the 
psychological profile of patients with PSF, a generic intervention targeting an 
‘emotional syndrome’ of these three symptoms but tailored towards the prominent 
symptom might be a reasonable approach in future studies. 
Although the current intervention was specifically designed to treat PSF, participants 
also showed improvement in mood from baseline to post-treatment and the 
improvement was maintained to three-month follow-up. This is not surprising 
because symptoms of fatigue, depression and anxiety often coexist in stroke patients 
and share some common associations such as sleep disorders and reduced physical 
activity (as discussed in Chapter 2). Also CBT is widely used in clinical practice to 
manage emotional conditions, including depression and anxiety (Chambless and 
Ollendick, 2001). This suggests that it might be possible to adapt the current fatigue 
intervention to address a wider range of conditions after stroke, which may include 
fatigue, low mood, and anxiety symptoms. Patients with clinical depression or 
clinical anxiety would not be included, because these are generally separate 
conditions from fatigue and patients with these conditions will require more specific 
psychological interventions. Patients with low mood or emotional distress that do not 
meet the criteria for depression or anxiety usually do not receive psychological care 
in the local health system, for whom the current intervention may provide a novel 
approach to address these problems. 
This does not mean that we can simply apply this fatigue intervention to patients 
with low mood or emotional distress. The psychotherapist (TC) in our project team 
suggested that, based on her experience, the therapeutic effects on fatigue and mood 
would be ‘diluted’ if the intervention is targeting both conditions simultaneously. 
  
205 
Therefore, more studies are needed to explore the mechanisms of low mood and 
emotional distress in stroke patients, and investigate their similarities and differences 
with PSF. If their psychosocial properties are comparable to PSF, we may be able to 
adapt the current fatigue intervention for these conditions but should incorporate 
symptom-specific contents (e.g. for fatigue the intervention was focused on physical 




Section 6.4 Conclusions 
The current study has presented an evidence-based process of developing a 
psychological intervention for PSF. The systematic review of natural history of PSF 
indicated that fatigue is common immediately after stroke and often persists over 
time, which justified the necessity of an intervention for PSF. A psychological 
intervention was proposed for treating PSF based on the clinical observation that PSF 
often coexists with low mood and reduced physical activity. To identify therapeutic 
targets for this psychological intervention, I systematically reviewed observational 
studies of PSF and found that PSF was associated with depressed mood, anxiety, 
lower self-efficacy, reduced physical activity, and sleep disorders. Based on 
psychological interventions for fatigue in conditions other than stroke, these 
psychological and behavioural factors that I have identified as being associated with 
PSF could be managed by a cognitive behavioural approach. Therefore, I developed 
a manualised CBT for PSF by adapting from a nurse-delivered intervention 
programme for cancer-related fatigue and a self-management programme for chronic 
fatigue syndrome (both of which share some psychosocial characteristics with PSF).  
The development process involved a multidisciplinary group of stroke-related health 
professionals and service users, considering both theoretical issues and practical 
issues in stroke care and clinical psychology. I modelled this intervention programme 
and tested the feasibility of recruitment, delivery process and follow-up procedures 
in a group of 12 patients with PSF, where the intervention was delivered by a clinical 
psychologist (i.e. the therapist). The intervention was well-received by the patients 
with PSF, and procedures of recruitment, intervention delivery and follow up were 
feasible in the local health system. I refined the intervention according to the 
feedback from both the participants and the therapist. The preliminary results showed 
improvement in self-reported fatigue severity, mood, mobility, and participation in 
social activity from baseline to three months after the end of treatment. 
This is the initial stage of the development of this psychological intervention. The 
success of this feasibility study suggests that an exploratory trial with the randomised 
controlled design would be a useful next step for the intervention development. 
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Firstly, in the current study the intervention was delivered by a clinical psychologist 
but clinical psychologists are not commonly involved in routine stroke care, thus we 
need to test whether delivering this intervention by stroke nurses, which may be a 
more practical approach, is acceptable and feasible in the NHS. Secondly, the current 
study was a single-arm pilot study based on a single NHS site, which provided no 
information about the feasibility of recruitment from multiple centres and of the 
randomised controlled design. These issues of the trial design will be tested in the 
future exploratory trial. Finally, the future exploratory trial will provide data to 
inform the sample size calculation for definitive trials. 
Although there is little information about the intervention efficacy, findings from this 
thesis contribute to a growing knowledge of PSF that could inform the clinical 
management of PSF. Fatigue is a common problem and often present immediately 
after stroke, thus information should be provided early after stroke to patients and 
their families as part of the general information about stroke, to prepare them for the 
potential PSF. Ideally, patients should be screened for PSF in the chronic phase (e.g. 
three months after stroke), in order to distinguish persistent fatigue from a transitory 
phenomenon. Fatigued patients should be provided information about potential 
mechanisms of PSF and reassured that their fatigue is often reversible if factors 
perpetuating their fatigue, such as distressed mood, lower self-efficacy, reduced 
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